

66958

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 19/26, C12N 9/00, 9/02, 9/04, 9/06, C07H 21/04	A1	(11) International Publication Number: WO 00/04182 (43) International Publication Date: 27 January 2000 (27.01.00)
(21) International Application Number: PCT/US99/15976 (22) International Filing Date: 15 July 1999 (15.07.99) (30) Priority Data: 09/115,475 15 July 1998 (15.07.98) US (71) Applicant: DCV, INC. d/b/a BIO-TECHNICAL RE-SOURCES [US/US]; 1035 S. Seventh Street, Manitowoc, WI 54220-5388 (US). (72) Inventors: BERRY, Alan; 126 Beverly Road, Bloomfield, NJ 07003 (US). BURLINGAME, Richard, P.; 808 North 9th Street, Manitowoc, WI 54220 (US). MILLIS, James, R.; 512 Audubon Road, Kohler, WI 53044 (US). (74) Agents: CONNELL, Gary, J. et al.; Sheridan Ross P.C., Suite 3500, 1700 Lincoln Street, Denver, CO 80203-4501 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PROCESS AND MATERIALS FOR PRODUCTION OF GLUCOSAMINE (57) Abstract <p>The present invention relates to a method and materials for producing glucosamine by fermentation of a genetically modified microorganism. Included in the present invention are genetically modified microorganisms useful in the present method for producing glucosamine, as well as recombinant nucleic acid molecules and the proteins produced by such recombinant nucleic acid molecules.</p>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

PROCESS AND MATERIALS FOR PRODUCTION OF GLUCOSAMINE

FIELD OF THE INVENTION

The present invention relates to a method for producing glucosamine by fermentation. The present invention also relates to genetically modified strains of microorganisms useful for producing glucosamine.

BACKGROUND OF THE INVENTION

Amino sugars are usually found as monomer residues in complex oligosaccharides and polysaccharides. Glucosamine is an amino derivative of the simple sugar, glucose. Glucosamine and other amino sugars are important constituents of many natural polysaccharides. For example, polysaccharides containing amino sugars can form structural materials for cells, analogous to structural proteins.

Glucosamine is manufactured as a nutraceutical product with applications in the treatment of osteoarthritic conditions in animals and humans. The market for glucosamine is experiencing tremendous growth. Furthermore, significant erosion of the world market price for glucosamine is not expected.

Glucosamine is currently obtained by acid hydrolysis of chitin, a complex carbohydrate derived from *N*-acetyl-D-glucosamine. Alternatively, glucosamine can also be produced by acid hydrolysis of variously acetylated chitosans. These processes suffer from poor product yields (in the range of 50% conversion of substrate to glucosamine). Moreover, the availability of raw material (i.e., a source of chitin, such as crab shells) is becoming increasingly limited. Therefore, there is a need in the industry for a cost-effective method for producing high yields of glucosamine for commercial sale and use.

SUMMARY OF THE INVENTION

One embodiment of the present invention relates to a method to produce glucosamine by fermentation of a microorganism. This method includes the steps of: (a) culturing in a fermentation medium a microorganism having a genetic modification in an amino sugar metabolic pathway; and (b) recovering a product produced from the step of culturing which is selected from the group of glucosamine-6-phosphate and glucosamine. Such an amino sugar metabolic pathway is selected from the group of a pathway for converting glucosamine-6-phosphate into another compound, a pathway for synthesizing

glucosamine-6-phosphate, a pathway for transport of glucosamine or glucosamine-6-phosphate out of the microorganism, a pathway for transport of glucosamine into the microorganism, and a pathway which competes for substrates involved in the production of glucosamine-6-phosphate. The fermentation medium includes assimilable sources of carbon, nitrogen and phosphate. In a preferred embodiment, the microorganism is a bacterium or a yeast, and more preferably, a bacterium of the genus *Escherichia*, and even more preferably, *Escherichia coli*.

In one embodiment, the product can be recovered by recovering intracellular glucosamine-6-phosphate from the microorganism and/or recovering extracellular glucosamine from the fermentation medium. In further embodiments, the step of recovering can include purifying glucosamine from the fermentation medium, isolating glucosamine-6-phosphate from the microorganism, and/or dephosphorylating the glucosamine-6-phosphate to produce glucosamine. In one embodiment, at least about 1 g/L of product is recovered.

In yet another embodiment, the step of culturing includes the step of maintaining the carbon source at a concentration of from about 0.5% to about 5% in the fermentation medium. In another embodiment, the step of culturing is performed at a temperature of from about 28°C to about 37°C. In yet another embodiment, the step of culturing is performed in a fermentor.

In one embodiment of the present invention, the microorganism has a modification in a gene which encodes a protein including, but not limited to, *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme II^{Nsg}, glucosamine-6-phosphate synthase, phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridylyltransferase, phosphofructokinase, enzyme II^{Glc} of the PEP:glucose PTS, EIIM_P/III^{Mam} of the PEP:mannose PTS, and/or a phosphatase.

In another embodiment, the genetic modification includes a genetic modification which increases the action of glucosamine-6-phosphate synthase in the microorganism. Such a genetic modification includes the transformation of the microorganism with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase to increase the action of glucosamine-6-phosphate synthase and/or to overexpress the

glucosamine-6-phosphate synthase by the microorganism. In one embodiment, the recombinant nucleic acid molecule is operatively linked to a transcription control sequence. In a further embodiment, the recombinant nucleic acid molecule is integrated into the genome of the microorganism. In yet another embodiment, the recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase has a genetic modification which increases the action of the synthase. Such genetic modifications can result in reduced glucosamine-6-phosphate product inhibition of the glucosamine-6-phosphate synthase, for example.

In one embodiment, a recombinant nucleic acid molecule of the present invention which comprises a nucleic acid sequence encoding a glucosamine-6-phosphate synthase encodes an amino acid sequence SEQ ID NO:16. In another embodiment, such a recombinant nucleic acid molecule comprises a nucleic acid sequence selected from the group of SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15. Preferred recombinant nucleic acid molecules of the present invention include pKLN23-28, nglmS-28₂₁₈₄ and nglmS-28₁₈₃₀.

Also included in the present invention are recombinant nucleic acid molecules encoding a glucosamine-6-phosphate synthase which comprises a genetic modification which increases the action of the glucosamine-6-phosphate synthase (i.e., a glucosamine-6-phosphate synthase homologue). Such a genetic modification can reduce glucosamine-6-phosphate product inhibition of the synthase, for example. In one embodiment, such a genetic modification in a recombinant nucleic acid molecule of the present invention which encodes a glucosamine-6-phosphate synthase results in at least one amino acid modification selected from the group of an addition, substitution, deletion, and/or derivatization of an amino acid residue of the glucosamine-6-phosphate synthase. In one embodiment, such an amino acid modification is in an amino acid sequence position in the modified protein (i.e., homologue) which corresponds to one or more of the following amino acid positions in amino acid sequence SEQ ID NO:16: Ile(4), Ile(272), Ser(450), Ala(39), Arg(250), Gly(472), Leu(469). In another embodiment, such an amino acid modification is selected from the group of a substitution of: (a) an amino acid residue having an aliphatic hydroxyl side group for Ile(4); (b) an amino acid residue having an aliphatic hydroxyl side group for Ile(272); (c) an amino acid residue having an aliphatic

side group for Ser(450); (d) an amino acid residue having an aliphatic hydroxyl side group for Ala(39); (e) an amino acid residue having a sulfur-containing side group for Arg(250); (f) an amino acid residue having an aliphatic hydroxyl side group for Gly(472); (g) an amino acid residue having an aliphatic side group for Leu(469); and, (h) combinations of (a)-(g).

In yet another embodiment of the present invention, an amino acid modification as described above is preferably a substitution selected from the group of: Ile(4) to Thr, Ile(272) to Thr, Ser(450) to Pro, Ala(39) to Thr, Arg(250) to Cys, Gly(472) to Ser, Leu(469) to Pro, and combinations thereof.

In another embodiment, a genetically modified recombinant nucleic acid molecule of the present invention comprises a nucleic acid sequence encoding glucosamine-6-phosphate synthase comprising an amino acid sequence selected from the group of SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:28 or SEQ ID NO:31. In another embodiment, a genetically modified recombinant nucleic acid molecule of the present invention comprises a nucleic acid sequence selected from the group of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:30. Preferred genetically modified recombinant nucleic acid molecule of the present invention include pKLN23-49, pKLN23-54, pKLN23-124, pKLN23-149, pKLN23-151, nglmS-49₂₁₈₄, nglmS-49₁₈₃₀, nglmS-54₂₁₈₄, nglmS-54₁₈₃₀, nglmS-124₂₁₈₄, nglmS-124₁₈₃₀, nglmS-149₂₁₈₄, nglmS-149₁₈₃₀, nglmS-151₂₁₈₄ and nglmS-151₁₈₃₀.

Another embodiment of the present invention relates to a glucosamine-6-phosphate synthase which has glucosamine-6-phosphate synthase action, such synthase being encoded by a nucleic acid sequence having a genetic modification that results in increased glucosamine-6-phosphate synthase action. Such a nucleic acid sequence has been describe above with regard to recombinant nucleic acid molecules of the present invention.

Yet another embodiment of the present invention relates to a method to produce glucosamine by fermentation, such method comprising: (a) culturing in a fermentation medium comprising assimilable sources of carbon, nitrogen and phosphate, a genetically

modified microorganism having increased glucosamine-6-phosphate synthase action, wherein the genetically modified microorganism is produced by a process comprising the steps of: 1) generating modifications in an isolated nucleic acid molecule comprising a nucleic acid sequence encoding glucosamine-6-phosphate synthase to create a plurality of modified nucleic acid sequences; (2) transforming microorganisms with the modified nucleic acid sequences to produce genetically modified microorganisms; (3) screening the genetically modified microorganisms for glucosamine-6-phosphate synthase action; and, (4) selecting the genetically modified microorganisms which have increased glucosamine-6-phosphate synthase action; ; and, (b) recovering the product. The step of culturing produces a product selected from the group of glucosamine-6-phosphate and glucosamine from the microorganism.

In another embodiment, a microorganism of the present invention has an additional genetic modification in genes encoding *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme II^{Nag}, phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridylyltransferase, phosphofructokinase, Enzyme II^{Glc} of the PEP:glucose PTS, EIIM,P/III^{Man} of the PEP:mannose PTS, wherein the modification decreases the action of such proteins. In another embodiment, a microorganism of the present invention has an additional genetic modification in a gene encoding a phosphatase, wherein the modification increases the action of the phosphatase. In a preferred embodiment, a microorganism of the present invention has an additional genetic modification in the genes encoding the following proteins: *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase and *N*-acetyl-glucosamine-specific enzyme II^{Nag}, such modifications including, but not limited to, a deletion of at least a portion of such genes.

Another embodiment of the present invention relates to a method to produce glucosamine by fermentation which includes the steps of (a) culturing an *Escherichia coli* transformed with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase in a fermentation medium comprising assimilable sources of carbon, nitrogen and phosphate to produce a product, and (b) recovering the product. The product includes intracellular glucosamine-6-phosphate which is recovered from the *Escherichia coli*

and/or extracellular glucosamine which is recovered from the fermentation medium. In this embodiment, the recombinant nucleic acid molecule increases expression of the glucosamine-6-phosphate synthase by the *Escherichia coli*, and is operatively linked to a transcription control sequence. In one embodiment, the recombinant nucleic acid molecule comprises a genetic modification which reduces glucosamine-6-phosphate product inhibition of the glucosamine-6-phosphate synthase. In another embodiment, the *Escherichia coli* has an additional genetic modification in at least one gene selected from the group of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, *manXYZ*, *glmM*, *pfkB*, *pfkA*, *glmU*, *glmS*, *ptsG* and/or a phosphatase gene. In yet another embodiment, the additional modification comprises a deletion of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, and a mutation in *manXYZ*, wherein the modification results in decreased enzymatic activity of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase and *N*-acetyl-glucosamine-specific enzyme II^{Nag}.

Yet another embodiment of the present invention relates to a microorganism for producing glucosamine by a biosynthetic process. The microorganism is transformed with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase, wherein the recombinant nucleic acid molecule is operatively linked to a transcription control sequence. The recombinant nucleic acid molecule further comprises a genetic modification which increases the action of the glucosamine-6-phosphate synthase. The expression of the recombinant nucleic acid molecule increases production of the glucosamine by the microorganism. In a preferred embodiment, the recombinant nucleic acid molecule is integrated into the genome of the microorganism. In yet another embodiment, the microorganism has at least one additional genetic modification in a gene encoding a protein selected from the group consisting of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme II^{Nag}, phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridylyltransferase, phosphofructokinase, Enzyme II^{Glc} of the PEP:glucose PTS, and/or EIIM, P/III^{Man} of the PEP:mannose PTS, wherein the genetic modification decreases the action of the protein. In another embodiment, the microorganism has a modification in a gene encoding a phosphatase, wherein the genetic modification increases the action of the phosphatase.

In yet another embodiment, the microorganism has a modification in genes encoding *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase and *N*-acetyl-glucosamine-specific enzyme II^{Nag}, wherein the genetic modification decreases enzymatic activity of the protein. In a preferred embodiment, the genetic modification is a deletion of at least a portion of the genes.

In a further embodiment, the microorganism is *Escherichia coli*, having a modification in a gene selected from the group of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, *manXYZ*, *glmM*, *pfkB*, *pfkA*, *glmU*, *ptsG* and/or a phosphatase gene. In one embodiment, such an *Escherichia coli* has a deletion of *nag* regulon genes, and in another embodiment, such an *Escherichia coli* has a deletion of *nag* regulon genes and a genetic modification in *manXYZ* genes such that the proteins encoded by the *manXYZ* genes have decreased action.

Yet another embodiment of the present invention is a microorganism as described above which produces at least about 1 g/L of glucosamine when cultured for about 10-60 hours at from about 28°C to about 37°C to a cell density of at least about 8 g/L by dry cell weight, in a pH 7.0 fermentation medium comprising: 14 g/L K₂HPO₄, 16 g/L KH₂PO₄, 1 g/L Na₃Citrate·2H₂O, 5 g/L (NH₄)₂SO₄, 20 g/L glucose, 10 mM MgSO₄, 1 mM CaCl₂, and from about 0.2mM to about 1 mM IPTG.

Another embodiment of the present invention is a microorganism for producing glucosamine by a biosynthetic process, which includes: (a) a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase operatively linked to a transcription control sequence; and, (b) at least one genetic modification in a gene encoding a protein selected from the group of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme II^{Nag}, phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridylyltransferase, phosphofructokinase, Enzyme II^{Glc} of the PEP:glucose PTS, and/or EIIM,P/III^{Man} of the PEP:mannose PTS, wherein the genetic modification decreases the action of the protein. In another embodiment, the microorganism includes at least one genetic modification in a gene encoding a phosphatase, wherein the genetic modification increases the action of the phosphatase. Expression of the recombinant nucleic acid molecule increases the action of the glucosamine-6-phosphate synthase in the

microorganism. In a further embodiment, the recombinant nucleic acid molecule is integrated into the genome of the microorganism.

BRIEF DESCRIPTION OF THE FIGURES OF THE INVENTION

5 Fig. 1 is a schematic representation of the pathways for the biosynthesis and catabolism of glucosamine and *N*-acetyl-glucosamine and their phosphorylated derivatives in *Escherichia coli*.

Fig. 2 is a schematic representation of the modifications to the pathways related to amino sugar metabolism for the overproduction of glucosamine in *Escherichia coli*.

10 Fig. 3 is a schematic representation of the production of *Escherichia coli* strains containing combinations of the *manXYZ*, *ptsG*, and Δ *nag* mutations.

Fig. 4 is a line graph illustrating the effects on glucosamine accumulation of feeding additional glucose and ammonium sulfate to cultures.

Fig. 5 is a line graph which shows that glucosamine-6-phosphate synthase is inhibited by glucosamine-6-phosphate and glucosamine.

15 Fig. 6 is a line graph illustrating product inhibition of glucosamine-6-phosphate synthase activity in mutant *glmS* clones.

Fig. 7 is a schematic representation of the strategy for constructions of *Escherichia coli* strains containing mutant *glmS* genes.

20 Fig. 8 is a line graph illustrating product inhibition of glucosamine-6-phosphate synthase in *Escherichia coli* strains with integrated mutant *glmS* genes.

Fig. 9 is a line graph showing glucosamine production in mutant *Escherichia coli* strains with integrated mutant *glmS* genes.

Fig. 10 is a line graph showing inhibition of glucosamine-6-phosphate synthase in glucosamine-producing strains.

25 Fig. 11A is a line graph showing the thermal stability at 45°C of glucosamine-6-phosphate synthase in glucosamine-producing strains.

Fig. 11B is a line graph illustrating the thermal stability at 50°C of glucosamine-6-phosphate synthase in glucosamine-producing strains.

30 Fig. 12 is a line graph showing the effect of IPTG concentration on glucosamine production.

Fig. 13 is a line graph demonstrating the effects of IPTG concentration and temperature on glucosamine production.

Fig. 14A is a line graph illustrating growth and glucosamine production by glucosamine-producing strain 2123-54 at 30°C.

5 Fig. 14B is a line graph illustrating growth and glucosamine production by glucosamine-producing strain 2123-54 at 37°C.

Fig. 15A is a line graph showing glucosamine production by strain 2123-49 at 30°C.

10 Fig. 15B is a line graph showing glucosamine production by strain 2123-124 at 30°C.

Fig. 16A is a line graph illustrating glucosamine production by a glucosamine-producing strain in a glucose limited fermentor at 37°C.

Fig. 16B is a line graph illustrating glucosamine production by a glucosamine-producing strain in a glucose limited fermentor at 30°C.

15 Fig. 16A is a line graph illustrating glucosamine production by a glucosamine-producing strain in a glucose excess fermentor at 30°C.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a biosynthetic method for producing glucosamine. Such a method includes fermentation of a genetically modified microorganism to produce
20 glucosamine. The present invention also relates to genetically modified microorganisms, such as strains of *Escherichia coli*, useful for producing glucosamine. As used herein, the terms glucosamine and *N*-glucosamine can be used interchangeably. Similarly, the terms glucosamine-6-phosphate and *N*-glucosamine-6-phosphate can be used interchangeably. Glucosamine can also be abbreviated as GlcN and glucosamine-6-phosphate can also be
25 abbreviated as GlcN-6-P.

The novel method of the present invention for production of glucosamine by fermentation is inexpensive and can produce a yield of glucosamine that exceeds the yield per cost of glucosamine produced by current hydrolysis methods. In addition, by using a genetically modified microorganism as described herein, the method of the present

invention can be easily modified to adapt to particular problems or changing needs relative to the production of glucosamine.

The amino sugars, *N*-acetylglucosamine (GlcNAc) and glucosamine (GlcN), are fundamentally important molecules in microorganisms, because they are the precursors for the biosynthesis of major macromolecules, and in particular, glycoconjugates (i.e., macromolecules containing covalently bound oligosaccharide chains). For example, in *Escherichia coli*, *N*-acetylglucosamine and glucosamine are precursors for two macromolecules of the cell envelope, peptidoglycan and lipopolysaccharide. Mutations that block the biosynthesis of peptidoglycan or lipopolysaccharide are lethal, resulting in loss of integrity of the cell envelope and ultimately in cell lysis.

One embodiment of the present invention relates to a method to produce glucosamine by fermentation of a microorganism. This method includes the steps of (a) culturing in a fermentation medium a microorganism having a genetic modification in an amino sugar metabolic pathway which includes: a pathway for converting glucosamine-6-phosphate into another compound, a pathway for synthesizing glucosamine-6-phosphate, a pathway for transport of glucosamine or glucosamine-6-phosphate out of said microorganism, a pathway for transport of glucosamine into said microorganism, and a pathway which competes for substrates involved in the production of glucosamine-6-phosphate, to produce a product which can include intracellular glucosamine-6-phosphate and/or extracellular glucosamine from the microorganism; and (b) recovering the product by recovering intracellular glucosamine-6-phosphate from the microorganism and/or recovering extracellular glucosamine from the fermentation medium. The fermentation medium includes assimilable sources of carbon, nitrogen and phosphate.

Another embodiment of the present invention relates to a method to produce glucosamine by fermentation. Such method includes the steps of: (a) culturing in a fermentation medium comprising assimilable sources of carbon, nitrogen and phosphate, an *Escherichia coli* transformed with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase operatively linked to a transcription control sequence; and (b) recovering a product selected from the group of glucosamine-6-phosphate and glucosamine. The recombinant nucleic acid molecule increases expression of the glucosamine-6-phosphate synthase by the *Escherichia coli*. In a further embodiment, the

recombinant nucleic acid molecule comprises a genetic modification which reduces glucosamine-6-phosphate product inhibition of the glucosamine-6-phosphate synthase. In yet another embodiment, the *Escherichia coli* has an additional genetic modification in at least one gene selected from the group of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, *manXYZ*,
5 *glmM*, *pfbB*, *pfbA*, *glmU*, *glmS*, *ptsG* and/or a phosphatase gene.

To produce significantly high yields of glucosamine by the fermentation method of the present invention, a microorganism is genetically modified to enhance production of glucosamine. As used herein, a genetically modified microorganism, such as *Escherichia coli*, has a genome which is modified (i.e., mutated or changed) from its
10 normal (i.e., wild-type or naturally occurring) form. Genetic modification of a microorganism can be accomplished using classical strain development and/or molecular genetic techniques. Such techniques are generally disclosed, for example, in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press. The reference Sambrook et al., *ibid.*, is incorporated by reference herein in its entirety.

15 Additionally, techniques for genetic modification of a microorganism are described in detail in the Examples section. A genetically modified microorganism can include a natural genetic variant as well as a microorganism in which nucleic acid molecules have been inserted, deleted or modified (i.e., mutated; e.g., by insertion, deletion, substitution, and/or inversion of nucleotides), in such a manner that such modifications provide the
20 desired effect within the microorganism. According to the present invention, a genetically modified microorganism includes a microorganism that has been modified using recombinant technology. As used herein, genetic modifications which result in a decrease in gene expression, in the function of the gene, or in the function of the gene product (i.e., the protein encoded by the gene) can be referred to as inactivation (complete or partial),
25 deletion, interruption, blockage or down-regulation of a gene. For example, a genetic modification in a gene which results in a decrease in the function of the protein encoded by such gene, can be the result of a complete deletion of the gene (i.e., the gene does not exist, and therefore the protein does not exist), a mutation in the gene which results in incomplete or no translation of the protein (e.g., the protein is not expressed), or a
30 mutation in the gene which decreases or abolishes the natural function of the protein (e.g., a protein is expressed which has decreased or no enzymatic activity or action). Genetic

modifications which result in an increase in gene expression or function can be referred to as amplification, overproduction, overexpression, activation, enhancement, addition, or up-regulation of a gene.

In one embodiment of the present invention, a genetic modification of a microorganism increases or decreases the action of a protein involved in an amino sugar metabolic pathway according to the present invention. Such a genetic modification includes any type of modification and specifically includes modifications made by recombinant technology and by classical mutagenesis. For example, in one embodiment, a microorganism of the present invention has a genetic modification that increases the action of glucosamine-6-phosphate synthase. It should be noted that reference to increasing the action (or activity) of glucosamine-6-phosphate synthase and other enzymes discussed herein refers to any genetic modification in the microorganism in question which results in increased functionality of the enzymes and includes higher activity of the enzymes (e.g., specific activity or *in vivo* enzymatic activity), reduced inhibition or degradation of the enzymes and overexpression of the enzymes. For example, gene copy number can be increased, expression levels can be increased by use of a promoter that gives higher levels of expression than that of the native promoter, or a gene can be altered by genetic engineering or classical mutagenesis to increase the action of an enzyme. Examples of nucleic acid molecules encoding glucosamine-6-phosphate synthase which have been genetically modified to increase the action of the glucosamine-6-phosphate synthase are described in the Examples section. Similarly, reference to decreasing the action of enzymes discussed herein refers to any genetic modification in the microorganism in question which results in decreased functionality of the enzymes and includes decreased activity of the enzymes (e.g., specific activity), increased inhibition or degradation of the enzymes and a reduction or elimination of expression of the enzymes. For example, the action of an enzyme of the present invention can be decreased by blocking or reducing the production of the enzyme, reducing enzyme activity, or inhibiting the activity of the enzyme. Blocking or reducing the production of an enzyme can include placing the gene encoding the enzyme under the control of a promoter that requires the presence of an inducing compound in the growth medium. By establishing conditions such that the inducer becomes depleted from the medium, the expression of the gene

encoding the enzyme (and therefore, of enzyme synthesis) could be turned off. Blocking or reducing the activity of an enzyme could also include using an excision technology approach similar to that described in U.S. Patent No. 4,743,546, incorporated herein by reference. To use this approach, the gene encoding the enzyme of interest is cloned
5 between specific genetic sequences that allow specific, controlled excision of the gene from the genome. Excision could be prompted by, for example, a shift in the cultivation temperature of the culture, as in U.S. Patent No. 4,743,546, or by some other physical or nutritional signal.

An amino sugar is an amino derivative of a saccharide (e.g., a saccharide having
10 an amino group in place of a hydroxyl group). According to the present invention, an amino sugar metabolic pathway is any biochemical pathway involved in, or affecting, the biosynthesis, anabolism or catabolism of an amino sugar. As used herein, amino sugar metabolic pathways include pathways involved in the transport of amino sugars and their precursors into and out of a cell, and can also include biochemical pathways which
15 compete for substrates involved in the biosynthesis or catabolism of an amino sugar. For example, the immediate precursor to one of the earliest formed amino sugars is fructose-6-phosphate (F-6-P), which, in a biochemical reaction with glutamine (Gln, the amino group donor), forms glucosamine-6-phosphate. Fructose-6-phosphate is also an intermediate in the glycolysis pathway. Therefore, the glycolytic pathway competes with the
20 glucosamine-6-phosphate biosynthetic pathway by competing for a substrate, fructose-6-phosphate. In addition, glucosamine-6-phosphate can be converted to other amino sugars and form constituents in various macromolecules by a series of biochemical reactions. As
25 ~~such, the~~ fructose-6-phosphate/glucosamine-6-phosphate pathway, the fructose-6-phosphate glycolytic pathway, to the extent that it affects the biosynthesis of glucosamine-6-phosphate, and the glucosamine-6-phosphate/macromolecule biosynthesis pathway are all considered to be amino sugar metabolic pathways in the present invention.

In general, a microorganism having a genetically modified amino sugar metabolic pathway has at least one genetic modification, as discussed above, which results in a change in one or more amino sugar metabolic pathways as described above as compared
30 to a wild-type microorganism cultured under the same conditions. Such a modification in an amino sugar metabolic pathway changes the ability of the microorganism to produce

an amino sugar. According to the present invention, a genetically modified microorganism preferably has an enhanced ability to produce glucosamine compared to a wild-type microorganism cultured under the same conditions. An amino sugar metabolic pathway which affects the production of glucosamine can generally be categorized into at least one of the following kinds of pathways: (a) pathways for converting glucosamine-6-phosphate into other compounds, (b) pathways for synthesizing glucosamine-6-phosphate, (c) pathways for transporting glucosamine into a cell, (d) pathways for transporting glucosamine or glucosamine-6-phosphate out of a cell, and (e) pathways which compete for substrates involved in the production of glucosamine-6-phosphate.

A genetically modified microorganism useful in a method of the present invention typically has at least one modified gene involved in at least one amino sugar metabolic pathway which results in (a) reduced ability to convert glucosamine-6-phosphate into other compounds (i.e., inhibition of glucosamine-6-phosphate catabolic or anabolic pathways), (b) an enhanced ability to produce (i.e., synthesize) glucosamine-6-phosphate, (c) a reduced ability to transport glucosamine into the cell, (d) an enhanced ability to transport glucosamine-6-phosphate or glucosamine out of the cell, and/or (e) a reduced ability to use substrates involved in the production of glucosamine-6-P for competing biochemical reactions.

It is to be understood that the present invention discloses a method comprising the use of a microorganism with an ability to produce commercially useful amounts of glucosamine in a fermentation process (i.e., preferably an enhanced ability to produce glucosamine compared to a wild-type microorganism cultured under the same conditions). This method is achieved by the genetic modification of one or more genes encoding a protein involved in an amino sugar metabolic pathway which results in the production (expression) of a protein having an altered (e.g., increased or decreased) function as compared to the corresponding wild-type protein. Such an altered function enhances the ability of the genetically engineered microorganism to produce glucosamine. It will be appreciated by those of skill in the art that production of genetically modified microorganisms having a particular altered function as described elsewhere herein (e.g., an enhanced ability to produce glucosamine-6-phosphate) such as by the specific selection techniques described in the Examples, can produce many organisms meeting the given

functional requirement, albeit by virtue of a variety of different genetic modifications. For example, different random nucleotide deletions and/or substitutions in a given nucleic acid sequence may all give rise to the same phenotypic result (e.g., decreased action of the protein encoded by the sequence). The present invention contemplates any such genetic modification which results in the production of a microorganism having the characteristics set forth herein.

For a variety of microorganisms, many of the amino sugar metabolic pathways have been elucidated. In particular, pathways for the biosynthesis and catabolism of glucosamine and *N*-acetylglucosamine and their phosphorylated derivatives have been elucidated in *Escherichia coli*. These pathways include the multiple transport systems for the utilization of these amino sugars as carbon sources. Genes encoding the enzymes and proteins directly related to the transport, catabolism and biosynthesis of amino sugars in *Escherichia coli* have been cloned and sequenced. In addition, mutant strains of *Escherichia coli* blocked in substantially every step of amino sugar metabolism have been isolated. The known pathways for amino sugar metabolism for *Escherichia coli* are illustrated in Fig. 1.

As will be discussed in detail below, even though many of the pathways and genes involved in the amino sugar metabolic pathways have been elucidated, until the present invention, it was not known which of the many possible genetic modifications would be necessary to generate a microorganism that can produce commercially significant amounts of glucosamine. Indeed, the present inventors are the first to design and engineer a glucosamine-producing microorganism that has glucosamine production capabilities that far exceed the glucosamine production capability of any known wild-type or mutant microorganism. The present inventors are also the first to appreciate that such a genetically modified microorganism is useful in a method to produce glucosamine for commercial use.

A microorganism to be used in the fermentation method of the present invention is preferably a bacterium or a yeast. More preferably, such a microorganism is a bacterium of the genus *Escherichia*. *Escherichia coli* is the most preferred microorganism to use in the fermentation method of the present invention. Particularly preferred strains of *Escherichia coli* include K-12, B and W, and most preferably, K-12.

Although *Escherichia coli* is most preferred, it is to be understood that any microorganism that produces glucosamine and can be genetically modified to enhance production of glucosamine can be used in the method of the present invention. A microorganism for use in the fermentation method of the present invention can also be referred to as a production organism.

The amino sugar metabolic pathways of the microorganism, *Escherichia coli*, will be addressed as specific embodiments of the present invention are described below. It will be appreciated that other microorganisms and in particular, other bacteria, have similar amino sugar metabolic pathways and genes and proteins having similar structure and function within such pathways. As such, the principles discussed below with regard to *Escherichia coli* are applicable to other microorganisms.

In one embodiment of the present invention, a genetically modified microorganism includes a microorganism which has an enhanced ability to synthesize glucosamine-6-phosphate. According to the present invention, "an enhanced ability to synthesize" a product refers to any enhancement, or up-regulation, in an amino sugar metabolic pathway related to the synthesis of the product such that the microorganism produces an increased amount of the product compared to the wild-type microorganism cultured under the same conditions. In one embodiment of the present invention, enhancement of the ability of a microorganism to synthesize glucosamine-6-phosphate is accomplished by amplification of the expression of the glucose-6-phosphate synthase gene, which in *Escherichia coli* is the *glmS* gene, the product of which is glucosamine-6-phosphate synthase. Glucosamine-6-phosphate synthase catalyzes the reaction in which fructose-6-phosphate and glutamine form glucosamine-6-phosphate and glutamic acid. Amplification of the expression of glucosamine-6-phosphate synthase can be accomplished in *Escherichia coli*, for example, by introduction of a recombinant nucleic acid molecule encoding the *glmS* gene.

Overexpression of *glmS* is crucial for the intracellular accumulation of glucosamine-6-phosphate and ultimately for production of glucosamine, since the level of glucosamine-6-phosphate synthase in the cell will control the redirection of carbon flow away from glycolysis and into glucosamine-6-phosphate synthesis. The *glmS* gene is located at 84 min on the *Escherichia coli* chromosome, and sequence analysis of this region of the chromosome reveals that *glmS* resides in an operon with the *glmU* gene,

which encodes the bifunctional enzyme, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridylyltransferase. Glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridylyltransferase functions within the amino sugar metabolic pathway in which glucosamine-6-phosphate is incorporated, through a series of biochemical reactions, into macromolecules. No obvious promoter sequence is detected upstream of *glmS*; transcription of the *glmUS* operon is initiated from two promoter sequences upstream of *glmU*. Thus, it is preferred that the *glmS* gene be cloned under control of an artificial promoter. The promoter can be any suitable promoter that will provide a level of *glmS* expression required to maintain a sufficient level of glucosamine-6-phosphate synthase in the production organism. Preferred promoters are constitutive (rather than inducible) promoters, since the need for addition of expensive inducers is therefore obviated. Such promoters include normally inducible promoter systems that have been made functionally constitutive or "leaky" by genetic modification, such as by using a weaker, mutant repressor gene. Particularly preferred promoters to be used with *glmS* are *lac*, λP_L and T7. The gene dosage (copy number) of *glmS* can be varied according to the requirements for maximum product formation. In one embodiment, the recombinant *glmS* gene is integrated into the *E. coli* chromosome.

Therefore, it is an embodiment of the present invention to provide a microorganism, such as *E. coli*, which is transformed with a recombinant nucleic acid molecule comprising a nucleic acid sequence encoding a glucosamine-6-phosphate synthase, which in *E. coli*, for example, is encoded by the *glmS* gene. Preferred recombinant nucleic acid molecules comprising such a nucleic acid sequence include recombinant nucleic acid molecules comprising a nucleic acid sequence which encodes a glucosamine-6-phosphate synthase comprising an amino acid sequence SEQ ID NO:16. Other preferred recombinant nucleic acid molecules of the present invention include nucleic acid molecules which comprise a nucleic acid sequence selected from the group of SEQ ID NO:13, SEQ ID NO:14 and/or SEQ ID NO:15. Particularly preferred recombinant nucleic acid molecules of the present invention include nucleic acid molecules comprising nucleic acid molecules *nglms*-28₂₁₈₄ and/or *nglms*-28₁₈₃₀. One recombinant molecule of the present invention, referred to herein as plasmid pKLN23-28, includes SEQ ID NOs:13, 14 and 15 and is particularly useful for expressing glucosamine-6-

phosphate synthase in a microorganism. The above identified nucleic acid molecules represent nucleic acid molecules comprising wild-type (i.e., naturally occurring or endogenous) nucleic acid sequences encoding glucosamine-6-phosphate synthase proteins. Genetically modified nucleic acid molecules which include nucleic acid sequences encoding homologues (i.e., modified and/or mutated) glucosamine-6-phosphate synthase proteins are also encompassed by the present invention and are described in detail below.

The reported K_m 's of glucosamine-6-phosphate synthase from *Escherichia coli* are 2mM and 0.4mM for fructose-6-phosphate and glutamine, respectively. These are relatively high values (i.e., the affinity of the enzyme for its substrates is rather weak). It is therefore another embodiment of the present invention to provide a microorganism having a glucosamine-6-phosphate synthase with improved affinity for its substrates. A glucosamine-6-phosphate synthase with improved affinity for its substrates can be produced by any suitable method of genetic modification or protein engineering. For example, computer-based protein engineering can be used to design a glucosamine-6-phosphate synthase protein with greater stability and better affinity for its substrate. See for example, Maulik et al., 1997, *Molecular Biotechnology: Therapeutic Applications and Strategies*, Wiley-Liss, Inc., which is incorporated herein by reference in its entirety.

White (1968, *Biochem. J.*, 106:847-858) first demonstrated that glucosamine-6-phosphate synthase was inhibited by glucosamine-6-phosphate. The present inventors determined that this inhibition was a key factor which limits glucosamine accumulation in glucosamine production strains of the present invention, which have been designed for commercial use. Therefore, it is yet another embodiment of the present invention to provide a microorganism having a glucosamine-6-phosphate synthase with reduced glucosamine-6-phosphate product feedback inhibition. A glucosamine-6-phosphate synthase with reduced product inhibition can be a mutated (i.e., genetically modified) glucosamine-6-phosphate synthase gene, for example, and can be produced by any suitable method of genetic modification. For example, a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase can be modified by any method for inserting, deleting, and/or substituting nucleotides, such as by error-prone PCR. In this method, the gene is amplified under conditions that lead to a high frequency of misincorporation errors by the DNA polymerase used for the amplification. As a result, a high frequency of

mutations are obtained in the PCR products. This method is described in detail in Example 5. The resulting glucosamine-6-phosphate synthase gene mutants can then be screened for reduced product inhibition by testing the mutant genes for the ability to confer increased glucosamine production onto a test microorganism, as compared to a microorganism carrying the non-mutated recombinant glucosamine-6-phosphate synthase nucleic acid molecule. It should be noted that decreased product inhibition of glucosamine-6-phosphate synthase typically results in a glucosamine-6-phosphate synthase with increased action, even when the specific activity of the enzyme is remains the same, or actually is decreased, relative to a naturally occurring glucosamine-6-phosphate enzyme. Therefore, it is an embodiment of the present invention to produce a genetically modified glucosamine-6-phosphate synthase with increased action and increased *in vivo* enzymatic activity, which has unmodified or even decreased specific activity as compared to a naturally occurring glucosamine-6-phosphate synthase. Also encompassed by the present invention are genetically modified glucosamine-6-phosphate synthases with increased specific activity.

Therefore, it is an embodiment of the present invention to provide a microorganism, such as *E. coli*, which is transformed with a genetically modified recombinant nucleic acid molecule comprising a nucleic acid sequence encoding a mutant, or homologue, glucosamine-6-phosphate synthase protein. Such glucosamine-6-phosphate synthase proteins can be referred to herein as glucosamine-6-phosphate synthase homologues. Protein homologues are described in detail below. Preferred recombinant nucleic acid molecules comprising such a nucleic acid sequence include recombinant nucleic acid molecules comprising a nucleic acid sequence which encodes a glucosamine-6-phosphate synthase comprising an amino acid sequence selected from the group of SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:28 and/or SEQ ID NO:31. Other preferred recombinant nucleic acid molecules comprise a nucleic acid sequence selected from the group of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29 and/or SEQ ID NO:30. Particularly preferred genetically modified recombinant nucleic acid molecules useful in the present invention include nucleic acid molecules comprising nucleic acid molecules selected from the group of ngImS-49₂₁₈₄, ngImS-49₁₈₃₀,

nglmS-54₂₁₈₄, nglmS-54₁₈₃₀, nglmS-124₂₁₈₄, nglmS-124₁₈₃₀, nglmS-149₂₁₈₄, nglmS-149₁₈₃₀,
nglmS-151₂₁₈₄ and nglmS-151₁₈₃₀. Plasmids pKLN23-49, pKLN23-54, pKLN23-124,
pKLN23-149 and pKLN23-151 are recombinant nucleic acid molecules of the present
invention which are particularly useful for expressing glucosamine-6-phosphate synthase
5 homologues in a microorganism.

An adequate intracellular supply of glutamine (Gln) is critical for the glucosamine-
6-phosphate synthase reaction. Inspection of the synthetic and degradative pathways for
glucosamine-6-phosphate reveals the presence of a potential futile cycle whereby
continuous interconversion of fructose-6-phosphate and glucosamine-6-phosphate results
10 in wasteful depletion of glutamine. In one embodiment of the present invention, the
supply of glutamine can be increased either by genetic modification of the production
organism to increase glutamine production in the cell, or by modifying the fermentation
medium (i.e., adding glutamine to the fermentation medium), to ensure that the supply of
glutamine will not limit the production of glucosamine-6-phosphate.

15 In another embodiment of the present invention, the potential futile cycling of
fructose-6-phosphate and glucosamine-6-phosphate is addressed by inhibiting, or
blocking, the reverse reaction in which glucosamine-6-phosphate is converted into
fructose-6-phosphate. In this embodiment, a microorganism is genetically modified to
have an inactivation or deletion of the gene which catalyzes this conversion, glucosamine-
20 6-phosphate deaminase, which in *Escherichia coli* is the *nagB* gene. *nagB* is one of
several *nag* genes which are part of the *nag* regulon. The *nag* genes involved in the
degradation of glucosamine and *N*-acetyl-glucosamine exist as a regulon located at 15 min
on the *Escherichia coli* chromosome. In another embodiment, the entire *nag* regulon is
inactivated or deleted. The advantages of deleting the entire *nag* regulon are discussed
25 in detail below.

As discussed above, overproduction of glucosamine-6-phosphate synthase results
in diversion of fructose-6-phosphate synthesis to glucosamine-6-phosphate synthesis.
However, many other enzymes can compete for the substrate, fructose-6-phosphate.
Therefore, one embodiment of the present invention includes a microorganism in which
30 these competitive side reactions are blocked. In a preferred embodiment, a microorganism
having complete or partial inactivation of the gene encoding phosphofructokinase is

provided. The second step in the glycolytic pathway is the conversion of fructose-6-phosphate to fructose-1,6-diphosphate by phosphofructokinase, which in *Escherichia coli* exists as two isozymes encoded by the *pfkA* and *pfkB* genes. Complete or partial inactivation of either the *pfkA* or *pfkB* genes slows the entry of fructose-6-phosphate into the glycolytic pathway and enhances the conversion of fructose-6-phosphate to glucosamine-6-phosphate. As used herein, inactivation of a gene can refer to any modification of a gene which results in a decrease in the activity (i.e., expression or function) of such a gene, including attenuation of activity or complete deletion of activity.

In a further embodiment of the present invention, a genetically modified microorganism has a decreased ability to convert glucosamine-6-phosphate into other compounds. Inactivation of glucosamine-6-phosphate deaminase, as described above, represents one such modification, however, glucosamine-6-phosphate serves as a substrate for other biochemical reactions. The first committed step in the pathway leading to production of macromolecules such as lipopolysaccharide and peptidoglycan in *Escherichia coli* is the conversion of glucosamine-6-phosphate to glucosamine-1-phosphate by phosphoglucosamine mutase, which in *Escherichia coli* is the product of the *glmM* gene. The involvement of this enzyme activity in the pathway of lipopolysaccharide and peptidoglycan biosynthesis was recently confirmed with the cloning of the *glmM* gene. Consequently, the regulation of *glmM* gene, and its cognate product, phosphoglucosamine mutase, has not been studied in detail. It has been shown, however, that the phosphoglucosamine mutase, like all other hexosephosphate mutase enzymes studied, is regulated by phosphorylation. This type of regulation at the enzyme level is typically exquisitely sensitive to levels of the pathway end products. Thus, carbon flow through phosphoglucosamine mutase can be self-regulating and may not be a problem as glucosamine-6-phosphate accumulates. Since the sequence of the *glmM* gene is known, however, it is a preferred embodiment of the present invention to provide a microorganism in which the gene encoding phosphoglucosamine mutase is interrupted or deleted. More preferably, the gene encoding phosphoglucosamine mutase is down-regulated, but not completely inactivated, by a mutation, so as not to completely block the biosynthesis of the critical cell envelope components.

Another pathway which results in the conversion of glucosamine-6-phosphate to another compound is catalyzed by the enzyme, *N*-acetylglucosamine-6-phosphate deacetylase. *N*-acetylglucosamine-6-phosphate deacetylase is capable of catalyzing the reverse reaction of converting glucosamine-6-phosphate (plus acetyl CoA) to *N*-acetylglucosamine-6-phosphate. This could result in futile cycling of glucosamine-6-phosphate and *N*-acetylglucosamine-6-phosphate and result in a product composed of a mixture of glucosamine and *N*-acetylglucosamine. Therefore, it is a further embodiment of the present invention to provide a genetically modified microorganism in which the gene encoding *N*-acetylglucosamine-6-phosphate deacetylase, which is the *nagA* gene in *Escherichia coli*, is inactivated.

It is a further embodiment of the present invention to inactivate the transport systems for glucosamine in a microorganism such that once the glucosamine is excreted by the cell it is not taken back up. This modification is helpful for avoiding a high intracellular level of glucosamine which could be toxic to the cells, and facilitates recovery of the product, since the product remains extracellular. In a preferred embodiment of the present invention, the transportation systems for glucosamine are inactivated to keep glucosamine outside of the microorganism once it is excreted by the microorganism. During growth of *Escherichia coli* on glucosamine as sole carbon source, glucosamine is transported into the cell by the PEP:mannose phosphotransferase (PTS) system, which is not only capable of transporting glucosamine into the cell, but is also induced by glucosamine. It is therefore an embodiment of the present invention to provide a microorganism lacking the ability to transport glucosamine into the cell. For example, a ~~manXYZ~~ mutant (i.e., an *Escherichia coli* lacking or having a mutation in the genes encoding EIIM,P/III^{Man} of the PEP:mannose PTS) can not transport glucosamine into the cell by this mechanism. The PEP:glucose PTS of *Escherichia coli*, on the other hand, is capable of transporting both glucose and glucosamine into the cell, but glucosamine cannot induce this system. Thus, in order to grow a *manXYZ* mutant on glucosamine, the cells must first be grown on glucose to induce expression of the (alternate) glucose transport system and allow glucose (the preferred carbon source) to be transported into the cell. These induced cells are then capable of transporting glucosamine into the cell via the glucose transporter. A similar situation exists for transport of glucosamine by the

PEP:fructose PTS, although in this case glucosamine transport by the enzyme Π^{Fr} is poor. Methods to inhibit these secondary glucosamine transport pathways are discussed below. It is yet another embodiment of the present invention to provide a microorganism having a decreased function in the PEP:glucose PTS (described above). Such a modification may be necessary to avoid "reabsorption of glucosamine from the culture medium. For example, a *ptsG* mutant (i.e., an *Escherichia coli* lacking or having a mutation in the genes encoding enzyme Π^{Glc} of the PEP:glucose PTS). Since such microorganisms will have reduced ability to grow using glucose as a carbon source, such organisms can be further genetically modified to take up glucose by a PEP:glucose PTS-independent mechanism. It has been shown, for example, that mutant microorganisms can be selected which are defective in the PEP:glucose PTS and still have an ability to grow on glucose (Flores et al., 1996, *Nature Biotechnology* 14:620-623).

DNA sequencing of the *nag* regulon in *Escherichia coli* reveals that the *nagE* gene, encoding the *N*-acetyl-glucosamine-specific enzyme Π^{Nag} protein of the PEP:sugar phosphotransferase (PTS) system, which is involved in glucosamine transport into the cell, resides on one arm of the regulon and is transcribed divergently from the other *nag* genes (*nagBACD*) located on the other arm of the regulon. Therefore, another genetic modification that would result in decreased ability of an *Escherichia coli* to transport glucosamine into the cell is an inactivation or deletion of the *nagE* gene, or a gene encoding a similar enzyme in any microorganism used in a method of the present invention.

As discussed above, in one embodiment of the present invention, a genetically modified *Escherichia coli* microorganism useful in a method of the present invention has a deletion of the entire *nag* regulon. Deletion of the entire chromosomal *nag* regulon is preferred, because many genes which are deleterious to the production of glucosamine-6-phosphate are inactivated together. The genes, *nagA*, *nagB* and *nagE*, have been discussed in detail above. The *nagC* gene encodes a regulatory protein that acts as a repressor of the *nag* regulon as well as both an activator and repressor of the *glmUS* operon. The *glm* genes are discussed in detail above. The function of the *nagD* gene is not known, but is believed to be related to amino sugar metabolism as it resides within the

nag regulon. Thus, in *Escherichia coli*, a complete deletion of the *nag* regulon avoids catabolism of the initial intracellular product (glucosamine-6-phosphate) in a strain of *Escherichia coli* designed to overproduce glucosamine. A preferred *Escherichia coli* mutant strain having a deletion of the *nag* regulon is an *Escherichia coli* having a Δ *nagEBACD*::*tc* deletion/insertion.

With regard to activation of the *glmUS* operon (a function of *nagC*), although activation of the *glmS* gene, encoding glucosamine-6-phosphate synthase, is desirable, an increase in the level of the *glmU* gene product, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridyltransferase could be deleterious to accumulation of glucosamine-6-phosphate as it could lead to siphoning off of carbon flow toward cell envelope components. It is therefore an embodiment of the present invention to inactivate glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridyltransferase in a microorganism useful in a method of the present invention. In a microorganism in which the *glmUS* operon, or its equivalent, has been inactivated or deleted, it is a further embodiment of the present invention to genetically modify the microorganism by recombinantly producing the gene encoding glucosamine-6-phosphate synthase under control of an artificial promoter in the microorganism.

The initial intracellular product in the genetically modified microorganism described herein is glucosamine-6-phosphate. In many microorganisms, including *Escherichia coli*, glucosamine-6-phosphate is typically dephosphorylated to glucosamine prior to transport out of the cell. Nonetheless, it is yet another embodiment of the present invention to provide a microorganism which is genetically modified to have a suitable phosphatase activity for the conversion of glucosamine-6-phosphate to glucosamine. Such a phosphatase can include, but is not limited to, for example, alkaline phosphatase. In a preferred embodiment, such an *Escherichia coli* has an enhanced (i.e., increased) level of phosphatase activity (i.e., phosphatase action).

As noted above, in the method for production of glucosamine of the present invention, a microorganism having a genetically modified amino sugar metabolic pathway is cultured in a fermentation medium for production of glucosamine. An appropriate, or effective, fermentation medium refers to any medium in which a genetically modified microorganism of the present invention, when cultured, is capable of producing

glucosamine. Such a medium is typically an aqueous medium comprising assimilable carbon, nitrogen and phosphate sources. Such a medium can also include appropriate salts, minerals, metals and other nutrients. One advantage of the genetic modifications to a microorganism described herein is that although such genetic modifications significantly alter the metabolism of amino sugars, they do not create any nutritional requirements for the production organism. Thus, a minimal-salts medium containing glucose as the sole carbon source is preferably used as the fermentation medium. The use of a minimal-salts-glucose medium for the glucosamine fermentation will also facilitate recovery and purification of the glucosamine product.

Microorganisms of the present invention can be cultured in conventional fermentation bioreactors. The microorganisms can be cultured by any fermentation process which includes, but is not limited to, batch, fed-batch, cell recycle, and continuous fermentation. Preferably, microorganisms of the present invention are grown by batch or fed-batch fermentation processes.

In one embodiment of the present invention, before inoculation, the fermentation medium is brought up to the desired temperature, typically from about 20°C to about 40°C, preferably from about 25°C to about 40°C, with temperatures of from about 28°C to about 37°C, and in some embodiments, about 30°C or about 37°C being more preferred. The present inventors have discovered that glucosamine production in microorganisms of the present invention transfected with a nucleic acid molecule under control of the T7-*lac* promoter (see Examples section) continues after growth has ceased when the microorganisms are cultured at 30°C, while at 37°C, growth and glucosamine production occur in concert. Growth at 37°C is slightly better than at 30°C, but glucosamine production at 30°C is significantly better than at 37°C. It is noted that the optimum temperature for growth and glucosamine production by a microorganism of the present invention can vary according to a variety of factors. For example, the selection of a particular promoter for expression of a recombinant nucleic acid molecule in the microorganism can affect the optimum culture temperature. One of ordinary skill in the art can readily determine the optimum growth and glucosamine production temperature for any microorganism of the present invention using standard techniques, such as those described in the Examples section for one microorganism of the present invention.

The medium is inoculated with an actively growing culture of the genetically modified microorganism in an amount sufficient to produce, after a reasonable growth period, a high cell density. The cells are grown to a cell density of at least about 10 g/l, preferably between about 10 g/l and about 40 g/l, and more preferably at least about 40 g/l. This process typically requires about 10-60 hours.

Sufficient oxygen must be added to the medium during the course of the fermentation to maintain cell growth during the initial cell growth and to maintain metabolism and glucosamine production. Oxygen is conveniently provided by agitation and aeration of the medium. Conventional methods, such as stirring or shaking, may be used to agitate and aerate the medium. Preferably the oxygen concentration in the medium is greater than about 15% of the saturation value (i.e., the solubility of oxygen in the medium at atmospheric pressure and about 30-40°C) and more preferably greater than about 20% of the saturation value, although excursions to lower concentrations may occur if fermentation is not adversely affected. The oxygen concentration of the medium can be monitored by conventional methods, such as with an oxygen electrode. Other sources of oxygen, such as undiluted oxygen gas and oxygen gas diluted with inert gas other than nitrogen, can be used.

Since the production of glucosamine by fermentation is preferably based on using glucose as the sole carbon source, in a preferred embodiment, in *Escherichia coli*, the PEP:glucose PTS will be induced. Accordingly, even in the absence of a functional EIIM,P/III^{Man} of the PEP:mannose PTS (e.g., in an *Escherichia coli* having a *manXYZ* mutation), the product, glucosamine, will still be taken up by the cells via the induced glucose transport system. In the presence of excess glucose, however, uptake of glucosamine is severely repressed. Thus, it is one embodiment of the present invention to prevent uptake of the glucosamine product by maintaining an excess of glucose in the fermentation bioreactor. As used herein, "an excess" of glucose refers to an amount of glucose above that which is required to maintain the growth of the microorganism under normal conditions, such as the culturing conditions described above. Preferably, the glucose concentration is maintained at a concentration of from about 0.5% to about 5% weight/volume of the fermentation medium. In another embodiment, the glucose concentration is maintained at a concentration of from about 5 g/L to about 50 g/L of the

fermentation medium, and even more preferably, from about 5 g/L to about 20 g/L of the fermentation medium. In one embodiment, the glucose concentration of the fermentation medium is monitored by any suitable method (e.g., by using glucose test strips), and when the glucose concentration is at or near depletion, additional glucose can be added to the medium. In another embodiment, the glucose concentration is maintained by semi-continuous or continuous feeding of the fermentation medium. The parameters disclosed herein for glucose can be applied to any carbon source used in the fermentation medium of the present invention. It is further understood that the carbon source can be allowed to reach undetectable levels for any appropriate amount of time during the fermentation if it enhances the glucosamine production process.

It is a further embodiment of the present invention to supplement and/or control other components and parameters of the fermentation medium, as necessary to maintain and/or enhance the production of glucosamine by a production organism. For example, in one embodiment, the fermentation medium includes ammonium sulfate, and the ammonium sulfate concentration in the culture medium is supplemented by the addition of excess ammonium sulfate. Preferably, the amount of ammonium sulfate is maintained at a level of from about 0.1% to about 1% (weight/volume) in the fermentation medium, and preferably, at about 0.5%. In yet another embodiment, the pH of the fermentation medium is monitored for fluctuations in pH. In the fermentation method of the present invention, the pH is preferably maintained at a pH of from about pH 6.0 to about pH 8.0, and more preferably, at about pH 7.0. In the method of the present invention, if the starting pH of the fermentation medium is pH 7.0, the pH of the fermentation medium is monitored for significant variations from pH 7.0, and is adjusted accordingly, for example, by the addition of sodium hydroxide.

A further embodiment of the present invention is to redirect carbon flux from acetate production to the production of less toxic byproducts. By such methods, problems of toxicity associated with an excess of glucose in the fermentation medium can be avoided. Methods to redirect carbon flux from acetate production are known in the art.

In a batch fermentation process of the present invention, fermentation is continued until the formation of glucosamine, as evidenced by the accumulation of extracellular

glucosamine, essentially ceases. The total fermentation time is typically from about 40 to about 60 hours, and more preferably, about 48 hours. In a continuous fermentation process, glucosamine can be removed from the bioreactor as it accumulates in the medium. The method of the present invention results in production of a product which
5 can include intracellular or extracellular glucosamine-6-phosphate and intracellular or extracellular glucosamine.

The method of the present invention further includes recovering the product, which can be intracellular glucosamine-6-phosphate or extracellular glucosamine. The phrase "recovering glucosamine" refers simply to collecting the product from the
10 fermentation bioreactor and need not imply additional steps of separation or purification. For example, the step of recovering can refer to removing the entire culture (i.e., the microorganism and the fermentation medium) from the bioreactor, removing the fermentation medium containing extracellular glucosamine from the bioreactor, and/or removing the microorganism containing intracellular glucosamine-6-phosphate from the
15 bioreactor. These steps can be followed by further purification steps. Glucosamine is preferably recovered in substantially pure form. As used herein, "substantially pure" refers to a purity that allows for the effective use of the glucosamine as a nutraceutical compound for commercial sale. In one embodiment, the glucosamine product is preferably separated from the production organism and other fermentation medium constituents. Methods to
20 accomplish such separation are described below.

Preferably, by the method of the present invention, at least about 1 g/L of product (i.e., glucosamine and/or glucosamine-6-phosphate) are recovered from the
microorganism and/or fermentation medium. More preferably, by the method of the present invention, at least about 5 g/L, and even more preferably, at least about 10 g/L,
25 and even more preferably, at least about 20 g/L and even more preferably, at least about 50 g/L of product are recovered. In one embodiment, glucosamine product is recovered in an amount from about 1 g/L to about 50 g/L.

Typically, most of the glucosamine produced in the present process is extracellular. The microorganism can be removed from the fermentation medium by conventional
30 methods, such as by filtration or centrifugation. In one embodiment, the step of recovering the product includes the purification of glucosamine from the fermentation

medium. Glucosamine can be recovered from the cell-free fermentation medium by conventional methods, such as chromatography, extraction, crystallization (e.g., evaporative crystallization), membrane separation, reverse osmosis and distillation. In a preferred embodiment, glucosamine is recovered from the cell-free fermentation medium by crystallization. In another embodiment, the step of recovering the product includes the step of concentrating the extracellular glucosamine.

In one embodiment, glucosamine-6-phosphate accumulates intracellularly, the step of recovering the product includes isolating glucosamine-6-phosphate from the microorganism. For example, the product can be recovered by lysing the microorganism cells by a method which does not degrade the glucosamine product, centrifuging the lysate to remove insoluble cellular debris, and then recovering the glucosamine and/or glucosamine-6-phosphate product by a conventional method as described above.

The initial intracellular product in the genetically modified microorganism described herein is glucosamine-6-phosphate. It is generally accepted that phosphorylated intermediates are dephosphorylated during export from the microorganism, most likely due to the presence of alkaline phosphatase in the periplasmic space of the microorganism. In one embodiment of the present invention, glucosamine-6-phosphate is dephosphorylated before or during export from the cell by naturally occurring phosphatases in order to facilitate the production of the desired product, glucosamine. In this embodiment, the need for amplification of a recombinantly provided phosphatase activity in the cell or treatment of the fermentation medium with a phosphatase is obviated. In another embodiment, the level of phosphatase in the production organism is increased by a method including, but not limited to, genetic modification of an endogenous phosphatase gene or by recombinant modification of the microorganism to express a phosphatase gene. In yet another embodiment, the recovered fermentation medium is treated with a phosphatase after glucosamine-6-phosphate is released into the medium, such as when cells are lysed as described above.

As noted above, the process of the present invention produces significant amounts of extracellular glucosamine. In particular, the process produces extracellular glucosamine such that greater than about 50% of total glucosamine is extracellular, more preferably greater than about 75% of total glucosamine is extracellular, and most preferably greater

than about 90% of total glucosamine is extracellular. By the method of the present invention, production of an extracellular glucosamine concentration can be achieved which is greater than about 1 g/l, more preferably greater than about 5 g/l, even more preferably greater than about 10 g/l, and even more preferably greater than about 20 g/L and even more preferably greater than about 50 g/l.

One embodiment of the present invention relates to a method to produce glucosamine by fermentation which includes the steps of (a) culturing an *Escherichia coli* having a genetically modified amino sugar metabolic pathway in a fermentation medium comprising assimilable sources of carbon, nitrogen and phosphate to produce a product, and (b) recovering the product. The product includes intracellular glucosamine-6-phosphate which is recovered from the *Escherichia coli* and/or extracellular glucosamine which is recovered from the fermentation medium.

One embodiment of the present invention relates to a microorganism for producing glucosamine by a biosynthetic process. The microorganism is transformed with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase operatively linked to a transcription control sequence. The recombinant nucleic acid molecule has a genetic modification which reduces glucosamine-6-phosphate product inhibition of the glucosamine-6-phosphate synthase. Expression of the recombinant nucleic acid molecule increases expression of the glucosamine-6-phosphate synthase by the microorganism. In a preferred embodiment, the recombinant nucleic acid molecule is integrated into the genome of the microorganism. In a further embodiment, the microorganism has at least one additional genetic modification in a gene encoding a protein selected from the group of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme Π^{Nag} , phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridyltransferase, phosphofructokinase, Enzyme Π^{Glc} of the PEP:glucose PTS, EIIM,P/III^{Man} of the PEP:mannose PTS, and/or a phosphatase. The genetic modification decreases the action of the protein, except in the case of the phosphatase, in which the action of the phosphatase is preferably increased. In another preferred embodiment, the microorganism has a modification in genes encoding *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase and *N*-

acetyl-glucosamine-specific enzyme Π^{Nag} , wherein the genetic modification decreases action of the protein. In one embodiment, the genetic modification is a deletion of at least a portion of the genes.

5 In a preferred embodiment, the genetically modified microorganism is a bacterium or a yeast, and more preferably, a bacterium of the genus *Escherichia*, and even more preferably, *Escherichia coli*. A genetically modified *Escherichia coli* preferably has a modification in a gene which includes, but is not limited to, *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, *manXYZ*, *glmM*, *pfkB*, *pfkA*, *glmU*, *glmS*, *ptsG* or a phosphatase gene. In another embodiment, such a genetically modified *Escherichia coli* has a deletion of *nag* regulon
10 genes, and in yet another embodiment, a deletion of *nag* regulon genes and a genetic modification in *manXYZ* genes such that the proteins encoded by the *manXYZ* genes have decreased action.

Yet another embodiment of the present invention relates to a microorganism for producing glucosamine by a biosynthetic process which has a recombinant nucleic acid
15 molecule encoding glucosamine-6-phosphate synthase operatively linked to a transcription control sequence; and at least one genetic modification in a gene encoding a protein selected from the group of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme Π^{Nag} , phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate
20 uridyltransferase, phosphofructokinase, Enzyme Π^{Glc} of the PEP:glucose PTS, and/or EIIM,P/III^{Man} of the PEP:mannose PTS. The genetic modification decreases action of said protein and expression of the recombinant nucleic acid molecule increases expression
of the glucosamine-6-phosphate synthase by the microorganism. In another embodiment, the microorganism has at least one genetic modification in a phosphatase gene, such that
25 the phosphatase encoded by such gene has increased action. In a preferred embodiment, the recombinant nucleic acid molecule is integrated into the genome of the microorganism.

Another embodiment of the present invention relates to any of the above-described microorganisms which produces at least about 1 g/L of glucosamine when cultured for about 24 hours at 37°C to a cell density of at least about 8 g/L by dry cell weight, in a pH
30 7.0 fermentation medium comprising: 14 g/L K_2HPO_4 , 16 g/L KH_2PO_4 , 1 g/L

Na₃Citrate·2H₂O, 5 g/L (NH₄)₂SO₄, 20 g/L glucose, 10 mM MgSO₄, 1 mM CaCl₂, and 1 mM IPTG.

A more preferred embodiment of the present invention relates to any of the above-described microorganisms which produces at least about 1 g/L of glucosamine when
5 cultured for about 10 to about 60 hours at from about 28°C to about 37°C to a cell density of at least about 8 g/L by dry cell weight, in a pH 7.0 fermentation medium comprising: 14 g/L K₂HPO₄, 16 g/L KH₂PO₄, 1 g/L Na₃Citrate·2H₂O, 5 g/L (NH₄)₂SO₄, 20 g/L glucose, 10 mM MgSO₄, 1 mM CaCl₂, and from about 0.2mM to about 1 mM IPTG. In a preferred embodiment, the amount of IPTG is about 0.2mM.

10 Yet another embodiment of the present invention relates to any of the above-described genetically modified microorganisms which produce at least about 1 g/L, and preferably at least about 5 g/L, and more preferably, at least about 10 g/L, and even more preferably, at least about 20 g/L, and even more preferably, at least about 50 g/L of glucosamine and/or glucosamine-6-phosphate when cultured under the culture conditions
15 as described herein. Another embodiment of the present invention relates to any of the above-described genetically modified microorganisms which produce at least about 2-fold more glucosamine and/or glucosamine-6-phosphate, and preferably at least about 5-fold, and more preferably at least about 10-fold, and more preferably at least about 25-fold, and more preferably at least about 50-fold, and even more preferably at least about 100-fold,
20 and even more preferably, at least about 200-fold more glucosamine and/or glucosamine-6-phosphate synthase than a wild-type (i.e., non-modified, naturally occurring) microorganism cultured under the same conditions as the genetically modified microorganism.

A number of specific microorganisms are identified in the Examples section. Additional embodiments of the present invention include these microorganisms
25 and microorganisms having the identifying characteristics of the microorganisms specifically identified in the Examples. Such microorganisms are preferably yeast or bacteria, more preferably, are bacteria, and most preferably are *E. coli*. Such identifying characteristics can include any or all genotypic and/or phenotypic characteristics of the microorganisms in the Examples, including their abilities to produce glucosamine.

30 Preferred microorganisms of the present invention include strains of *Escherichia coli* which have been transformed with a recombinant nucleic acid molecule encoding

glucosamine-6-phosphate synthase. Preferably, such a nucleic acid molecule is integrated into the genome of the microorganism. A particularly preferred microorganism is *Escherichia coli* strain 2123-12. Strain 2123-12 has integrated into its genome a recombinant nucleic acid molecule comprising a nucleic acid sequence SEQ ID NO:15, which represents the coding region of a wild-type (i.e., normal, unmodified, or naturally occurring) glucosamine-6-phosphate synthase enzyme having amino acid sequence SEQ ID NO:16. Particularly preferred microorganisms of the present invention have been transformed with a nucleic acid molecule comprising a nucleic acid sequence encoding a glucosamine-6-phosphate synthase that has been genetically modified such that the synthase has increased action (described above). Most preferably, such genetic modification enhances the ability of the microorganism to produce glucosamine as compared to a microorganism which has not been transformed with such a nucleic acid molecule. Particularly preferred genetically modified microorganisms of the present invention are described in the Examples section, and include *E. coli* strains 2123-49, 2123-54, 2123-124, 2123-149 and 2123-151.

Development of a microorganism with enhanced ability to produce glucosamine by genetic modification can be accomplished using both classical strain development and molecular genetic techniques. In general, the strategy for creating a microorganism with enhanced glucosamine production is to (1) inactivate or delete at least one, and preferably more than one of the amino sugar metabolic pathways in which production of glucosamine-6-phosphate is negatively affected (e.g., inhibited), and (2) amplify at least one, and preferably more than one of the amino sugar metabolic pathways in which glucosamine-6-phosphate production is enhanced. As such, genetically modified microorganisms of the present invention have a (a) reduced ability to convert glucosamine-6-phosphate into other compounds (i.e., inhibition of glucosamine-6-phosphate catabolic or anabolic pathways), (b) an enhanced ability to produce (i.e., synthesize) glucosamine-6-phosphate, (c) a reduced ability to transport glucosamine into the cell, (d) an enhanced ability to transport glucosamine-6-phosphate or glucosamine out of the cell, and/or (e) a reduced ability to use substrates involved in the production of glucosamine-6-P for competing biochemical reactions.

As previously discussed herein, in one embodiment, a genetically modified microorganism can be a microorganism in which nucleic acid molecules have been deleted, inserted or modified, such as by insertion, deletion, substitution, and/or inversion of nucleotides, in such a manner that such modifications provide the desired effect within the microorganism. Such genetic modifications can, in some embodiments, be within the coding region for a protein encoded by the nucleic acid molecule which results in amino acid modifications such as insertions, deletions, substitutions in the amino acid sequence of the protein which provide the desired effect within the microorganisms. A genetically modified microorganism can be modified by recombinant technology, such as by introduction of an isolated nucleic acid molecule into a microorganism. For example, a genetically modified microorganism can be transfected with a recombinant nucleic acid molecule encoding a protein of interest, such as a protein for which increased expression is desired. The transfected nucleic acid molecule can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transfected (i.e., recombinant) host cell in such a manner that its ability to be expressed is retained. Preferably, once a host cell of the present invention is transfected with a nucleic acid molecule, the nucleic acid molecule is integrated into the host cell genome. A significant advantage of integration is that the nucleic acid molecule is stably maintained in the cell. In a preferred embodiment, the integrated nucleic acid molecule is operatively linked to a transcription control sequence (described below) which can be induced to control expression of the nucleic acid molecule.

A nucleic acid molecule can be integrated into the genome of the host cell either by random or targeted integration. Such methods of integration are known in the art. For example, as described in detail in Example 2, *E. coli* strain ATCC 47002 (Table 1) contains mutations that confer upon it an inability to maintain plasmids which contain a ColE1 origin of replication. When such plasmids are transferred to this strain, selection for genetic markers contained on the plasmid results in integration of the plasmid into the chromosome. This strain can be transformed, for example, with plasmids containing the gene of interest and a selectable marker flanked by the 5'- and 3'-termini of the *E. coli lacZ* gene. The *lacZ* sequences target the incoming DNA to the *lacZ* gene contained in the chromosome. Integration at the *lacZ* locus replaces the intact *lacZ* gene, which

encodes the enzyme β -galactosidase, with a partial *lacZ* gene interrupted by the gene of interest. Successful integrants can be selected for β -galactosidase negativity. A genetically modified microorganism can also be produced by introducing nucleic acid molecules into a recipient cell genome by a method such as by using a transducing bacteriophage. The use of recombinant technology and transducing bacteriophage technology to produce several different genetically modified microorganism of the present invention is known in the art and is described in detail in the Examples section.

According to the present invention, a gene, for example the *pstG* gene, includes all nucleic acid sequences related to a natural *pstG* gene such as regulatory regions that control production of the *pstG* protein (Enzyme II^{Glc} of the PEP:glucose PTS) encoded by that gene (such as, but not limited to, transcription, translation or post-translation control regions) as well as the coding region itself. In another embodiment, a gene, for example the *pstG* gene, can be an allelic variant (i.e., a naturally occurring allelic variant) that includes a similar but not identical sequence to the nucleic acid sequence encoding a given *pstG* gene. An allelic variant of a *pstG* gene which has a given nucleic acid sequence is a gene that occurs at essentially the same locus (or loci) in the genome as the gene having the given nucleic acid sequence, but which, due to natural variations caused by, for example, mutation or recombination, has a similar but not identical sequence. Allelic variants typically encode proteins having similar activity to that of the protein encoded by the gene to which they are being compared. Allelic variants can also comprise alterations in the 5' or 3' untranslated regions of the gene (e.g., in regulatory control regions). Allelic variants are well known to those skilled in the art and would be expected to be found within a given microorganism, such as an *E. coli*, and/or among a group of two or more microorganisms.

Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a gene involved in an amino sugar metabolic pathway. In addition, the phrase "recombinant molecule" primarily refers to a nucleic acid molecule operatively

linked to a transcription control sequence, but can be used interchangeably with the phrase "nucleic acid molecule" which is isolated and expressed in a host cell.

Knowing the nucleic acid sequences of certain nucleic acid molecules of the present invention, and particularly *Escherichia coli* nucleic acid molecules, allows one skilled in the art to, for example, (a) make copies of those nucleic acid molecules and/or (b) obtain nucleic acid molecules including at least a portion of such nucleic acid molecules (e.g., nucleic acid molecules including full-length genes, full-length coding regions, regulatory control sequences, truncated coding regions). Such nucleic acid molecules can be obtained in a variety of ways including traditional cloning techniques using oligonucleotide probes of to screen appropriate libraries or DNA and PCR amplification of appropriate libraries or DNA using oligonucleotide primers. Preferred libraries to screen or from which to amplify nucleic acid molecule include bacterial and yeast genomic DNA libraries, and in particular, *Escherichia coli* genomic DNA libraries. Techniques to clone and amplify genes are disclosed, for example, in Sambrook et al., *ibid.*

In accordance with the present invention, an isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation). As such, "isolated" does not reflect the extent to which the nucleic acid molecule has been purified. An isolated nucleic acid molecule can include DNA, RNA, or derivatives of either DNA or RNA. There is no limit, other than a practical limit, on the maximal size of a nucleic acid molecule in that the nucleic acid molecule can include a portion of a gene, an entire gene, or multiple genes, or portions thereof.

An isolated nucleic acid molecule of the present invention can be obtained from its natural source either as an entire (i.e., complete) gene or a portion thereof capable of forming a stable hybrid with that gene. An isolated nucleic acid molecule can also be produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Isolated nucleic acid molecules include natural nucleic acid molecules and homologues thereof, including, but not limited to, natural allelic variants and modified nucleic acid molecules in which nucleotides have been

inserted, deleted, substituted, and/or inverted in such a manner that such modifications provide the desired effect within the microorganism.

A nucleic acid molecule homologue can be produced using a number of methods known to those skilled in the art (see, for example, Sambrook et al., *ibid.*). For example, nucleic acid molecules can be modified using a variety of techniques including, but not limited to, classic mutagenesis techniques and recombinant DNA techniques, such as site-directed mutagenesis, chemical treatment of a nucleic acid molecule to induce mutations, restriction enzyme cleavage of a nucleic acid fragment, ligation of nucleic acid fragments, PCR amplification and/or mutagenesis of selected regions of a nucleic acid sequence, synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid molecules and combinations thereof. Nucleic acid molecule homologues can be selected from a mixture of modified nucleic acids by screening for the function of the protein encoded by the nucleic acid and/or by hybridization with a wild-type gene. Examples of such techniques are described in detail in the Examples section.

In one embodiment of the present invention, a nucleic acid homologue of a nucleic acid molecule of the present invention preferably comprises a genetic modification which results in an modification of the action of the protein encoded by the nucleic acid homologue. For example, in one embodiment of the present invention, a genetically modified recombinant nucleic acid molecule is provided which comprises a nucleic acid sequence encoding a glucosamine-6-phosphate synthase protein homologue, wherein the genetic modification increases the action of the glucosamine-6-phosphate synthase homologue, preferably as compared to a recombinant nucleic acid molecule encoding a naturally occurring glucosamine-6-phosphate synthase in the absence of such genetic modification. Such a genetic modification can increase the action of the glucosamine-6-phosphate synthase, for example, by encoding a glucosamine-6-phosphate synthase having reduced glucosamine-6-phosphate product inhibition and/or increased specific activity. Such recombinant nucleic acid molecules having genetic modifications are referred to herein as nucleic acid homologues of wild-type nucleic acid molecules encoding glucosamine-6-phosphate synthase. According to the present invention, proteins having modifications as a result of genetic modifications in the nucleic acid molecules encoding

the proteins are referred to herein as protein homologues, or homologues of the given protein.

Accordingly, a glucosamine-6-phosphate synthase protein, for example, which has glucosamine-6-phosphate synthase activity and is useful in the present invention, can be a full-length glucosamine-6-phosphate synthase protein, an enzymatically active portion of a full-length glucosamine-6-phosphate synthase protein, or any homologue of such proteins, such as a glucosamine-6-phosphate synthase protein having at least one or a few amino acid modifications in which amino acid residues have been deleted (e.g., a truncated version of the protein, such as a peptide), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition of glycosylphosphatidyl inositol).

A protein homologue of any of the proteins within the amino sugar metabolic pathways as described in the present invention is a protein having an amino acid sequence that is sufficiently similar to a natural protein amino acid sequence (i.e., naturally occurring, unmodified, or wild-type) that a nucleic acid sequence encoding the homologue is capable of hybridizing under stringent conditions to (i.e., with) a nucleic acid molecule encoding the natural protein (i.e., to the complement of the nucleic acid strand encoding the natural protein amino acid sequence). A nucleic acid sequence complement of any nucleic acid sequence of the present invention refers to the nucleic acid sequence of the nucleic acid strand that is complementary to (i.e., can form a double helix with the entire molecule) the strand for which the sequence is cited. It is to be noted that a double-stranded nucleic acid molecule of the present invention for which a nucleic acid sequence has been determined for one strand that is represented by a SEQ ID NO also comprises a complementary strand having a sequence that is a complement of that SEQ ID NO. As such, nucleic acid molecules of the present invention, which can be either double-stranded or single-stranded, include those nucleic acid molecules that form stable hybrids under stringent hybridization conditions with either a given SEQ ID NO denoted herein and/or with the complement of that SEQ ID NO, which may or may not be denoted herein. Methods to deduce a complementary sequence are known to those skilled in the art.

The minimal size of a protein homologue of the present invention is a size sufficient to be encoded by a nucleic acid molecule capable of forming a stable hybrid with

the complementary sequence of a nucleic acid molecule encoding the corresponding natural protein. Additionally, the minimal size of a protein homologue of the present invention is a size sufficient to have glucosamine-6-phosphate synthase action (e.g., a catalytically or enzymatically active portion), and preferably, increased glucosamine-6-phosphate synthase action. As such, the size of the nucleic acid molecule encoding such a protein homologue is dependent on nucleic acid composition and percent homology between the nucleic acid molecule and complementary sequence as well as upon hybridization conditions per se (e.g., temperature, salt concentration, and formamide concentration). There is no limit, other than a practical limit, on the maximal size of such a nucleic acid molecule in that the nucleic acid molecule can include a portion of a gene, an entire gene, or multiple genes, or portions thereof. Similarly, the minimal size of a protein homologue of the present invention is from about 4 to about 6 amino acids in length, with preferred sizes depending on whether a full-length, multivalent (i.e., fusion protein having more than one domain each of which has a function), or functional portions of such proteins are desired.

As used herein, stringent hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules are used to identify similar nucleic acid molecules. Such standard conditions are disclosed, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press, 1989. Sambrook et al., *ibid.*, is incorporated by reference herein in its entirety (see specifically, pages 9.31-9.62, 11.7 and 11.45-11.61). In addition, formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting varying degrees of mismatch of nucleotides are disclosed, for example, in Meinkoth et al., 1984, *Anal. Biochem.* 138, 267-284; Meinkoth et al., *ibid.*, is incorporated by reference herein in its entirety.

More particularly, stringent hybridization conditions, as referred to herein, refer to conditions which permit isolation of nucleic acid molecules having at least about 70% nucleic acid sequence identity with the nucleic acid molecule being used to probe in the hybridization reaction, more particularly at least about 75%, and most particularly at least about 80%. Such conditions will vary, depending on whether DNA:RNA or DNA:DNA hybrids are being formed. Calculated melting temperatures for DNA:DNA hybrids are

10°C less than for DNA:RNA hybrids. In particular embodiments, stringent hybridization conditions for DNA:DNA hybrids include hybridization at an ionic strength of 0.1X SSC (0.157 M Na⁺) at a temperature of between about 20°C and about 35°C, more preferably, between about 28°C and about 40°C, and even more preferably, between about 35°C and about 45°C. In particular embodiments, stringent hybridization conditions for DNA:RNA hybrids include hybridization at an ionic strength of 0.1X SSC (0.157 M Na⁺) at a temperature of between about 30°C and about 45°C, more preferably, between about 38°C and about 50°C, and even more preferably, between about 45°C and about 55°C. These values are based on calculations of a melting temperature for molecules larger than about 100 nucleotides, 0% formamide and a G + C content of about 50%. Alternatively, T_m can be calculated empirically as set forth in Sambrook et al., *supra*, pages 11.55 to 11.57.

Protein homologues of proteins involved in an amino sugar metabolic pathway according to the present invention can be the result of natural allelic variation or natural mutation. Protein homologues of the present invention can also be produced using techniques known in the art including, but not limited to, direct modifications to the protein or modifications to the gene encoding the protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis, as discussed above.

In one embodiment of the present invention, a genetic modification in a recombinant nucleic acid molecule of the present invention which encodes a glucosamine-6-phosphate synthase results in at least one amino acid modification (i.e., modification in the amino acid sequence of the encoded protein) selected from the group of an addition, substitution, deletion, and/or derivatization of an amino acid residue of the glucosamine-6-phosphate synthase. Such a modification in the amino acid sequence of the encoded protein can be determined as compared to a wild-type, or naturally occurring glucosamine-6-phosphate synthase, such as a glucosamine-6-phosphate synthase having an amino acid sequence SEQ ID NO:16. One or more of such amino acid modifications results in increased action of glucosamine-6-phosphate synthase as compared to the naturally occurring glucosamine-6-phosphate synthase having amino acid sequence SEQ ID NO:16. In one embodiment, such an amino acid modification is in an amino acid

sequence position in the modified protein (i.e., homologue) which corresponds to one or more of the following amino acid positions in amino acid sequence SEQ ID NO:16: Ile(4), Ile(272), Ser(450), Ala(39), Arg(250), Gly(472), Leu(469).

In another embodiment, such an amino acid modification is selected from the group of a substitution of: (a) an amino acid residue having an aliphatic hydroxyl side group for Ile(4); (b) an amino acid residue having an aliphatic hydroxyl side group for Ile(272); (c) an amino acid residue having an aliphatic side group for Ser(450); (d) an amino acid residue having an aliphatic hydroxyl side group for Ala(39); (e) an amino acid residue having a sulfur-containing side group for Arg(250); (f) an amino acid residue having an aliphatic hydroxyl side group for Gly(472); (g) an amino acid residue having an aliphatic side group for Leu(469); and, (h) combinations of (a)-(g). According to the present invention, amino acid residues having an aliphatic hydroxyl group include serine and threonine, and amino acid residues having aliphatic side groups include glycine, alanine, valine, leucine, isoleucine and proline.

In yet another embodiment of the present invention, an amino acid modification as described above is preferably a substitution selected from the group of: Ile(4) to Thr, Ile(272) to Thr, Ser(450) to Pro, Ala(39) to Thr, Arg(250) to Cys, Gly(472) to Ser, Leu(469) to Pro, and combinations thereof. Specific examples of recombinant nucleic acid molecules having genetic modifications resulting in such amino acid modifications are described in detail in the Examples section.

Preferred genetically modified recombinant nucleic acid molecules comprising a nucleic acid sequence encoding a glucosamine-6-phosphate synthase having increased ~~action~~ include recombinant nucleic acid molecules comprising a nucleic acid sequence which encodes a glucosamine-6-phosphate synthase comprising an amino acid sequence selected from the group of SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:28 and/or SEQ ID NO:31. Other preferred genetically modified recombinant nucleic acid molecules comprise a nucleic acid sequence selected from the group of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29 and/or SEQ ID NO:30. Particularly preferred genetically modified recombinant nucleic acid molecules useful in the present invention include nucleic acid molecules comprising nucleic acid molecules

selected from the group of pKLN23-49, pKLN23-54, pKLN23-124, pKLN23-149, pKLN23-151, ngImS-49₂₁₈₄, ngImS-49₁₈₃₀, ngImS-54₂₁₈₄, ngImS-54₁₈₃₀, ngImS-124₂₁₈₄, ngImS-124₁₈₃₀, ngImS-149₂₁₈₄, ngImS-149₁₈₃₀, ngImS-151₂₁₈₄ and ngImS-151₁₈₃₀.

5 The present invention includes a recombinant vector, which includes at least one isolated nucleic acid molecule of the present invention, inserted into any vector capable of delivering the nucleic acid molecule into a bacterial cell. Such a vector can contain bacterial nucleic acid sequences that are not naturally found adjacent to the isolated nucleic acid molecules to be inserted into the vector. The vector can be either RNA or DNA and typically is a plasmid. Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulating of nucleic acid molecules. One type of recombinant vector, referred to herein as a recombinant nucleic acid molecule and described in more detail below, can be used in the expression of nucleic acid molecules. Preferred recombinant vectors are capable of replicating in a transformed bacterial or yeast cell, and in particular, in an *Escherichia coli* cell.

15 Transformation of a nucleic acid molecule into a cell can be accomplished by any method by which a nucleic acid molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation and microinjection.

Recombinant molecules of the present invention, which can be either DNA or RNA, can also contain additional regulatory sequences, such as translation regulatory sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell. One or more recombinant molecules of the present invention can be used to produce an encoded product (e.g., a glucosamine-6-phosphate synthase). In one embodiment, an encoded product is produced by expressing a nucleic acid molecule of the present invention under conditions effective to produce the protein. Such conditions (i.e., culture conditions) have been described above and are further discussed in the Examples section. A preferred method to produce an encoded protein is by transfecting a host cell with one or more recombinant molecules of the present invention to form a recombinant cell.

25 As discussed above, preferred recombinant molecules of the present invention include, ngImS-28₂₁₈₄, ngImS-28₁₈₃₀, ngImS-49₂₁₈₄, ngImS-49₁₈₃₀, ngImS-54₂₁₈₄, ngImS-54₁₈₃₀, ngImS-124₂₁₈₄, ngImS-124₁₈₃₀, ngImS-149₂₁₈₄, ngImS-149₁₈₃₀, ngImS-151₂₁₈₄, ngImS-

151₁₈₃₀, pKLN23-28, pKLN23-49, pKLN23-54, pKLN23-124, pKLN23-149 and/or pKLN23-151.

5 A recombinant cell is preferably produced by transforming a bacterial cell (i.e., a host cell) with one or more recombinant molecules, each comprising one or more nucleic acid molecules operatively linked to an expression vector containing one or more transcription control sequences. The phrase, operatively linked, refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. As used herein, an expression vector is a DNA or RNA vector that is capable of transforming a host cell and of effecting
10 expression of a specified nucleic acid molecule. Preferably, the expression vector is also capable of replicating within the host cell. In the present invention, expression vectors are typically plasmids. Expression vectors of the present invention include any vectors that function (i.e., direct gene expression) in a yeast host cell or a bacterial host cell, preferably an *Escherichia coli* host cell. Preferred recombinant cells of the present invention are set
15 forth in the Examples section.

Nucleic acid molecules of the present invention can be operatively linked to expression vectors containing regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression
20 of nucleic acid molecules of the present invention. In particular, recombinant molecules of the present invention include transcription control sequences. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor
25 sequences. Suitable transcription control sequences include any transcription control sequence that can function in yeast or bacterial cells and preferably, *Escherichia coli*. A variety of such transcription control sequences are known to those skilled in the art.

It may be appreciated by one skilled in the art that use of recombinant DNA technologies can improve expression of transformed nucleic acid molecules by
30 manipulating, for example, the number of copies of the nucleic acid molecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, the

efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications. Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, operatively linking nucleic acid molecules to high-copy number plasmids, integration of the nucleic acid molecules into the host cell chromosome, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals, modification of nucleic acid molecules of the present invention to correspond to the codon usage of the host cell, deletion of sequences that destabilize transcripts, and use of control signals that temporally separate recombinant cell growth from recombinant enzyme production during fermentation. The activity of an expressed recombinant protein of the present invention may be improved by fragmenting, modifying, or derivatizing nucleic acid molecules encoding such a protein. Such modifications are described in detail in the Examples section.

The following experimental results are provided for the purposes of illustration and are not intended to limit the scope of the invention.

EXAMPLES

Example 1

The following example describes the production of mutant *Escherichia coli* strains which are blocked in amino acid sugar metabolic pathways involving degradation of glucosamine.

The starting strain for the construction of all glucosamine overproducing strains described herein was *E. coli* W3110 (publicly available from the American Type Culture Collection as ATCC No. 25947), a prototrophic, F⁻ λ derivative of *E. coli* K-12 (Bachmann, 1987, "*Escherichia coli* and *Salmonella typhimurium*", Cellular and Molecular Biology, pp.1190-1219; incorporated herein by reference in its entirety). A list of all strains used and produced in the following examples is provided in Table 1.

Table 1. Bacterial strains.

Strain	Alias	Genotype	Source/Reference
W3110		F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ	ATCC
IBPC 522		<i>thi-1 argG6 argE3 his-4 mtl-1 xyl-5 rpsL tsx-29? ΔlacX74 manXYZ8 nagE47 ptsG22 zcf-229::Tn10</i>	J. Plumbridge
IBPC 566		<i>thi-1 argG6 argE3 his-4 mtl-1 xyl-5 rpsL tsx-29? ΔlacX74 manXYZ8 zdj-225::Tn10</i>	J. Plumbridge
IBPC 590		<i>thi-1 argG6 argE3 his-4 mtl-1 xyl-5 rpsL tsx-29? ΔlacX74 Δnag::TcR</i>	J. Plumbridge
7101-6	W3110 ptsM	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10</i>	W3110 x P1 _{vir} (IBPC566)
7101-7	W3110 ptsM	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10</i>	W3110 x P1 _{vir} (IBPC566)
7101-9	W3110 Δ nag	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>Δnag::TcR</i>	W3110 x P1 _{vir} (IBPC590)
7101-13	W3110 ptsM TcS	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10? TcS</i>	7101-6 selected on TCS medium
7101-14	W3110 ptsM TcS	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10? TcS</i>	7101-7 selected on TCS medium
7101-15	W3110 ptsM ptsG	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10? ptsG22 zcf-229::Tn10</i>	7101-14 x P1 _{vir} (IBPC522)
7101-17	W3110 ptsM Δ nag	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10? TcS Δnag::TcR</i>	7101-13 x P1 _{vir} (IBPC590)
7101-22	W3110 ptsM ptsG TcS	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10? ptsG22 zcf-229::Tn10? TcS</i>	7101-15 selected on TCS medium
2123-4	W3110 ptsM ptsG Δ nag	F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ <i>manXYZ8 zdj-225::Tn10? ptsG22 zcf-229::Tn10? TcS Δnag::TcR</i>	7101-22 x P1 _{vir} (IBPC590)
W3110(DE3)		F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ DE3	W3110 lysogenized with λ DE3
7101-9(DE3)		F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ DE3 <i>Δnag::TcR</i>	7101-9 lysogenized with λ DE3
7101-17(DE3)		F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ DE3 <i>manXYZ8 zdj-225::Tn10? TcS Δnag::TcR</i>	7101-17 lysogenized with λ DE3
2123-4(DE3)		F <i>mcrA mcrB</i> IN(<i>rrnD-rrnE</i>)1 λ DE3 <i>manXYZ8 zdj-225::Tn10? ptsG22 zcf-229::Tn10 TcS Δnag::TcR</i>	2123-4 lysogenized with λ DE3
BL21(DE3)		F <i>ompT hsdS_B gal dcm</i> λ DE3	Novagen, Inc.
ATCC 47002	JC7623	F <i>recB21 recC22 sbcB15 leu-6 ara-14 his-4</i> λ	ATCC
T-71		F <i>recB21 recC22 sbcB15 leu-6 ara-14 his-4</i> λ <i>lacZ::pT7-glmS-Cm8H7</i>	Integration of pT7-glmS-Cm into <i>lacZ</i> of ATCC47002 by transformation with pKLN23-28
T-81		F <i>recB21 recC22 sbcB15 leu-6 ara-14 his-4</i> λ <i>lacZ::pT7-glmS-Cm8H8</i>	Integration of pT7-glmS-Cm into <i>lacZ</i> of ATCC47002 by transformation with pKLN23-28
2123-5		W3110(DE3) <i>lacZ::pT7-glmS-Cm8H7</i>	W3110(DE3) x P1 _{vir} (T-71)

Strain	Alias	Genotype	Source/Reference
2123-6		W3110(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H8	W3110(DE3) x P1 _{vir} (T-81)
2123-7		W3110(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H7	W3110(DE3) x P1 _{vir} (T-71)
2123-8		W3110(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H8	W3110(DE3) x P1 _{vir} (T-81)
2123-9		7101-9(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H7	7101-9(DE3) x P1 _{vir} (T-71)
2123-10		7101-9(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H8	7101-9(DE3) x P1 _{vir} (T-81)
2123-11		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H7	7101-17(DE3) x P1 _{vir} (T-71)
2123-12		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H8	7101-17(DE3) x P1 _{vir} (T-81)
2123-13		2123-4(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H7	2123-4(DE3) x P1 _{vir} (T-71)
2123-14		2123-4(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> -Cm8H8	2123-4(DE3) x P1 _{vir} (T-81)
NovaBlue		<i>endA1 hsdR17 supE44 thi-1 recA1 gyrA96 relA1 lac</i> [F' <i>proA⁺B⁺ lac⁺ZΔM15::Tn10</i>]	Novagen
LE392		F' <i>e14⁺</i> (McrA ⁺) <i>hsdR514(rm⁺) supE44 supF58 lacY1 or Δlac(IZY)6 galK2 galT22 metB1 trpR55</i>	Lab collection
2123-16		LE392 <i>glmS13</i>	NG mutagenesis of LE392
2123-49		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS11C</i> -Cm8H8	Error-prone PCR with pKLN23-28; integration of mutant <i>glmS</i> into ATCC47002; transfer to 7101-17(DE3) by P1 transduction
2123-51		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS52B</i> -Cm8H8	Error-prone PCR with pKLN23-28; integration of mutant <i>glmS</i> into ATCC47002; transfer to 7101-17(DE3) by P1 transduction
2123-54		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS8A</i> -Cm8H8	Error-prone PCR with pKLN23-28; integration of mutant <i>glmS</i> into ATCC47002; transfer to 7101-17(DE3) by P1 transduction
2123-124		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS94A</i> -Cm8H8	Error-prone PCR with pKLN23-28; integration of mutant <i>glmS</i> into ATCC47002; transfer to 7101-17(DE3) by P1 transduction
2123-149		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS149</i> -Cm8H8	pKLN23-54 <i>EcoRI</i> - <i>HindIII</i> (1.0 kb) x pKLN23-28 <i>EcoRI</i> - <i>HindIII</i> (6.4 kb); integration of mutant <i>glmS</i> into ATCC47002; transfer to 7101-17(DE3) by P1 transduction

Strain	Alias	Genotype	Source/Reference
2123-151		7101-17(DE3) <i>lacZ</i> ::pT7- <i>glmS</i> 151- Cm8H8	pKLN23-54 <i>EcoRI</i> - <i>HindIII</i> (1.0 kb) x pKLN23-28 <i>EcoRI</i> - <i>HindIII</i> (6.4 kb); integration of mutant <i>glmS</i> into ATCC47002; transfer to 7101-17(DE3) by P1 transduction

Host strains blocked for glucosamine uptake and degradation were constructed by introducing mutations in the *nagE*, *manXYZ* and *ptsG* genes, which block transport of glucosamine, and the *nagA*, *-B*, *-C*, and *-D* genes, which are involved in metabolism of glucosamine-6-phosphate. Each of these genes has been described in detail previously herein. Mutations in these genes were introduced into strains using the transducing bacteriophage P1_{vir} (as described in Miller, 1972, "Experiments in Molecular Genetics", Cold Spring Harbor Laboratory, which is incorporated herein by reference in its entirety).

In this technique, genes or mutations from one strain (the donor strain) are transferred to a recipient strain using the bacteriophage P1_{vir}. When bacteriophage P1_{vir} is grown on the donor strain, a small portion of the phage particles that are produced contain chromosomal DNA from the donor rather than the normal complement of phage DNA. Upon infection of the recipient strain with bacteriophage grown on the donor strain, those bacteriophage particles containing chromosomal DNA from the donor strain can transfer that DNA to the recipient strain. If there is a strong selection for the DNA from the donor strain, recipient strains containing the appropriate gene or mutation from the donor strain can be selected.

To grow P1_{vir} on a donor strain, an existing bacteriophage stock was used to infect a culture of that strain. The recipient strain was grown at 37°C in LBMC medium (10 g/L Bacto tryptone, 5 g/L yeast extract, 10 g/L NaCl, 1 mM MgCl₂, 5 mM CaCl₂) until the absorbance at 600 nm was approximately 1.0, corresponding to approximately 6 x 10⁸ cells per mL of culture. One mL of the culture was then infected with a dilution of the phage stock at a ratio of approximately one phage per 10 cells. The mixture was incubated without shaking for 20 minutes at 37°C, then transferred to 10 mL of prewarmed LBMC broth in a 125 mL baffled Erlenmeyer flask. The resulting culture was shaken vigorously for 2-3 hours at 37°C. During this period, it was generally observed that the culture would become more turbid, indicating bacterial growth. Toward the end

of this incubation period, the culture would become clear, indicating cell lysis due to bacteriophage growth. After lysis had occurred, the culture was cooled on ice, a few drops of chloroform were added, and the flask was shaken briefly. The contents of the flask were then centrifuged to remove the cell debris and chloroform, and the resulting supernatant generally contained between 10^8 and 10^9 bacteriophage per mL.

Mutations were transferred to recipient strains by transduction with $P1_{vir}$ grown on the appropriate donor strain as described above. For transduction with $P1_{vir}$, a culture of the recipient strain was grown overnight at 37°C in LBMC broth. 0.1 mL of culture was mixed with 0.1 mL of bacteriophage lysate or a serial dilution of the lysate in a sterile test tube and incubated at 37°C for 20 minutes. 0.2 mL of 1 M sodium citrate was added to the tube, and the mixture was plated to selective medium. For each transduction, controls containing uninfected cells and bacteriophage lysates without cells were performed as described above. For the production of strains blocked in glucosamine degradation, selections were for tetracycline resistance as described below. Tetracycline resistant mutants were selected by plating to LB medium (10 g/L Bacto tryptone, 5 g/L yeast extract, 10 g/L NaCl) containing 12.5 $\mu\text{g/mL}$ tetracycline and 10 mM sodium citrate.

The mutations in the *nag* genes were introduced simultaneously as a deletion mutation ($\Delta nag::Tc^R$). In strain IBPC590 (Plumbridge, Table 1), which contains this mutation, the *nag* genes have been replaced by a tetracycline-resistance (Tc^R) determinant. As a result, the mutation which removes the *nag* functions was transferred to appropriate recipient hosts by selection for tetracycline resistance. In this case, since the Tc^R determinant was contained within the mutation of interest, the Δnag and Tc^R mutations were 100% linked. That is, all of the recipient strains receiving the Tc^R determinant from IBPC590 also received the Δnag mutation. This was confirmed by examining the growth phenotype of the tetracycline resistant strains resulting from infection with $P1_{vir}$ grown on IBPC590. All such strains were unable to grow on media containing glucosamine or N-acetylglucosamine as carbon sources, indicating the presence of the Δnag mutation.

Mutations in the *manXYZ* and *ptsG* genes were also introduced by $P1_{vir}$ transduction using phage grown on strains IBPC566 and IBPC522 (Plumbridge, Table 1), respectively. These strains also contained tetracycline-resistance determinants linked to

the mutations of interest (designated *zdj-225::Tn10* and *zcf-229::Tn10*, respectively). In these strains, the Tc^R determinants were not within the gene but were linked to the gene. Accordingly, not all recipient strains receiving the Tc^R determinant contained the mutations of interest. The degree of linkage is indicative of the distance on the chromosome between the Tc^R determinant and the mutation of interest. As a result, it was necessary to screen tetracycline resistant strains for *manXYZ* and *ptsG*. The *manXYZ* strains grew slowly on mannose and failed to grow on glucosamine as sole carbon sources for growth. The *ptsG* strains grew slowly on glucose as sole carbon source.

Because all of the selections for the mutations described above were for tetracycline resistance, it was necessary to render strains tetracycline sensitive between steps if multiple mutations were to be introduced. To accomplish this, tetracycline-resistant strains were plated to TCS medium (15 g/L agar, 5 g/L Bacto tryptone, 5 g/L yeast extract, 50 mg/L chlortetracycline hydrochloride, 10 g/L NaCl, 10 g/L $NaH_2PO_4 \cdot H_2O$, 12 mg/L fusaric acid, and 0.1 mM $ZnCl_2$) which selects for tetracycline sensitive mutants (described in Maloy and Nunn, 1981, *J. Bacteriol.*, 145:1110-1112, which is incorporated herein by reference in its entirety). Colonies arising on this medium were purified by restreaking to the same medium, then checking individual colonies for tetracycline sensitivity by plating to LB media with and without 12.5 μ g/mL tetracycline.

The scheme described above for the production of strains containing combinations of the *manXYZ*, *ptsG*, and Δnag mutations is presented schematically in Fig. 3.

Example 2

The following Example describes the cloning and overexpression of the *glmS* gene and the integration of the T7-*glmS* gene cassette into the *E. coli* chromosome.

Cloning and Overexpression of the *glmS* Gene.

Using information obtained from the published sequence of the *glmS* gene (Walker *et al.*, 1984, *Biochem. J.*, 224:799-815, which is incorporated herein by reference in its entirety), primers were synthesized to amplify the gene from genomic DNA isolated from strain W3110 (Table 1) using the polymerase chain reaction (PCR). The primers used for PCR amplification were designated Up1 and Lo8 and had the following sequences:

Up1: 5'-CGGTCTCCCATGTGTGGAATTGTTGGCGC-3' (SEQ ID NO:1)

Lo8: 5'-CTCTAGAGCGTTGATATTCAAGTCAATTACAAACA-3' (SEQ ID NO:2)

The Up1 primer contained sequences corresponding to the first twenty nucleotides of the *glmS* gene (represented in nucleotides 10-29 of SEQ ID NO:1) preceded by a *BsaI* restriction endonuclease recognition site (GGTCTC, represented in nucleotides 2-7 of SEQ ID NO:1). The Lo8 primer contained sequences corresponding to positions between 145 and 171 bases downstream of the *glmS* gene (represented in nucleotides 8-34 of SEQ ID NO:2) preceded by a *XbaI* restriction endonuclease site (TCTAGA, represented in nucleotides 2-7 of SEQ ID NO:2). PCR amplification was conducted using a standard protocol to generate a fragment of DNA containing the *glmS* gene with 171 base pairs of DNA downstream of the gene flanked by *BsaI* and *XbaI* sites. This DNA fragment was cloned into the vector pCR-ScriptTMSK(+) (Stratagene Cloning Systems, La Jolla, California) using materials and instructions supplied by the manufacturer. The resulting plasmid was designated pKLN23-20.

One consequence of this cloning was that it placed a unique *SacI* restriction endonuclease site downstream of the gene. This allowed excision of a fragment of DNA containing the *glmS* gene from pKLN23-20 using the restriction endonucleases *BsaI* and *SacI*. This fragment was then cloned between the *NcoI* and *SacI* sites of the expression vector pET-24d(+) (Novagen, Inc., Madison, Wisconsin) to generate plasmid pKLN23-23. The pET-24d(+) expression vector is based on the T7 promoter system (Studier and Moffatt, 1986, *J. Mol. Biol.*, 189:113-130). Cloning in this manner resulted in placement of the *glmS* gene behind the T7-*lac* promoter contained on pET-24d(+). The T7-*lac* promoter is specifically recognized by the T7 RNA polymerase and is only expressed in strains containing a cloned T7 gene 1, which encodes the T7 RNA polymerase. The cloned T7 polymerase gene is contained on a defective bacteriophage λ phage designated λ DE3. Strains in which the λ DE3 element is integrated into the chromosome contain the T7 RNA polymerase gene driven by the *lacUV5* promoter. In those strains, expression of the T7 RNA polymerase gene can be induced using the lactose analog isopropylthio- β -D-galactopyranoside (IPTG). Accordingly, addition of IPTG to such cultures results in induction of the T7 RNA polymerase gene and expression of any genes controlled by the T7 or T7-*lac* promoter.

To verify that pKLN23-23 contained the *glmS* gene driven by the T7-*lac* promoter, the plasmid was transferred to strain BL21(DE3) (Novagen, Inc.) (Table 1). Strain BL21(DE3)/pKLN23-23 was grown in duplicate in LB medium containing 50 mg/L kanamycin (kanamycin resistance is encoded by the plasmid). One of the duplicates was induced with 1 mM IPTG; the other was not. When the total proteins were examined from these two cultures by sodium dodecyl sulfate polyacrylamide gel electrophoresis, a prominent protein of approximately 70,000 molecular weight, corresponding to the predicted size for the *glmS* gene product, was observed in cells from the induced culture but not in cells from the uninduced culture. A preliminary enzyme assay from an induced culture indicated several hundred fold higher glucosamine-6-phosphate synthase activity in the induced culture than in what had typically been observed in a wild type strain.

Integration of the T7-*glmS* Gene Cassette into the *E. coli* Chromosome.

The *glmS* gene driven by the T7-*lac* (the T7-*glmS* gene cassette) promoter was transferred to the chromosome of *E. coli* strains by a multistep process. First, the cassette was cloned into plasmid pBRINT-Cm (Balbás *et al.*, 1996, *Gene* 96:65-69), which is incorporated herein by reference in its entirety). The gene cassette was then integrated into the chromosome of strain ATCC47002 (Table 1) by the techniques described by Balbás *et al.*, 1996, *supra*, to generate strains T-71 and T-81 (Table 1). Finally, the gene cassette was transferred to strains of interest by transduction with P1_{vir}, as described below.

The T7-*glmS* cassette was excised from pKLN23-23 by performing a partial digest of the plasmid with restriction endonuclease *Bgl*II and a complete digest with restriction endonuclease *Hin*DIII. Plasmid pKLN23-23 contains a *Bgl*II site approximately 20 base pairs upstream of the T7 promoter. The *glmS* gene also contains two *Bgl*II sites. A partial digest with this enzyme was necessary to cut the plasmid upstream of the T7 promoter while avoiding the two internal sites. Plasmid pKLN23-23 also contains a unique *Hin*DIII site downstream of the *glmS* gene. The excised T7-*glmS* cassette was then cloned between the unique *Bam*HI and *Hin*DIII sites of pBRINT-Cm. This resulted in the production of plasmids designated pKLN23-27 and pKLN23-28. Plasmids pKLN23-27 and pKLN23-28 contain the T7-*glmS* cassette in addition to a

chloramphenicol resistance determinant flanked by the 5'- and 3'-termini of the *E. coli lacZ* gene.

Strain ATCC 47002 (Table 1) contains mutations that confer upon it an inability to maintain plasmids such as pBRINT-Cm which contain a ColE1 origin of replication. When such plasmids are transferred to this strain, selection for genetic markers contained on the plasmid results in integration of the plasmid into the chromosome (Balbás *et al.*, 1996, *supra*). As mentioned above, plasmids pKLN23-27 and -28 contain the T7-*glmS* cassette and a chloramphenicol resistance determinant flanked by the 5'- and 3'-termini of the *E. coli lacZ* gene. The *lacZ* sequences target the incoming DNA to the *lacZ* gene contained in the chromosome. Integration at the *lacZ* locus replaces the intact *lacZ* gene, which encodes the enzyme β -galactosidase, with a partial *lacZ* gene interrupted by the T7-*glmS*-Cm cassette. As a result, integration at *lacZ* results in the strain becoming β -galactosidase negative. The plasmid also contains an ampicillin resistance determinant remote from the 5'-*lacZ*-T7-*glmS*-Cm-*lacZ*-3' cassette. Integration at *lacZ* and plasmid loss also results in ampicillin sensitivity.

Plasmids pKLN23-27 and -28 were transferred to strain ATCC 47002, and cells were plated to LB medium containing 10 μ g/mL chloramphenicol, 1 mM IPTG, and 40 μ g/mL 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-gal). The X-gal contained in the medium is a chromogenic β -galactosidase substrate. Hydrolysis of X-gal by β -galactosidase results in a blue derivative. Inclusion of X-gal and IPTG, which induces the native *lacZ* gene, results in blue *lacZ*-positive colonies and white *lacZ*-negative colonies. White (*lacZ*-negative) chloramphenicol resistant colonies were then selected and purified. The strains were then verified for sensitivity to ampicillin by plating to LB media with and without 100 μ g/mL ampicillin. DNA integration was further confirmed using a PCR scheme as described by Balbás *et al.*, 1996, *supra*. Integrants T-71 and T-81 (Table 1) resulted from the integration of the desired segments of plasmids pKLN23-27 and pKLN23-28, respectively, into the chromosome of ATCC 47002.

The T7-*glmS*-Cm cassette was then transferred to strains W3110(DE3), 7101-9(DE3), 7101-17(DE3), and 2123-4(DE3) by P1_{vir} transduction, as described in Example 1, using lysates prepared on strains T-71 and T-81. These strains contain various combinations of the Δ *nag*, *manXYZ*, and *ptsG* mutations in addition to the λ DE3 element

necessary for expression from the T7-*lac* promoter. The λ DE3 element was introduced to these strains using the λ DE3 lysogenization kit produced by Novagen, Inc. (Madison, Wisconsin). Transductants were selected on LB agar plates containing 30 μ g/mL chloramphenicol and 10 mM sodium citrate. Loss of β -galactosidase activity was verified on plates containing X-gal and IPTG and DNA integration was further confirmed using a PCR scheme as described by Balbás *et al.*, 1996, *supra*.

Glucosamine-6-phosphate synthase activity was measured in production strains containing integrated T7-*glmS* cassettes after growth in LB medium with and without IPTG (Table 2). Glucosamine-6-phosphate synthase was assayed in crude cell extracts using either colorimetric or spectrophotometric assays (Badet *et al.*, 1987, *Biochemistry* 26:1940-1948) as described below. The extracts used for those assays were prepared by suspending washed cell pellets in 5 mL of 0.1 M $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$, pH 7.5 per gram of wet cell paste, passing the suspension through a French press at 16,000 psi, and centrifuging the disrupted cell suspension at 35,000-40,000 $\times g$ for 15 to 20 minutes. The supernatant was used as the source of enzyme for the assay.

For a colorimetric assay, 1 mL reactions were prepared containing 45 mM $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$, 20 mM fructose-6-phosphate, 15 mM L-glutamine, 2.5 mM EDTA, pH 7.5, and cell extract. The reactions were incubated at 37°C for 20 minutes and stopped by boiling for 4 minutes. The resulting precipitate was removed by centrifugation and the supernatant was assayed for glucosamine-6-phosphate by a modification of the method of Elson and Morgan (1933, *Biochem. J.* 27:1824-1828) essentially as described by Zalkin (1985, *Meth. Enzymol.* 113:278-281), both publications of which are incorporated herein by reference in their entireties. To 100 μ L of the above supernatant was added 12.5 μ L of saturated NaHCO_3 and 12.5 μ L of cold, freshly prepared 5% aqueous acetic anhydride. After incubating for 3 minutes at room temperature, the mixture was boiled for 3 minutes to drive off excess acetic anhydride. After cooling to room temperature, 150 μ L of 0.8 M potassium borate, pH 9.2 (0.8 M H_3BO_3 adjusted to pH 9.2 with KOH) was added and the mixture was boiled for 3 minutes. After cooling to room temperature, 1.25 mL Ehrlich's reagent (1% *p*-dimethylaminobenzaldehyde in glacial acetic acid containing 0.125 N HCl) was added to each tube. After incubating at 37°C for 30 minutes, the absorbance at 585 nm was measured and the amount of glucosamine-6-phosphate formed

was determined using a standard curve. In the absence of the substrate, fructose-6-phosphate, or when boiled extract was used in the assay, no significant absorbance at 585 nm was observed.

In the spectrophotometric assay, 1 mL reactions containing 50 mM $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$, 10 mM fructose-6-phosphate, 6 mM L-glutamine, 10 mM KCl, 0.6 mM acetylpyridine adenine dinucleotide (APAD), and 50-60 Units of L-glutamic dehydrogenase (Sigma Type II from bovine liver) were run at room temperature. The activity was followed by monitoring the absorbance at 365 nm after the addition of extract and corrected for the small absorbance increase observed in the absence of extract. The activity was calculated using a molar extinction coefficient for APAD of 9100.

Table 2

Glucosamine 6-Phosphate Synthase Activity in Production Strains Containing Integrated T7-*glmS* Cassettes

Strain	Host Genotype	Activity, ($\mu\text{mole per minute per mL of extract}$)	
		- IPTG	+ IPTG
2123-5	DE3	23	64
2123-6	DE3	4	4
2123-7	DE3	23	96
2123-8	DE3	25	89
2123-9	DE3 <i>Δnag</i>	26	58
2123-10	DE3 <i>Δnag</i>	33	67
2123-11	DE3 <i>Δnag manXYZ</i>	32	59
2123-12	DE3 <i>Δnag manXYZ</i>	17	67
2123-13	DE3 <i>Δnag manXYZ ptsG</i>	21	68
2123-14	DE3 <i>Δnag manXYZ ptsG</i>	20	88

Table 2 shows that, on average, the activity of glucosamine-6-phosphate synthase in production strains containing integrated T7-*glmS* cassettes was about three- to four-fold higher with IPTG induction than without. The activities were substantially higher than those obtained with a wild type *glmS* strain driven by its native promoter, which typically were in the range of 0.05-0.1 $\mu\text{mole per minute per mL of extract}$. One of the strains, 2123-6, apparently suffered an aberrant integration event since the activity was lower than that observed in the other strains and was not influenced by the presence of IPTG in the medium.

Example 3

The following example shows the effect of strain genotype on glucosamine accumulation.

Strains with T7-*glmS* integrants, produced as described in Example 2, as well as the corresponding parent strains without integrated DNA, were grown in shake flasks containing M9A medium (14 g/L K₂HPO₄, 16 g/L KH₂PO₄, 1 g/L Na₃Citrate·2H₂O, 5 g/L (NH₄)₂SO₄, pH 7.0) supplemented with 20 g/L glucose, 10 mM MgSO₄, 1 mM CaCl₂, and 1 mM IPTG. Samples were taken periodically over the course of two days, and the glucosamine concentration in the culture supernatant was measured using the modified Elson-Morgan assay as described in Example 2. Samples were assayed with and without acetic anhydride treatment, and the amount of glucosamine present was determined from the net absorbance using a standard curve.

Glucosamine concentrations after 24 hours of cultivation, at which time the concentration peaked, are indicated in Table 3. The results shown in Table 3 indicate that for significant glucosamine production to occur, the T7-*glmS* gene cassette must be present. The data also indicate that the presence of the Δ *nag* mutation in the host results in a significant increase in glucosamine accumulation compared with its absence. Little effect of the *manXYZ* mutation was observed in this experiment. In further shake flask experiments, however, strain 2123-12 accumulated slightly higher glucosamine concentrations on a consistent basis.

Table 3**Glucosamine in Culture Supernatants of Production Strains**

Strain	Genotype	Glucosamine Concentration, mg/L (24 hours)
2123-5	DE3, T-71 integrant	21
2123-7	DE3, T-71 integrant	23
2123-9	DE3 Δ <i>nag</i> , T-71 integrant	67
2123-10	DE3 Δ <i>nag</i> , T-81 integrant	80
2123-11	DE3 Δ <i>nag manXYZ</i> , T-71 integrant	65
2123-12	DE3 Δ <i>nag manXYZ</i> , T-81 integrant	63
W3110(DE3)	DE3, no integrant	4
7101-9(DE3)	DE3 Δ <i>nag</i> , no integrant	0
7101-17(DE3)	DE3 Δ <i>nag manXYZ</i> , no integrant	0

Example 4

The following example demonstrates the effect feeding nutrients to the cultures has on glucosamine accumulation.

In early experiments, it was observed that glucosamine accumulation ceased when glucose was depleted from cultures. In the experiment summarized by Table 4 and Fig. 4, it was found that increased glucosamine accumulation could be accomplished by feeding additional glucose and ammonium sulfate as they became depleted. For this experiment, strain 2123-12 was grown in M9A medium supplemented with 10 mM MgSO₄, 1 mM CaCl₂, and 1 mM IPTG. Initial glucose concentrations and feeding regimens were varied as indicated in Table 4. In one of the flasks, the initial ammonium sulfate concentration was 10 g/L rather than the 5 g/L normally used in M9A medium. Glucose concentration was monitored in shake flasks during cultivation using Diastix® glucose test strips (Bayer Corporation Diagnostics Division, Elkhart, Indiana). When the glucose concentration was at or near depletion (<5 g/L remaining), glucose and/or ammonium sulfate were supplemented as indicated in Table 4. pH was also monitored during cultivation. When the pH varied significantly from the initial pH of 7.0, it was adjusted to 7.0 with sodium hydroxide.

Table 4**Shake Flask Experiment to Examine the Effect of Glucose Feeding**

Flask No.	Initial Glucose, g/L	Initial Ammonium Sulfate, g/L	Feed
1	20	5	None
2	50	5	None
3	50	10	None
4	20	5	20g/L Glucose
5	20	5	20 g/L Glucose + 5 g/L AmSO ₄

As Fig. 4 indicates, increasing the supply of glucose had a positive effect on glucosamine accumulation. By periodically feeding with glucose and ammonium sulfate (20 g/L and 5 g/L additions, respectively), a maximum accumulation of 0.4 g/L of glucosamine was observed, approximately four-fold higher than what was observed in the absence of feeding.

Example 5

The following example describes the isolation of mutant *glmS* genes encoding glucosamine-6-phosphate synthase enzymes with decreased sensitivity to glucosamine-6-phosphate product inhibition.

5 White (1968, *Biochem. J.*, 106:847-858) first demonstrated that glucosamine-6-phosphate synthase was inhibited by glucosamine-6-phosphate. Using the spectrophotometric assay for glucosamine-6-phosphate synthase as described in Example 2, the effects of glucosamine-6-phosphate and glucosamine on glucosamine-6-phosphate synthase were measured. For determination of product inhibition, assays were run in the
10 presence of various concentrations of added glucosamine-6-phosphate.

As indicated in Fig. 5, the enzyme is significantly inhibited by glucosamine-6-phosphate and slightly inhibited by glucosamine. These results are similar to those obtained by White, 1968, *supra*. This inhibition may be a key factor in limiting glucosamine accumulation in the glucosamine production strains.

15 To further increase glucosamine synthesis in production strains, efforts were made to isolate mutants of the *glmS* gene encoding glucosamine-6-phosphate synthase variants with reduced product inhibition. To accomplish this, the cloned gene was amplified using the technique of error-prone PCR. In this method, the gene is amplified under conditions that lead to a high frequency of misincorporation errors by the DNA polymerase used for
20 the amplification. As a result, a high frequency of mutations are obtained in the PCR products.

Plasmid pKLN23-28 contains a unique *SpeI* restriction endonuclease site 25 base pairs upstream of the T7 promoter and 111 base pairs upstream of the start of the *glmS* gene. The plasmid also contains a unique *HinDIII* site 177 base pairs downstream of the
25 *glmS* gene. PCR primers of the following sequences were synthesized to correspond to regions just upstream of the *SpeI* and downstream of the *HinDIII* sites, respectively:

5'-ATGGATGAGCAGACGATGGT-3' (SEQ ID NO:3)

5'-CCTCGAGGTCGACGGTATC-3' (SEQ ID NO:4)

30 Amplification with these primers (SEQ ID NO:3 and SEQ ID NO:4) allowed mutagenesis of a 2247 base pair region that included the entire *glmS* gene. PCR conditions were as described by Moore and Arnold, 1996, *Nature Biotechnology* 14:458-

467, which is incorporated herein by reference in its entirety. Briefly, a 100 μ L solution was prepared containing 1 mM each of the four deoxynucleotide triphosphates, 16.6 mM ammonium sulfate, 67 mM Tris-HCl, pH 8.8, 6.1 mM $MgCl_2$, 6.7 μ M EDTA, 10 mM β -mercaptoethanol, 10 μ L DMSO, 30 ng each of the primers (SEQ ID NO:3 and SEQ ID NO:4), either 7 or 35 ng of plasmid pKLN23-28 linearized with *Kpn* I, and 2.5 Units of *Taq* DNA polymerase (Perkin Elmer-Cetus, Emeryville, California). The reaction mixture was covered with 70 μ L of mineral oil and placed in a thermocycler, where the following steps were repeated for 25 cycles:

1 minute at 94°C

1 minute at 42°C

2 minutes at 72°C

Under these conditions, an error frequency of approximately one mutation per 1000 base pairs has been reported (Moore and Arnold, 1996, *supra*). The product of the reaction was recovered, purified, and digested with *Spe*I and *Hin*DIII, and cloned into the *Spe*I-*Hin*DIII backbone fragment of pKLN23-28, which effectively substitutes for the wild type *glmS* gene on the *Spe*I-*Hin*DIII fragment of pKLN23-28. The cloned DNA was used to transform strain NovaBlue (Novagen, Inc., Madison, Wisconsin), and the transformed cells were plated to LB agar containing ampicillin. A total of 9000 plasmid-containing colonies were pooled from the ampicillin plates and plasmid DNA was prepared from the pooled cells to generate a library of pKLN23-28 derivative plasmids containing mutations in the cloned *glmS* gene.

The mutant plasmids generated by error-prone PCR were screened for their ability to confer increased glucosamine production in a *Δnag manXYZ* DE3 host background. This screen was in the form of a bioassay in which the ability of plasmid-containing strains to crossfeed glucosamine-requiring strains of *E. coli* was assessed.

Strains of *E. coli* (Sarvas, 1971, *J. Bacteriol.* 105:467-471; Wu and Wu, 1971, *J. Bacteriol.* 105:455-466) and *Bacillus subtilis* (Freese *et al.*, 1970, *J. Bacteriol.* 101:1046-1062) which are defective for glucosamine-6-phosphate synthase require glucosamine or N-acetylglucosamine for growth. A glucosamine-requiring strain of *E. coli* was isolated after mutagenesis with *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (NG). Strain LE392 (Table 1) was grown in LB medium to a cell density of 6×10^8 cells per mL.

μ L of 2.5 mg/mL NG dissolved in methanol was added to 2 mL of this culture and the mixture was incubated at 37°C for 20 minutes. This treatment resulted in about 10% survival of the strain. The mutagenized cells were harvested by centrifugation, and the cells were washed twice by suspension in 0.9% NaCl and recentrifugation. The washed
5 cells were diluted and plated to nutrient agar medium (NA; 5 g/L Bacto peptone, 3 g/L beef extract, 15 g/L agar) containing 0.2 g/L N-acetylglucosamine at a density of between 50 and 200 colony forming units per plate. Approximately 13,000 colonies were plated. These colonies were replica-plated to NA agar with and without 0.2 g/L N-acetylglucosamine. Twenty-two colonies grew on NA with 0.2 g/L N-acetylglucosamine
10 but not on NA without 0.2 g/L N-acetylglucosamine. These colonies were purified by streaking to NA with 0.2 g/L N-acetylglucosamine, and their growth phenotype was rechecked. Of the original 22 colonies selected, five had the phenotype expected of a *glmS* mutant of LE392. They failed to grow on NA but grew on NA supplemented with 0.2 g/L of glucosamine or 0.2 g/L N-acetylglucosamine. They also failed to grow on
15 glucose minimal agar, but grew on glucose minimal agar supplemented with 0.2 g/L N-acetylglucosamine. One of these mutants was designated 2123-16 (Table 1).

For the cross-feeding assay, agar plates containing either glycerol or fructose as the principle carbon source for growth were overlaid with cells from a culture of strain 2123-16, the glucosamine-requiring strain isolated as described above. Glucosamine-
20 producing strains were stabbed into the agar and the ability to produce glucosamine was assessed based on the size of the "halo" of growth of the indicator strain surrounding the stab. Those stabs surrounded by larger halos were considered to produce greater amounts
of glucosamine.

The media used for the cross-feeding assays consisted of M9 minimal medium (6
25 g/L Na_2HPO_4 , 3 g/L KH_2PO_4 , 0.5 g/L NaCl, 1 g/L NH_4Cl , 1 mM MgSO_4 , 0.1 mM CaCl_2) supplemented with 40 mg/L of L-methionine (required for growth of strains LE392 or 2123-16) and 2 g/L of either glycerol or fructose. These plates were overlaid with strain 2123-16 as follows. A culture of strain 2123-16 was grown overnight at 37°C in LB medium containing 1 g/L N-acetylglucosamine. The culture was harvested by
30 centrifugation, and the cells were washed twice by suspension in 0.9% NaCl and recentrifugation. The washed cells were suspended in the original volume of 0.9% NaCl.

For each plate to be overlaid, 0.1 mL of washed cell suspension was mixed with 3 mL of molten (50°C) F-top agar (8 g/L NaCl, 8 g/L agar) and poured onto the plate.

The library of pKLN23-28 mutant plasmids was transferred to strain 7101-17(DE3) and transformed cells were plated to LB agar containing 100 µg/mL ampicillin.

5 Each colony arising on these plates contained an individual member of the mutant plasmid library. The colonies were screened by picking them from the LB + ampicillin plates and stabbing them sequentially into:

(1) LB agar + ampicillin;

(2) glycerol minimal agar overlaid with strain 2123-16; and,

10 (3) fructose minimal agar overlaid with strain 2123-16

All plates were incubated for about 24 hours at 37°C. After this incubation period, halos of growth of the 2123-16 indicator strain could be observed surrounding the stabs in the overlaid plates. Those colonies giving rise to the larger halos were picked from the corresponding LB + ampicillin plate and streaked for purification. In an initial
15 screen, 4368 mutant candidates were screened, and 96 initial candidates were identified. Upon rescreening those, 30 appeared to be superior to the rest, *i.e.* resulted in larger halos of the indicator strain.

Enzyme assays performed with six of the plasmid-containing strains isolated as described above indicated that three of the strains were less sensitive to inhibition by
20 glucosamine-6-phosphate than the enzyme from the control strain 7101-17(DE3)/pKLN23-28. The strains were grown overnight in LB broth containing 100 µg/mL ampicillin and 1 mM IPTG. Extracts prepared from cells harvested from those
cultures were assayed for glucosamine-6-phosphate synthase using the spectrophotometric
assay (described in Example 2) in the presence and absence of added glucosamine-6-
25 phosphate. The mutant clones designated 11C, 65A, and 8A were significantly less sensitive to glucosamine-6-phosphate than the control strain (Fig. 6). Other mutants were not distinguishable from the control by this assay.

Example 6

The following example describes the construction and characterization of
30 glucosamine production strains with mutations in *glmS* which result in reduced product inhibition.

Plasmid DNA isolated from clones 11C, 52B, and 8A described above were transferred to strain ATCC 47002, which had been used previously to integrate the cloned T7-*glmS* construct into the *E. coli* chromosome. Integration was readily accomplished using the methods described in Example 2, and the integrated DNA was transferred to strain 7101-17(DE3) by P1 transduction as described in Example 1. These procedures produced strains that have the same genotype as strain 2123-12 except for the presence of mutations in the *glmS* gene generated by PCR. These new mutant production strains were designated 2123-49, 2323-51, and 2123-54, respectively. A summary of the strain construction strategy is presented in Fig. 7.

Strains 2123-12, 2123-49, 2123-51, and 2123-54 were grown overnight in LB broth containing 1 mM IPTG. Extracts prepared from cells harvested from those cultures were assayed for glucosamine-6-phosphate synthase using the spectrophotometric assay described in Example 2 in the presence and absence of added glucosamine-6-phosphate. The results of these assays are shown in Fig. 8.

Glucosamine production in these mutants was significantly elevated compared to that in 2123-12. When glucosamine production was assayed in shake flask cultures grown using the glucose and ammonium sulfate feeding protocol previously described in Example 4, when the cultures were grown to a cell density (measured as O.D.₆₀₀) of about 14 (about 8.4 g/L by dry cell weight), strains 2123-49, 2123-51, and 2123-54 produced 1.5, 2.4, and 5.8 g/L glucosamine, respectively (Fig. 9) compared with 0.3 g/L for 2123-12.

Example 7

The following example describes the production of yet another strain with a mutation in *glmS* which results in reduced product inhibition.

An additional 6,344 colonies containing mutant plasmids generated by error-prone PCR as described in Example 5 were screened using the cross-feeding assay, also described in Example 5. Fifty four colonies resulted in larger halos than the rest of the colonies. DNA was isolated from all 54 colonies and strains isogenic to 2123-12 except for the mutations in *glmS* were constructed as described in Example 6.

Glucosamine production in most of these mutants was significantly elevated compared to strain 2123-12. Among the newly isolated mutants, the strain that produced

the most glucosamine was a strain designated 2123-124. This strain produced 3.6 g/L of glucosamine when production was assayed in shake flasks using the glucose and ammonium sulfate feeding protocol described in Example 4 compared with 4.3 g/L for strain 2123-54 in a side-by-side experiment.

5 Example 8

The following example describes the sequencing of the cloned wild type *glmS* gene present in plasmid pKLN23-28. In addition, the sequences present in plasmids pKLN23-49, pKLN23-54, and pKLN23-124, containing the mutant *glmS* genes used to construct strains 2123-49, 2123-54, and 2123-124, respectively were sequenced and are described.

DNA sequencing reactions were performed using the Applied Biosystems (ABI) Prism Dye Terminator Cycle sequencing method with AmpliTaq DNA polymerase. The extended products were separated by gel electrophoresis on an ABI DNA sequencer 373A or 377. Sequences were analyzed using ABI Sequencing Analysis 3.0 software from ABI and Sequencher 3.1 from Gene Codes.

The primers used for sequencing were as follows:

PK-1: 5'-TGGATGAGCAGACGATGG-3' (SEQ ID NO:5)

PK-2: 5'-TCCGTCACAGGTATTTATTC-3' (SEQ ID NO:6)

PK-3: 5'-AGCTGCGTGGTTCGTAC-3' (SEQ ID NO:7)

20 PK-4: 5'-GGACCGTGTTTCAGTTCG-3' (SEQ ID NO:8)

PK-5A: 5'-GCCGTGGCGATCAGTAC-3' (SEQ ID NO:9)

~~PK-6A:~~ 5'-GCCAATCACCAGCGGAC-3' (SEQ ID NO:10)

PK-7: 5'-ATGGTTTCCCGCTACTGG-3' (SEQ ID NO:11)

PK-8: 5'-GAACCAAGGTAACCCAGC-3' (SEQ ID NO:12)

25 The nucleotide sequence of plasmid pKLN23-28, containing the wild-type *glmS* gene, was determined to be a 7408 bp nucleic acid sequence represented herein as SEQ ID NO:13. The 2184 base pairs between positions 1130 and 3313 of SEQ ID NO:13 were determined using the primers described above. The nucleic acid molecule representing positions 1130-3313 of SEQ ID NO:13 is referred to herein as *nglmS*-28₂₁₈₄ and is further identified as SEQ ID NO:14. *nglmS*-28₂₁₈₄ was shown to include the *SpeI*

30

and *Hin*DIII sites used to construct the mutant plasmids as described in Example 5. The remaining DNA sequence of SEQ ID NO:13 is based on the known sequences of the vectors used for the construction of pKLN23-28. The same 2184 base pair region was sequenced in plasmids pKLN23-49, pKLN23-54, and pKLN23-124. It is noted that for the discussion of the mutant *glmS* genes of these plasmids (Table 5), the specific nucleotide position of mutations in the nucleotide sequence of the mutant *glmS*-containing plasmids will be described using SEQ ID NO:13 as a reference.

SEQ ID NOs:13 and 14 contain an open reading frame that encodes the *glmS* gene product (i.e., GlcN6P synthase enzyme) which is a nucleic acid molecule referred to herein as nglmS-28₁₈₃₀, the nucleic acid sequence of which is represented by SEQ ID NO:15. SEQ ID NO:15 spans nucleotides 1253 to 3082 of SEQ ID NO:13, with an initiation codon spanning from nucleotides 1253-1255 and a termination codon spanning from nucleotides 3080-3082. SEQ ID NO:15 encodes a protein of 609 amino acids referred to herein as GlcN6P-S-28, the deduced amino acid sequence of which is represented herein as SEQ ID NO:16. It is noted that for the discussion of the mutant *glmS* gene products produced by the mutant strains described herein, specific mutations in the amino acid sequence of the mutant *glmS* gene products will be described using SEQ ID NO:16 as a reference.

The primers described above correspond to the following nucleotide positions of SEQ ID NO:13:

- PK-1 (SEQ ID NO:5): positions 1087-1104 of SEQ ID NO:13;
- PK-2 (SEQ ID NO:6): positions 3378-3359 of a nucleic acid sequence complementary to SEQ ID NO:13;
- PK-3 (SEQ ID NO:7): positions 1707-1723 of SEQ ID NO:13;
- PK-4 (SEQ ID NO:8): positions 2772-2755 of a nucleic acid sequence complementary to SEQ ID NO:13;
- PK-5A (SEQ ID NO:9): positions 2667-2683 of SEQ ID NO:13;
- PK-6A (SEQ ID NO:10): positions 1798-1782 of a nucleic acid sequence complementary to SEQ ID NO:13;
- PK-7 (SEQ ID NO:11): positions 2177-2194 of SEQ ID NO:13;

PK-8 (SEQ ID NO:12): positions 2364-2347 of a nucleic acid sequence complementary to SEQ ID NO:13.

The nucleic acid sequence of nucleic acid molecule nglmS-28₁₈₃₀ (SEQ ID NO:15, or positions 1253-3082 of SEQ ID NO:13) from pKLN23-28, differs from the published sequence (Walker, J.E, et al., 1984, "DNA sequence around the *Escherichia coli unc* operon", *Biochem. J.* 224:799-815) at positions 2509 and 2510 (with reference to SEQ ID NO:13). The nucleotides for pKLN23-28 at these positions as determined in this example were G and C, respectively, while those reported in the published sequence were C and G. Otherwise, the published and determined sequences of the *glmS* gene were identical. The sequences determined upstream and downstream from the *glmS* gene were those expected based on the known sequences of the vectors used for the construction of pKLN23-28 and the methods used to construct the plasmid.

The nucleotide sequences for the mutant *glmS* genes for plasmids pKLN23-49, pKLN23-54, and pKLN23-124 were determined as described above for pKLN23-28. Mutations were found in each of those plasmids. The mutations and the predicted amino acid changes in the corresponding mutant *glmS* gene products, as compared to the wild-type sequence determined for pKLN23-28 (SEQ ID NO:13) are summarized in Table 5.

Table 5
Mutations in *glmS* Genes of Glucosamine-Overproducing strains.

Plasmid	Position*	Base Change	Amino Acid Change (Position**)
pKLN23-49	1263	T to C	Ile to Thr (4)
	2067	T to C	Ile to Thr (272)
	2600	T to C	Ser to Pro (450)
pKLN23-54	1367	G to A	Ala to Thr (39)
	2000	C to T	Arg to Cys (250)
	2239	T to C	Silent (329)
	2666	G to A	Gly to Ser (472)
	3264	A to G	Outside gene
pKLN23-124	1525	T to C	Silent (91)
	2658	T to C	Leu to Pro (469)
	3280	G to A	Outside gene

*Refers to nucleic acid position as indicated in the sequence of pKLN23-28 (SEQ ID NO:13)

**The *glmS* gene (nglmS-28₁₈₃₀; SEQ ID NO:15) encodes a protein of 609 amino acids in length (SEQ ID NO:16); the methionine residue at position 1 is removed by a hydrolase.

Plasmid pKLN23-49 contains a 2184 bp nucleic acid molecule referred to herein
 5 as nglmS-49₂₁₈₄, which comprises a mutant *glmS* gene. The nucleic acid sequence of
 nglmS-49₂₁₈₄ is represented herein as SEQ ID NO:17. A nucleic acid molecule spanning
 from nucleotide 124 through 1953 of SEQ ID NO:17, referred to herein as nglmS-49₁₈₃₀,
 represents an open reading frame encoding a mutant glucosamine-6-phosphate synthase
 of the present invention, with an initiation codon spanning from nucleotides 124-126 and
 10 a termination codon spanning from nucleotides 1951-1953 of SEQ ID NO:17. The
 nucleic acid sequence of nglmS-49₁₈₃₀ is represented herein as SEQ ID NO:18. SEQ ID
 NO:18 encodes a mutant glucosamine-6-phosphate synthase protein of 609 amino acids
 referred to herein as GlcN6P-S-49, the deduced amino acid sequence of which is
 represented herein as SEQ ID NO:19. SEQ ID NO:17 has a nucleic acid sequence that
 15 is identical to positions 1130 through 3313 of SEQ ID NO:13 (i.e., SEQ ID NO:14),
 except for the mutations as indicated for plasmid pKLN23-49 in Table 5. SEQ ID NO:18
 has a nucleic acid sequence that is identical to positions 1253 through 3082 of SEQ ID
 NO:13 (i.e., SEQ ID NO:15), except for the mutations as indicated for plasmid pKLN23-
 49 in Table 5.

20 Plasmid pKLN23-54 contains a 2184 bp nucleic acid molecule referred to herein
 as nglmS-54₂₁₈₄, which comprises a mutant *glmS* gene. The nucleic acid sequence of
 nglmS-54₂₁₈₄ is represented herein as SEQ ID NO:20. A nucleic acid molecule spanning
 from nucleotide 124 through 1953 of SEQ ID NO:20, referred to herein as nglmS-54₁₈₃₀,
 represents an open reading frame encoding a mutant glucosamine-6-phosphate synthase
 25 of the present invention, with an initiation codon spanning from nucleotides 124-126 and
 a termination codon spanning from nucleotides 1951-1953 of SEQ ID NO:20. The
 nucleic acid sequence of nglmS-54₁₈₃₀ is represented herein as SEQ ID NO:21. SEQ ID
 NO:21 encodes a mutant glucosamine-6-phosphate synthase protein of 609 amino acids
 referred to herein as GlcN6P-S-54, the deduced amino acid sequence of which is
 30 represented herein as SEQ ID NO:22. SEQ ID NO:20 has a nucleic acid sequence that
 is identical to positions 1130 through 3313 of SEQ ID NO:13 (i.e., SEQ ID NO:14),
 except for the mutations as indicated for plasmid pKLN23-54 in Table 5. SEQ ID NO:21

has a nucleic acid sequence that is identical to positions 1253 through 3082 of SEQ ID NO:13 (i.e., SEQ ID NO:15), except for the mutations as indicated for plasmid pKLN23-54 in Table 5.

5 Plasmid pKLN23-124 contains a 2184 bp nucleic acid molecule referred to herein as nglmS-124₂₁₈₄, which comprises a mutant *glmS* gene. The nucleic acid sequence of nglmS-124₂₁₈₄ is represented herein as SEQ ID NO:23. A nucleic acid molecule spanning from nucleotide 124 through 1953 of SEQ ID NO:23, referred to herein as nglmS-124₁₈₃₀, represents an open reading frame encoding a mutant glucosamine-6-phosphate synthase of the present invention, with an initiation codon spanning from nucleotides 124-126 and
10 a termination codon spanning from nucleotides 1951-1953 of SEQ ID NO:23. The nucleic acid sequence of nglmS-124₁₈₃₀ is represented herein as SEQ ID NO:24. SEQ ID NO:24 encodes a mutant glucosamine-6-phosphate synthase protein of 609 amino acids referred to herein as GlcN6P-S-124, the deduced amino acid sequence of which is represented herein as SEQ ID NO:25. SEQ ID NO:23 has a nucleic acid sequence that
15 is identical to positions 1130 through 3313 of SEQ ID NO:13 (i.e., SEQ ID NO:14), except for the mutations as indicated for plasmid pKLN23-124 in Table 5. SEQ ID NO:24 has a nucleic acid sequence that is identical to positions 1253 through 3082 of SEQ ID NO:13 (i.e., SEQ ID NO:15), except for the mutations as indicated for plasmid pKLN23-124 in Table 5.

20 To verify that the same mutations were present in the strains into which the mutant *glmS* genes were integrated into the chromosome, PCR products were generated from genomic DNA isolated from strains 2123-49, 2123-54, and 2123-124. For PCR
amplification, the primers listed in Example 3 for the mutagenesis of the gene (SEQ ID NO:3 and SEQ ID NO:4) were used. PCR reactions were carried out in 50 μ L reactions
25 consisting of 20 mM TrisHCl (pH 8.8), 10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM MgSO₄, 0.1% Triton X-100, 0.1 mg/mL nuclease-free bovine serum albumin, 0.05 mM each deoxynucleotide triphosphate, 2 μ M each primer, 1.25 U cloned *Pfu* DNA polymerase (Stratagene), and 160 ng of genomic DNA. The complete reactions were placed in a RoboCycler Gradient 96 Temperature Cycler (Stratagene). After 3 minutes at 94°C, the
30 following three steps were repeated for 30 cycles: (1) 30 seconds at 94°C; (2) 30 seconds at 47°C; and (3) 2 minutes at 72°. This was followed with a 7 minute incubation at 72°C.

The resulting DNA contained the expected amplification product in addition to extraneous products. The product containing the *glmS* gene was purified using a QIAquick PCR purification kit, followed by electrophoresis of the purified product on an agarose gel, isolation of the correct band using a QIAquick gel extraction kit, and reamplification using this isolated DNA as a template. The reactions with the isolated DNA were amplified in a similar fashion as the original amplification described above, except that 40 ng of DNA was used as template, and only 20 cycles of amplification were performed. The product from this second amplification reaction was recovered as described above.

The presence of mutations in the genomic DNA was verified using primers specific for the DNA regions containing the mutations identified in the plasmids. For 2123-49, these included primers PK-1 (SEQ ID NO:5), PK-3 (SEQ ID NO:7), PK-4 (SEQ ID NO:8), and PK-5A (SEQ ID NO:9). For 2123-124, primers PK-1 (SEQ ID NO:5), PK-4 (SEQ ID NO:8) and PK-5 (SEQ ID NO:9) were used. For 2123-54, the entire PCR product was sequenced using all eight primers described earlier (SEQ ID NOs:5-12). Sequencing of the PCR products confirmed the presence of the mutations identified from the plasmids and listed in Table 5.

Example 9

This example describes the construction of strains containing a mutant *glmS* gene encoding a product containing only the glycine to serine alteration at position 472 (SEQ ID NO:22) from strain 2123-54.

As indicated in Table 5, the only amino acid change in the GlcN6P synthase enzyme for strain 2123-124 (GlcN6P-S-124) is a leucine to proline alteration at position 469 (SEQ ID NO:25), unambiguously defining this mutation as being responsible for the overproduction of glucosamine by strain 2123-124. This would suggest the possibility that the glycine to serine alteration at position 472 (gly-ser472; SEQ ID NO:22) of GlcN6P-S-54 in strain 2123-54 was likewise responsible for the glucosamine overproduction phenotype for this strain. In an effort to demonstrate this, the alteration was isolated away from the other two amino acid alterations in the GlcN6P-S-54 amino acid sequence (SEQ ID NO:22) of strain 2123-54 (i.e., Ala-Thr39 and Arg-Cys250) by

digesting plasmid pKLN23-54 with *EcoRI* and *HinDIII*. These enzymes each have unique cleavage sites on the plasmid and cut at positions 2241 and 3305, respectively (positions indicated with respect to the equivalent positions in SEQ ID NO:13 for pKLN23-28), resulting in fragments of 1064 and 6344 base pairs. The smaller fragment contains mutations in which the gly→ser472 alteration is the only amino acid change in this portion of GlcN6P-S-54. This smaller fragment was ligated to the corresponding larger fragment from pKLN23-28 containing the wild type *glmS* gene.

Two plasmids resulting from this ligation were designated pKLN23-149 and pKLN23-151. Sequencing the DNA from these plasmids using primers PK-1 (SEQ ID NO:5), PK-3 (SEQ ID NO:7), and PK-4 (SEQ ID NO:8) verified that these plasmids contained the mutation at position 2666 present in plasmid pKLN23-54 but not the mutations at positions 1367 and 2000 (Table 5 with reference to SEQ ID NO:13).

The nucleic acid sequence of the 2184 base pairs between positions 1130 and 3313 of plasmid pKLN23-149 (these positions being determined relative to the equivalent positions in SEQ ID NO:13) are referred to herein as nucleic acid molecule nglmS-149₂₁₈₄, the nucleic acid sequence of which is represented by SEQ ID NO:26. SEQ ID NO:26 contains a nucleic acid sequence spanning nucleotides 124 through 1953, referred to herein as nglmS-149₁₈₃₀, which represents an open reading frame encoding a mutant glucosamine-6-phosphate synthase of the present invention, with an initiation codon spanning from nucleotides 124-126 and a termination codon spanning from nucleotides 1951-1953 of SEQ ID NO:26. The nucleic acid sequence of nglmS-149₁₈₃₀ is represented herein as SEQ ID NO:27. SEQ ID NO:27 encodes a mutant glucosamine-6-phosphate synthase protein of 609 amino acids referred to herein as GlcN6P-S-149, the deduced amino acid sequence of which is represented herein as SEQ ID NO:28.

The nucleic acid sequence of the 2184 base pairs between positions 1130 and 3313 of plasmid pKLN23-151 (these positions being determined relative to the equivalent positions in SEQ ID NO:13) are referred to herein as nucleic acid molecule nglmS-151₂₁₈₄, the nucleic acid sequence of which is represented by SEQ ID NO:29. SEQ ID NO:29 contains a nucleic acid sequence spanning nucleotides 124 to 1953, referred to herein as nglmS-151₁₈₃₀, which represents an open reading frame encoding a mutant glucosamine-6-phosphate synthase of the present invention, with an initiation codon spanning from

nucleotides 124-126 and a termination codon spanning from nucleotides 1951-1953 of SEQ ID NO:29. The nucleic acid sequence of nglmS-151₁₈₃₀ is represented herein as SEQ ID NO:30. SEQ ID NO:30 encodes a mutant glucosamine-6-phosphate synthase protein of 609 amino acids referred to herein as GlcN6P-S-151, the deduced amino acid sequence of which is represented herein as SEQ ID NO:31.

Strains isogenic to strain 2123-12 except for mutations conferring the gly→ser472 alteration were constructed using the scheme indicated in Fig. 7. Strains 2123-149 and 2123-151 were generated from plasmids pKLN23-149 and pKLN23-151, respectively. The presence of the mutation at position 2666 (SEQ ID NO:13) and the absence of mutations at positions 1367 and 2000 were verified by sequencing of PCR products from genomic DNA of these strains using the methods described in Example 8.

Example 10

This example compares properties of GlcN6P synthase enzymes from strains 2123-12, 2123-49, 2123-54, 2123-124, 2123-149, and 2123-151.

Strains 2123-12, 2123-49, 2123-54, 2123-124, 2123-149, and 2123-151, described in the examples above, were grown overnight in LB broth at 37°C then transferred to fresh LB broth. Cultures were grown to an absorbance at 600 nm of 0.8 to 0.9, then induced for GlcN6P synthase production by the addition of 1 mM IPTG. The cultures were grown for an additional three hours at 37° and harvested. Extracts were prepared from cells harvested from those cultures as described in Example 2 and were assayed for glucosamine-6-phosphate synthase using the spectrophotometric assay as described in Example 2 except that a fructose-6-phosphate concentration of 20 mM was used. The enzyme was assayed in the presence and absence of added glucosamine-6-phosphate. In the absence of glucosamine-6-phosphate, the specific activities measured for these enzymes were similar except for that from strain 2123-124. The data from Table 6 suggests that the latter strain encodes a less active variant of the enzyme.

Table 6

Specific Activities of GlcN6P Synthase from Glucosamine-Producing Strains

Strain	Specific Activity, $\mu\text{mol min}^{-1} \text{mg}^{-1}$
2123-12	0.385
2123-49	0.375
2123-54	0.416
2123-124	0.0076
2123-149	0.494
2123-151	0.515

Fig. 10 shows that the GlcN6P synthase enzymes from strains 2123-49, 2123-54, and 2123-124 are significantly less inhibited by GlcN6P than the enzyme from strain 2123-12. Enzymes from strains 2123-149 and 2123-151 are slightly less inhibited by

Thermal stability of the enzymes was also examined using these extracts. The extracts were incubated at 45°C (Fig. 11A) or 50°C (Fig. 11B) for various periods then assayed using the spectrophotometric assay. Figs. 11A and 11B show that the enzymes from 2123-49 and 2123-54 are much less stable than the wild type enzyme from strain 2123-12. The enzyme from strain 2123-124 is comparable in stability to the wild type enzyme, and the enzymes from 2123-149 and 2123-151 are slightly less stable under the incubation conditions described here.

Example 11

The following example illustrates the effects of isopropylthio- β -D-galactoside (IPTG) concentration and temperature on glucosamine production.

Cultures of strains 2123-54 and 2123-124 were grown for 20 hours at 37°C on M9A medium (14 g/L K_2HPO_4 , 16 g/L KH_2PO_4 , 1 g/L $\text{Na}_3\text{Citrate} \cdot 2\text{H}_2\text{O}$, 5 g/L $(\text{NH}_4)_2\text{SO}_4$, pH 7.0) supplemented with 20 g/L glucose, 1 mM MgSO_4 , 0.1 mM CaCl_2 , and varying amounts of IPTG. At the end of the growth period, a sample was taken and the glucosamine concentration in the culture supernatant was assayed using the

Elson-Morgan assay described in Example 2. The results shown in Fig. 12 indicate that the optimum IPTG concentration for production is about 0.2 mM.

Subsequently, strain 2123-54 was grown in the same medium as described above in shake flasks with either 0.2 or 1 mM IPTG and at 30°C or 37°C. These flask cultures were also fed glucose and ammonium sulfate as described in Example 4. At various intervals, samples were taken and the glucosamine concentrations in culture supernatants were assayed using the Elson-Morgan assay described in Example 2. Fig. 13 shows that under the conditions of this experiment, there was little difference in glucosamine production associated with the differences in IPTG concentration. However, growth at 30°C resulted in higher glucosamine production than did growth at 37°C. Results shown in Figs. 14A and 14B further indicated that at 30°C (Fig. 14A), glucosamine production continued after growth had ceased, while at 37°C (Fig. 14B), growth and glucosamine production occurred in concert.

When strains 2123-49 and 2123-124 were grown with 0.2 mM IPTG at 30°C, glucosamine production also occurred after growth had ceased, as shown in Figs. 15A (2123-49) and 15B (2123-124). As observed at 37°C, the highest concentrations of glucosamine were obtained with strain 2123-54, followed by 2123-124 and 2123-49. Also tested were strains 2123-149 and 2123-151 which produced negligibly higher concentrations of glucosamine than did 2123-12 (Table 7).

Table 7

Production of Glucosamine at 30°

Strain	Maximum Glucosamine Production, g/L
2123-12	0.3
2123-49	4.6
2123-54	7.2
2123-124	5.3
2123-149	0.6
2123-151	0.6

Example 12

The following example illustrates that glucosamine can be produced at higher concentrations in fermentor cultures of strain 2123-54 as compared to shake flasks. This example also illustrates that in fermentors, strain 2123-54 produces more glucosamine at 30°C than at 37°C.

Fermentation cultures of strain 2123-54 were cultivated in the medium shown in Table 8. Fermentations were run using NaOH for pH control to pH 6.7 and were fed a mixture of 33% glucose, 8% ammonium sulfate. Aeration and agitation were adjusted to maintain a dissolved oxygen concentration of greater than 20% of air saturation.

Table 8
Fermentation Medium

Component	Amount, g/L
K ₂ HFO ₄	14
KH ₂ PO ₄	16
Na ₃ Citrate·2H ₂ O	1
(NH ₄) ₂ SO ₄	5
MgSO ₄	0.12
CaCl ₂	0.011
Mazu 204 Antifoam	0.5 mL/L
IPTG	0.048
Glucose	20
Trace Metals	*

*Trace metal composition is 0.7 mg/L CoCl₂, 1.7 mg/L H₃BO₃, 0.6 mg/L CuCl₂·2H₂O, 10.5 mg/L FeCl₃·6H₂O, 12 mg/L MnCl₂·4H₂O, 1.5 mg/L Na₂Mo₄·2H₂O, 1.5 mg/L ZnCl₂.

In the following experiment, three fermentations were run in one-liter vessels containing an initial volume of 600 mL. Variables tested were as follows.

Fermentor #1: The mixture of 33% glucose and 8% ammonium sulfate was fed at such a rate that no glucose accumulated in the fermentor. Growth was at 37°.

Fermentor #2: As with fermentation #1 except that growth was at 30°.

Fermentor #3: As with fermentation #2 except that the feed rate was increased to maintain a constant glucose concentration in the fermentor of 5 to 10 g/L.

Results from these fermentations are shown in Figs. 16A, 16B and 16C. Comparison of the results from fermentors 1 (Fig. 16A) and 2 (Fig. 16B) shows that
5 glucosamine titers are markedly higher at 30°C than they are at 37°C, as observed in shake flasks. The maximum glucosamine concentration observed was in the glucose-excess fermentor 3 grown at 30°C (Fig. 16C), at 10.9 g/L. At 30°C, growth and glucosamine concentration appeared to coincide, and there appeared to be a slight advantage to growth under glucose-excess. In subsequent fermentation experiments, run under conditions
10 similar to fermentor #3, glucosamine concentrations in excess of 12 g/L have been obtained (data not shown).

In summary, the present inventors have described herein the use of metabolic engineering to create the first glucosamine overproducing strains of *E. coli*. The concept, proven here, will be generally applicable to any microorganism having a pathway for the
15 production of amino sugars, or to any recombinant microorganism into which a pathway for the production of amino sugars has been introduced. In addition to the present strategy for creating a glucosamine-producing strain (i.e., eliminating glucosamine degradation and uptake and increasing expression of the *glmS* gene), the present inventors have also established that reducing product inhibition of glucosamine-6-phosphate
20 synthase by glucosamine-6-phosphate improves glucosamine production.

While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those
skilled in the art. However, it is to be expressly understood that such modifications and adaptations are within the spirit and scope of the present invention, as set forth in the
25 following claims.

What is claimed:

1. A method to produce glucosamine by fermentation, comprising:
 - (a) culturing in a fermentation medium comprising assimilable sources of carbon, nitrogen and phosphate, a microorganism having a genetic modification in an amino sugar metabolic pathway, said amino sugar metabolic pathway selected from the group consisting of a pathway for converting glucosamine-6-phosphate into another compound, a pathway for synthesizing glucosamine-6-phosphate, a pathway for transport of glucosamine or glucosamine-6-phosphate out of said microorganism, a pathway for transport of glucosamine into said microorganism, and a pathway which competes for substrates involved in the production of glucosamine-6-phosphate;
wherein said step of culturing produces a product selected from the group consisting of glucosamine-6-phosphate and glucosamine from said microorganism; and
 - (b) recovering said product.
2. The method of Claim 1, wherein said glucosamine-6-phosphate is intracellular and said glucosamine is extracellular, wherein said step of recovering comprises a recovering step selected from the group consisting of recovering said glucosamine-6-phosphate from said microorganism, recovering said glucosamine from said fermentation medium, and a combination thereof.
3. The method of Claim 1, wherein said product is glucosamine which is secreted into said fermentation medium by said microorganism and wherein said step of recovering comprises purification of said glucosamine from said fermentation medium.
4. The method of Claim 1, wherein said product is intracellular glucosamine-6-phosphate and said step of recovering comprises isolating said glucosamine-6-phosphate from said microorganism.
5. The method of Claim 1, wherein said product is intracellular glucosamine-6-phosphate and said step of recovering further comprises dephosphorylating said glucosamine-6-phosphate to produce glucosamine.
6. The method of Claim 1, wherein said step of culturing comprises maintaining said source of carbon at a concentration of from about 0.5% to about 5% in said fermentation medium.

7. The method of Claim 1, wherein said step of culturing is performed at a temperature from about 28°C to about 37°C.

8. The method of Claim 1, wherein said step of culturing is performed in a fermentor.

5 9. The method of Claim 1, wherein at least about 1 g/L of said product is recovered.

10 10. The method of Claim 1, wherein said genetic modification is a modification in a nucleic acid molecule encoding a protein selected from the group consisting of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme II^{Nag}, glucosamine-6-phosphate synthase, phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridyltransferase, phosphofructokinase, Enzyme II^{Glc} of the PEP:glucose PTS, EIIM₁P/III^{Man} of the PEP:mannose PTS, and a phosphatase.

15 11. The method of Claim 1, wherein said microorganism has a genetic modification that increases glucosamine-6-phosphate synthase action.

12. The method of Claim 11, wherein said genetic modification results in overexpression of glucosamine-6-phosphate synthase by said microorganism.

20 13. The method of Claim 11, wherein said genetic modification comprises transformation of said microorganism with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase which has glucosamine-6-phosphate synthase enzymatic activity, wherein said recombinant nucleic acid molecule is operatively linked to a transcription control sequence.

25 14. The method of Claim 13, wherein said recombinant nucleic acid molecule comprises a nucleic acid sequence encoding a homologue of glucosamine-6-phosphate synthase.

15. The method of Claim 13, wherein said recombinant nucleic acid molecule comprises a nucleic acid sequence encoding amino acid sequence SEQ ID NO:16.

30 16. The method of Claim 13, wherein said recombinant nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15.

17. The method of Claim 13, wherein said recombinant nucleic acid molecule comprises a nucleic acid molecule selected from the group consisting of pKLN23-28, nglmS-28₂₁₈₄ and nglmS-28₁₈₃₀.

18. The method of Claim 13, wherein said recombinant nucleic acid molecule is integrated into the genome of said microorganism.

19. The method of Claim 13, wherein said recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase comprises a genetic modification which increases the action of said glucosamine-6-phosphate synthase.

20. The method of Claim 19, wherein said recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase comprises a genetic modification which reduces glucosamine-6-phosphate product inhibition of said glucosamine-6-phosphate synthase.

21. The method of Claim 19, wherein said genetic modification results in at least one amino acid modification selected from the group consisting of deletion, insertion, inversion, substitution and derivatization of at least one amino acid residue of said glucosamine-6-phosphate synthase, said at least one amino acid modification resulting in increased glucosamine-6-phosphate synthase action.

22. The method of Claim 21, wherein said at least one amino acid modification is at an amino acid sequence position, corresponding to amino acid sequence SEQ ID NO:16, selected from the group consisting of Ile(4), Ile(272), Ser(450), Ala(39), Arg(250), Gly(472), Leu(469), and combinations thereof.

23. The method of Claim 22, wherein said amino acid modification is a substitution selected from the group consisting of:

(a) an amino acid residue having an aliphatic hydroxyl side group for

Ile(4);

(b) an amino acid residue having an aliphatic hydroxyl side group for

Ile(272);

(c) an amino acid residue having an aliphatic side group for Ser(450);

(d) an amino acid residue having an aliphatic hydroxyl side group for

Ala(39);

(e) an amino acid residue having a sulfur-containing side group for Arg(250);

(f) an amino acid residue having an aliphatic hydroxyl side group for Gly(472);

5 (g) an amino acid residue having an aliphatic side group for Leu(469);

(h) and combinations of (a)-(g).

24. The method of Claim 22, wherein said amino acid modification is a substitution selected from the group consisting of: Ile(4) to Thr, Ile(272) to Thr, Ser(450) to Pro, Ala(39) to Thr, Arg(250) to Cys, Gly(472) to Ser, Leu(469) to Pro, and
10 combinations thereof.

25. The method of Claim 22, wherein said amino acid modification is a substitution of a proline residue for a leucine residue at amino acid sequence position Leu(469).

26. The method of Claim 22, wherein said amino acid modification is a substitution of an amino acid residue selected from the group consisting of:
15

- (a) a threonine residue for an alanine residue at position Ala(39);
- (b) a cysteine residue for an arginine residue at position Arg(250);
- (c) a serine residue for a glycine residue at position Gly(472); and
- (d) any combination of (a), (b), or (c).

20 27. The method of Claim 22, wherein said amino acid modification is a substitution selected from the group consisting of:

- (a) a threonine residue for an isoleucine residue at position Ile(4);
- (b) a threonine residue for an isoleucine residue at position Ile(272);
- (c) a proline residue for a serine residue at position Ser(450); and
- 25 (d) any combination of (a), (b), or (c).

28. The method of Claim 19, wherein said recombinant nucleic acid molecule comprises a nucleic acid sequence encoding a glucosamine-6-phosphate synthase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:28 and SEQ ID NO:31.

30 29. The method of Claim 19, wherein said recombinant nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:17,

SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:30.

30. The method of Claim 19, wherein said recombinant nucleic acid molecule comprises a nucleic acid molecule selected from the group consisting of pKLN23-49, pKLN23-54, pKLN23-124, pKLN23-149, pKLN23-151, nglmS-49₂₁₈₄, nglmS-49₁₈₃₀, nglmS-54₂₁₈₄, nglmS-54₁₈₃₀, nglmS-124₂₁₈₄, nglmS-124₁₈₃₀, nglmS-149₂₁₈₄, nglmS-149₁₈₃₀, nglmS-151₂₁₈₄ and nglmS-151₁₈₃₀.

31. The method of Claim 19, wherein said recombinant nucleic acid molecule is integrated into the genome of said microorganism.

32. The method of Claim 11, wherein said microorganism has at least one additional genetic modification in a gene encoding a protein selected from the group consisting of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme II^{Nag}, phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridyltransferase, phosphofructokinase, Enzyme II^{Glc} of the PEP:glucose PTS, and EIIM,P/III^{Mam} of the PEP:mannose PTS, wherein said genetic modification decreases the action of said protein.

33. The method of Claim 11, wherein said microorganism has at least one additional genetic modification in a gene encoding a phosphatase, wherein said genetic modification increases the action of said phosphatase.

34. The method of Claim 11, wherein said microorganism has additional modifications in genes encoding the following proteins: *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase and *N*-acetyl-glucosamine-specific enzyme II^{Nag};

wherein said genetic modification decreases the action of said proteins.

35. The method of Claim 34, wherein said genetic modification is a deletion of at least a portion of said genes.

36. The method of Claim 1, wherein said microorganism is selected from the group consisting of bacteria and yeast.

37. The method of Claim 1, wherein said microorganism is a bacterium of the genus *Escherichia*.

38. The method of Claim 1, wherein said microorganism is *Escherichia coli*.

39. The method of Claim 38, wherein said genetic modification is a mutation in an *Escherichia coli* gene selected from the group consisting of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, *manXYZ*, *glmM*, *pfkB*, *pfkA*, *glmU*, *glmS*, *ptsG* and a phosphatase gene.

5 40. A method to produce glucosamine by fermentation, comprising:

(a) culturing in a fermentation medium comprising assimilable sources of carbon, nitrogen and phosphate, an *Escherichia coli* transformed with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase, wherein said recombinant nucleic acid molecule increases glucosamine-6-phosphate synthase action in
10 said *Escherichia coli*, and wherein said recombinant nucleic acid molecule is operatively linked to a transcription control sequence;

wherein said step of culturing produces a product selected from the group consisting of glucosamine-6-phosphate and glucosamine from said *Escherichia coli*; and

(b) recovering said product.

15 41. The method of Claim 40, wherein said *Escherichia coli* has at least one additional genetic modification in at least one gene selected from the group consisting of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, *manXYZ*, *glmM*, *pfkB*, *pfkA*, *glmU*, *glmS*, *ptsG* and a phosphatase gene.

20 42. The method of Claim 40, wherein said at least one additional genetic modification comprises a deletion of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, and a mutation in *manXYZ*, said modification resulting in decreased action of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase and *N*-acetyl-glucosamine-specific enzyme II^{Nag}.

25 43. A microorganism for producing glucosamine by a biosynthetic process, said microorganism being transformed with a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase, said recombinant nucleic acid molecule being operatively linked to a transcription control sequence and comprising a genetic modification which increases the action of said glucosamine-6-phosphate synthase;

30 wherein expression of said recombinant nucleic acid molecule increases production of glucosamine by said microorganism.

44. The microorganism of Claim 43, wherein said microorganism has at least one additional genetic modification in a gene encoding a protein selected from the group consisting of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme Π^{Nag} , phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridyltransferase, phosphofructokinase, Enzyme Π^{Glc} of the PEP:glucose PTS, and EIIM_P/III^{Man} of the PEP:mannose PTS, wherein said genetic modification decreases the action of said protein.

45. The microorganism of Claim 43, wherein said microorganism has at least one additional genetic modification in a gene encoding a phosphatase, wherein said genetic modification increases the action of said phosphatase.

46. The microorganism of Claim 43, wherein said microorganism is *Escherichia coli* which has at least one additional genetic modification in a gene selected from the group consisting of *nagA*, *nagB*, *nagC*, *nagD*, *nagE*, *manXYZ*, *glmM*, *pfkB*, *pfkA*, *glmU*, and *ptsG*, wherein said genetic modification decreases the action of a protein encoded by said gene.

47. The microorganism of Claim 43, wherein said microorganism is *Escherichia coli* which has a deletion of *nag* regulon genes.

48. The microorganism of Claim 43, wherein said microorganism is *Escherichia coli* which has a deletion of *nag* regulon genes and a genetic modification in *manXYZ* genes such that proteins encoded by said *manXYZ* genes have decreased action.

49. The microorganism of Claim 43, wherein said microorganism produces at least about 1 g/L of glucosamine when cultured from about 10 to about 60 hours at from about 28°C to about 37°C to a cell density of at least about 8 g/L by dry cell weight, in a pH 7.0 fermentation medium comprising: 14 g/L K₂HPO₄, 16 g/L KH₂PO₄, 1 g/L Na₃Citrate·2H₂O, 5 g/L (NH₄)₂SO₄, 20 g/L glucose, 10 mM MgSO₄, 1 mM CaCl₂, and from about 0.2mM to about 1 mM IPTG.

50. A microorganism for producing glucosamine by a biosynthetic process, said microorganism comprising:

(a) a recombinant nucleic acid molecule encoding glucosamine-6-phosphate synthase, said recombinant nucleic acid molecule being operatively linked to

a transcription control sequence, wherein expression of said recombinant nucleic acid molecule increases the action of glucosamine-6-phosphate synthase by said microorganism; and,

(b) at least one genetic modification in a gene encoding a protein selected from the group consisting of *N*-acetylglucosamine-6-phosphate deacetylase, glucosamine-6-phosphate deaminase, *N*-acetyl-glucosamine-specific enzyme II^{Nag}, phosphoglucosamine mutase, glucosamine-1-phosphate acetyltransferase-*N*-acetylglucosamine-1-phosphate uridylyltransferase, phosphofructokinase, Enzyme II^{Glc} of the PEP:glucose PTS, and EIIM,P/III^{Man} of the PEP:mannose PTS, wherein said genetic modification decreases the action of said protein.

51. The microorganism of Claim 50, wherein said microorganism has at least one additional genetic modification in a gene encoding a phosphatase, wherein said genetic modification increases the action of said phosphatase.

52. A recombinant nucleic acid molecule comprising a nucleic acid sequence encoding a glucosamine-6-phosphate synthase having a genetic modification that results in increased glucosamine-6-phosphate synthase action.

53. The recombinant nucleic acid molecule of Claim 52, wherein said genetic modification results in at least one amino acid modification selected from the group consisting of deletion, insertion, inversion, substitution and derivatization of at least one amino acid residue of said glucosamine-6-phosphate synthase, said at least one amino acid modification resulting in increased glucosamine-6-phosphate synthase action.

54. The recombinant nucleic acid molecule of Claim 52, wherein said recombinant nucleic acid molecule comprises a nucleic acid sequence encoding a glucosamine-6-phosphate synthase comprising an amino acid sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:28 and SEQ ID NO:31.

55. The recombinant nucleic acid molecule of Claim 52, wherein said recombinant nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:30.

56. A glucosamine-6-phosphate synthase which has glucosamine-6-phosphate synthase action, said synthase being encoded by a nucleic acid sequence having a genetic modification that results in increased glucosamine-6-phosphate synthase action.

57. The glucosamine-6-phosphate synthase of Claim 56, wherein said synthase
5 comprises at least one amino acid modification selected from the group consisting of deletion, insertion, inversion, substitution and derivatization of at least one amino acid residue.

58. The glucosamine-6-phosphate synthase of Claim 56, wherein said synthase is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID
10 NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:29 and SEQ ID NO:30.

59. The glucosamine-6-phosphate synthase of Claim 56, wherein said synthase comprises an amino acid sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:28 and SEQ ID NO:31.

60. A method to produce glucosamine by fermentation, comprising:
15

(a) culturing in a fermentation medium comprising assimilable sources of carbon, nitrogen and phosphate, a genetically modified microorganism having increased glucosamine-6-phosphate synthase action, wherein said genetically modified microorganism is produced by a process comprising the steps of:

20 (1) generating modifications in an isolated nucleic acid molecule comprising a nucleic acid sequence encoding glucosamine-6-phosphate synthase to create a plurality of modified nucleic acid sequences;

(2) transforming microorganisms with said modified nucleic acid sequences to produce genetically modified microorganisms;

25 (3) screening said genetically modified microorganisms for glucosamine-6-phosphate synthase action; and,

(4) selecting said genetically modified microorganisms which have increased glucosamine-6-phosphate synthase action; wherein said step of culturing produces a product selected from the group
30 consisting of glucosamine-6-phosphate and glucosamine from said microorganism; and,

(b) recovering said product.

1/16




Fig. 1




Fig. 2

Strain Construction Scheme




Fig. 3

4/16

Effects of Initial Glucose Concentrations and Glucose Feeds
on Glucosamine Production




Fig. 4

5/16




Fig. 5


Product Inhibition of Glucosamine 6-phosphate Synthase in Mutant *glmS* Clones

Fig. 6

7/16




Fig. 7

8/16

Product Inhibition of Glucosamine 6-phosphate Synthase in Strains with Integrated Mutant *glnS* Genes




Fig. 8

9/16


Glucosamine Production in Strains with Integrated Mutant *glmS* Genes

Fig. 9

10/16




Fig. 10

11/16




Fig. 11A




Fig. 11B

12/16




Fig. 12

13/16




Fig. 13

14/16




Fig. 14A




Fig. 14B

15/16




Fig. 15A




Fig. 15B

16/16




Fig. 16A




Fig. 16B




Fig. 16C

SEQUENCE LISTING

<110> Berry, Alan
Burlingame, Richard P.
Millis, James R.

<120> PROCESS AND MATERIALS FOR PRODUCTION OF GLUCOSAMINE

<130> 3161-18-C1-PCT

<140>

<141>

<150> PCT/US98/00800

<151> 1998-01-14

<150> 60/035,494

<151> 1997-01-14

<160> 31

<170> PatentIn Ver. 2.0

<210> 1

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 1

cggctctccca tgtgtggaat tggtggcgc

29

<210> 2

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 2

ctctagagcg ttgatattca gtcaattaca aaca

34

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 3
atggatgagc agacgatggt

20

<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 4
cctcgaggtc gacggtatc

19

<210> 5
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 5
tggatgagca gacgatgg

18

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 6
tccgtcacag gtatttattc

20

<210> 7
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:primer

<400> 7
agctgcgtgg tgcgtac

17

<210> 8
<211> 18
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 8

ggaccgtggt tcagttcg

18

<210> 9

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 9

gccgtggcga tcagtac

17

<210> 10

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

gccaatcacc agcggac

17

<210> 11

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 11

atggtttccc gctactgg

18

<210> 12

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 12

gaaccaaggt aaccacgc

18

<210> 13

<211> 7408

<212> DNA
 <213> Escherichia coli

<220>
 <221> RBS
 <222> (1240)..(1245)

<220>
 <221> promoter
 <222> (1165)..(1181)

<220>
 <221> conflict
 <222> (2509)..(2510)

<400> 13
 gaattgatcc cgctcgtttta caacgtcgtg actgggaaaa ccctggcgtt acccaactta 60
 atcgccttgc agcacatccc cctttcgcca gctggcgtaa tagcgaagag gcccgaccg 120
 atcgcccttc ccaacagttg cgcagcctga atggcgaatg gcgctttgcc tggtttccgg 180
 caccagaagc ggtgccggaa agctggctgg agtgcgatct tcctgaggcc gatactgtcg 240
 tcgtcccctc aaactggcag atgcacggtt acgatgcgcc catctacacc aacgtaacct 300
 atcccattac ggtcaatccg ccgtttgttc ccacggagaa tccgacgggt tgttactcgc 360
 tcacatttaa tgttgatgaa agctggctac aggaaggcca gacgcgaatt atttttgatg 420
 gcgttaactc ggcgtttcat ctgtggtgca acgggcgctg ggtcggttac ggccaggaca 480
 gtcgtttgcc gtctgaattt gacctgagcg catttttacg cgccggagaa aaccgcctcg 540
 cggatgatgg gctgcgttgg agtgacggca gttatctgga agatcaggat atgtggcgga 600
 tgagcggcat tttccgtgac gtctcgttgc tgcataaacc gactacacaa atcagcgatt 660
 tccatgttgc cactcgcttt aatgatgatt tcagccgcgc tgtactggag gctgaagttc 720
 agatgtgcgg cgagttgcgt gactacctac gggtaacagt ttctttatgg cagggtgaaa 780
 cgcaggtcgc cagcggcacc gcgcctttcg gcggtgaaat tatcgatgag cgtggtggtt 840
 atgccgatcg cgtcacacta cgtctgaacg tcgaaaacc gaaactgtgg agcgcgaaa 900
 tccggaatct cctatcgtcg gtggttgaac tgcacaccgc cgacggcacg ctgattgaag 960
 cagaagcctg cgatgtcgggt ttccgcgagg tgccgattga aaatggctctg ctgctgctga 1020
 acggcaagcc gttgctgatt cgaggcgta accgtcacga gcatcatcct ctgcatggtc 1080
 aggtcatgga tgagcagacg atggtgcagg atctccaccg cggcggcggc cgctctagaa 1140
 ctagtggatc tcgatccgc gaaattaata cgactcacta taggggaatt gtgagcggat 1200
 aacaattccc ctctagaaat aattttgttt aactttaaga aggagatata ccatgtgtgg 1260

aattgttggc gcgatcgcg aacgtgatgt agcagaaatc cttcttgaag gtttacgtcg 1320
tctggaatac cgcgatatg actctgccgg tctggccgtt gttgatgcag aaggatcatat 1380
gacccgcctg cgtcgccctg gtaaagtcca gatgctggca caggcagcgg aagaacatcc 1440
tctgcatggc ggcactggta ttgctcacac tctgtggcg acccacggtg aaccttcaga 1500
agtgaatgcg catccgcagt tttctgaaca cattgtggtg gtgcataacg gcatcatcga 1560
aaaccatgaa ccgctgcgtg aagagctaaa agcgcggtggc tataccttcg tttctgaaac 1620
cgacaccgaa gtgattgccc atctgggtgaa ctgggagctg aaacaaggcg ggactctgcy 1680
tgaggccgtt ctgctgcta tcccgagct gcgtggtgcy tacggtacag tgatcatgga 1740
ctcccgctac ccggataccc tgctggcgcc acgttctggt agtccgctgg tgattggcct 1800
ggggatgggc gaaaacttta tctcttctga ccagctggcg ctgttgccgg tgaccgcgtc 1860
ctttatcttc cttgaagagg gcgatattgc ggaaatcact cgccgttcgg taaacatctt 1920
cgataaaaact ggcgcggaag taaaacgtca ggatatcgaa tccaatctgc aatatgacgc 1980
gggcgataaa ggcatttacc gtcactacat gcagaaagag atctacgaac agccgaacgc 2040
gatcaaaaac acccttaccg gacgcatcag ccacggctcag gttgatttaa gcgagctggg 2100
accgaacgcc gacgaactgc tgcgaaggt tgagcatatt cagatcctcg cctgtggtac 2160
ttcttataac tccggtatgg tttcccgcta ctggtttgaa tctgtagcag gtattccgtg 2220
cgacgtcgaa atcgctctg aattccgcta tgcgaaatct gccgtgcgtc gtaacagcct 2280
gatgatcacc ttgtcacagt ctggcgaaac cgcgataacc ctggctggcc tgcgtctgtc 2340
gaaagagctg ggttaccttg gttcactggc aatctgtaac gttccgggtt cttctctggt 2400
gcgcgaatcc gatctggcg taatgaccaa cgcggtgaca gaaatcgcg tggcatccac 2460
taaagcattc accactcagt taactgtgt gttgatgctg gtggcgaagc tgtctgcct 2520
gaaaggctct gatgcctcca ttgaacatga catcgtgcat ggtctgcagg cgctgccgag 2580
ccgtattgag cagatgctgt ctcaggacaa acgcatgaa gcgctggcag aagatttctc 2640
tgacaaaacat cacgcgctgt tcctgggccc tggcgatcag taccgaatcg cgctggaagg 2700
cgcatgaag ttgaaagaga tctcttacat tcacgctgaa gcctacgctg ctggcgaact 2760
gaaacacggt ccgctggcg taattgatgc cgatatgccg gttattgtt ttgcaaccgaa 2820
caacgaattg ctggaaaaac tgaaatccaa cattgaagaa gttcgcgcg gtggcggtca 2880
gttgatgtc ttcgccgatc aggatgcggg ttttgtaagt agcgataaca tgcacatcat 2940

cgagatgccg catgtggaag aggtgattgc accgatcttc tacaccgttc cgctgcagct 3000
gctggcttac catgtcgcgc tgatcaaagg caccgacgtt gaccagccgc gtaacctggc 3060
aaaatcgggt acggttgagt aataaatgga tgccctgcgt aagcggggca tttttcttcc 3120
tgttatgttt ttaatcaaac atcctgcaa ctccatgtga caaacgtca tcttcggcta 3180
ctttttctct gtcacagaat gaaaattttt ctgtcatctc ttcgttatta atgtttgtaa 3240
ttgactgaat atcaacgtc tagaggggct agagcggccg ccaccgcgtt ggagctccgt 3300
cgacaagctt atcgataccg tcgacctcga gggggggccc ggtaccgagg acgcgttcga 3360
ataaatacct gtgacggaag atcacttcgc agaataaata aatcctgggt tccctgttga 3420
taccgggaag ccctgggcca acttttggcg aaaatgagac gttgatcggc acgtaagagg 3480
ttccaacttt caccataatg aaataagatc actaccgggc gtattttttg agttatcgag 3540
attttcagga gctaaggaag ctaaaatgga gaaaaaatc actggatata ccaccgttga 3600
tatatcccaa tggcatcgta aagaacattt tgaggcattt cagtcagttg ctcaatgtac 3660
ctataaccag accgttcagc tggatattac ggccttttta aagaccgtaa agaaaaataa 3720
gcacaagttt tatccggcct ttattcacat tcttgccgc ctgatgaatg ctcatccgaa 3780
attccgtatg gcaatgaaag acggtgagct ggtgatatgg gatagtgttc acccttgta 3840
caccgttttc catgagcaa ctgaaacgtt ttcacgcgc tggagtgaat accacgacga 3900
ttccggcag tttctacaca tatattcgca agatgtggcg tgttacggtg aaaacctggc 3960
ctatttcctt aaagggttta ttgagaatat gtttttcgtc tcagccaatc cctgggtgag 4020
ttcaccagt tttgatttaa acgtggccaa tatggacaac ttcttcgccc cgttttcac 4080
catgggcaaa tattatacgc aaggcgacaa ggtgctgatg ccgctggcga ttcaggttca 4140
tcatgccgtt tgtgatggct tccatgtcgg cagaatgctt aatgaattac aacagtactg 4200
cgatgagtgg cagggcgggg cgtaattttt ttaaggcagt tattggtgcc cttaaagcc 4260
tggtgctacg cctgaataag tgataataag cggatgaatg gcagaaattc ggacgcgtca 4320
attcgagctc ctgcaactgga tgggtggcgt ggtatgtaag ccgctggcaa geggtgaagt 4380
gcctctggat gtcgtccac aaggtaaaca gttgattgaa ctgcctgaac taccgcagcc 4440
ggagagcgcc gggcaactct ggctcacagt acgcgtagtg caaccgaacg cgaccgcatg 4500
gtcagaagcc gggcacatca gcgcctggca gcagtggcgt ctggcgaaa acctcagtgt 4560
gacgtcccc gccgcgtccc acgccatccc gcatctgacc accagcgaaa tggatttttg 4620
catcgagctg ggtaataagc gttggcaatt taaccgccag tcaggctttc tttcacagat 4680

gtggattggc gataaaaaac aactgctgac gccgctgcgc gatcagttca cccgtgcacc 4740
gctggataac gacattggcg taagtgaagc gaccgcatt gaccctaacg cctgggtcga 4800
acgctggaag gcggcgggcc attaccaggc cgaagcagcg ttgttgagc gcacggcaga 4860
tacacttgct gatgcggtgc tgattacgac cgctcacgcg tggcagcatc aggggaaaaac 4920
cttatttatc agccggaaaa cctaccggat tgatggtagt ggtcaaattg cgattaccgt 4980
tgatgttgaa gtggcgagcg atacaccgca tccggcgcg attggcctga actgccagct 5040
ggcgagcagta gcagagcggg taaactggct cggattaggc ccgcaagaaa actatcccg 5100
ccgccttact gccgcctgtt ttgaccgctg ggatctgccca ttgtcagaca tgtatacccc 5160
gtacgtcttc ccgagcgaaa acggctctgc ctgcgggacg cgcaattga attatggccc 5220
acaccagtgg cgcggcgact tccagttcaa catcagccgc tacagtcaac agcaactgat 5280
ggaaaccagc catcgccatc tgctgcacgc ggaagaaggc acatggctga atatcgacgg 5340
tttccatagc cgggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg 5400
ctcttccgct tctcgcctca ctgactcgtc gcgctcggc gttcggctgc ggcgagcgg 5460
atcagctcac tcaaaggcgg taatacgggt atccacagaa tcaggggata acgcaggaaa 5520
gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cggtgctggc 5580
gtttttccat aggtccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag 5640
gtggcgaaaac ccgacaggac tataaagata ccaggcggtt cccctggaa gctccctcgt 5700
gcgctctcct gttccgacct tgccgcttac cggatacctg tccgccttc tcccttcggg 5760
aagcgtggcg ctttctcaat gctcacgctg taggtatctc agttcgggtg aggtcgttcg 5820
ctccaagctg ggctgtgtgc acgaaccccc cggtcagccc gaccgctgcg ccttatccgg 5880
taactatcgt cttgagtcca acccggtgag acacgactta tcgccactgg cagcagccac 5940
tggtaacagg attagcagag cgaggtatgt aggcgggtgct acagagttct tgaagtgggtg 6000
gcctaactac ggctacacta gaaggacagt atttgggtatc tgcgctctgc tgaagccagt 6060
taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg 6120
tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc 6180
tttgatcttt tctacggggc ctgacgctca gtggaacgaa aactcacgtt aagggatttt 6240
ggatcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt 6300
taaataatc taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag 6360

tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt 6420
 cgtgtagata actacgatac gggagggcctt accatctggc cccagtgtg caatgatacc 6480
 gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc 6540
 cgagcgcaga agtggctctg caactttatc cgcctccatc cagtctatta attgttgccg 6600
 ggaagctaga gtaagtagtt cgccagttaa tagtttgccg aacgttggtg ccattgctac 6660
 aggcacgtg gtgtcacgct cgctgtttgg tatggcttca ttcagctccg gttcccaacg 6720
 atcaaggcga gttacatgat ccccatgtt gtgcaaaaaa gcggttagct ccttcgggtcc 6780
 tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggta tggcagcact 6840
 gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc 6900
 aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat 6960
 acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc 7020
 ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaaccac 7080
 tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa 7140
 aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact 7200
 catactcttc ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg 7260
 atacatattt gaattgattt agaaaaataa acaaataagg gttccgcgca catttccccg 7320
 aaaagtgcc cctgacgtct aagaaacat tattatcatg acattaacct ataaaaatag 7380
 gcgtatcacg aggccctttc gtcttcaa 7408

<210> 14

<211> 2184

<212> DNA

<213> Escherichia coli

<400> 14

ccgctctaga actagtggat ctgatcccg cgaaattaat acgactcact ataggggaat 60
 tgtgagcga taacaattcc cctctagaaa taattttgtt taactttaag aaggagatat 120
 accatgtgtg gaattgttgg cgcgatcgcg caacgtgatg tagcagaaat ccttcttgaa 180
 ggtttacgtc gtctggaata ccgcgatgat gactctgccg gtctggccgt tgttgatgca 240
 gaaggtcata tgaccgcct gcgtcgctc ggtaaagtcc agatgctggc acaggcagcg 300
 gaagaacatc ctctgcatgg cggcactggg attgtcaca ctgctgggc gaccacggg 360
 gaaccttcag aagtgaatgc gcatccgat gttctgaac acattgtggg ggtgcataac 420

ggcatcatcg aaaaccatga accgctgcgt gaagagctaa aagcgctgg ctataccttc 480
 gtttctgaaa ccgacaccga agtgattgcc catctggtga actgggagct gaaacaaggc 540
 gggactctgc gtgaggccgt tctgcgtgct atccccgagc tgcgtggtgc gtacgggtaca 600
 gtgatcatgg actcccgta cccggatacc ctgctggcgg caggttctgg tagtccgctg 660
 gtgattggcc tggggatggg cgaaaacttt atcgcttctg accagctggc gctgttgccg 720
 gtgaccgctc gctttatctt ccttgaagag ggcgatattg cggaaatcac tcgccgttcg 780
 gtaaacaatct tcgataaaac tggcgcgga gtaaaacgtc aggatatcga atccaatctg 840
 caatatgacg cgggcgataa aggcatttac cgtcactaca tgcagaaaga gatctacgaa 900
 cagccgaacg cgatcaaaaa cacccttacc ggacgcata gccacggtca ggttgattta 960
 agcgagctgg gaccgaacgc cgacgaactg ctgtcgaagg ttgagcatat tcagatcctc 1020
 gcctgtggta cttcttataa ctccggtatg gtttcccgct actggtttga atcgctagca 1080
 ggtattccgt gcgacgtcga aatgcctct gaattccgct atcgcaaata tgcgctgcgt 1140
 cgtaacagcc tgatgatcac cttgtcacag tctggcgaaa ccgcggtac cctggctggc 1200
 ctgcgtctgt cgaaagagct gggttacctt ggttcaactg caatctgtaa cgttccgggt 1260
 tcttctctgg tgcgcgaatc cgatctggcg ctaatgacca acgcgggtac agaaatcggc 1320
 gtggcatcca ctaaagcatt caccactcag ttaactgtgc tgttgatgct ggtggcgaag 1380
 ctgtctcgcc tgaaaggctt ggatgcctcc attgaacatg acatcgtgca tggctcgcag 1440
 gcgctgccga gccgtattga gcagatgctg tctcaggaca aacgcattga agcgtggca 1500
 gaagatttct ctgacaaaca tcacgcgctg ttcctgggcc gtggcgatca gtaccaatac 1560
 gcgctggaag gcgcattgaa gttgaaagag atctcttaca ttcacgtga agcctacgct 1620
 gctggcgaac tgaaacacgg tccgctggcg ctaattgatg ccgatatgcc ggttattgtt 1680
 gttgcaccga acaacgaatt gctggaaaaa ctgaaatcca acattgaaga agttcgcgcg 1740
 cgtggcggtc agttgtatgt cttcgccgat caggatgcgg gttttgtaag tagcgataac 1800
 atgcacatca tcgagatgcc gcattgtgaa gaggtgattg caccgatctt ctacaccgtt 1860
 ccgctgcagc tctgtgctta ccatgtcgcg ctgatcaaag gcaccgacgt tgaccagccg 1920
 cgtaacctgg caaaatcggt tacggttgag taataaatgg atgccctgcg taagcggggc 1980
 atttttcttc ctgttatgtt tttaataaaa catcctgcc actccatgtg acaaaccgtc 2040
 atcttcggct actttttctc tgtcacagaa tgaaaatctt tctgtcatct cttcgttatt 2100
 aatgtttgta attgactgaa tatcaacgct ctgagggggc tagagcggcc gccaccgcgg 2160

tggagctccg tcgacaagct tatc

2184

<210> 15
 <211> 1830
 <212> DNA
 <213> Escherichia coli

<220>
 <221> CDS
 <222> (1)..(1830)

<400> 15
 atg tgt gga att gtt ggc gcg atc gcg caa cgt gat gta gca gaa atc 48
 Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15

ctt ctt gaa ggt tta cgt cgt ctg gaa tac cgc gga tat gac tct gcc 96
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30

ggt ctg gcc gtt gtt gat gca gaa ggt cat atg acc cgc ctg cgt cgc 144
 Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45

ctc ggt aaa gtc cag atg ctg gca cag gca gcg gaa gaa cat cct ctg 192
 Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60

cat ggc ggc act ggt att gct cac act cgc tgg gcg acc cac ggt gaa 240
 His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80

cct tca gaa gtg aat gcg cat ccg cat gtt tct gaa cac att gtg gtg 288
 Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95

gtg cat aac ggc atc atc gaa aac cat gaa ccg ctg cgt gaa gag cta 336
 Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110

aaa gcg cgt ggc tat acc ttc gtt tct gaa acc gac acc gaa gtg att 384
 Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
 115 120 125

~~gcc cat atg~~ gtg aac tgg gag ctg aaa caa ggc ggg act ctg cgt gag 432
 Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
 130 135 140

gcc gtt ctg cgt gct atc ccg cag ctg cgt ggt gcg tac ggt aca gtg 480
 Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
 145 150 155 160

atc atg gac tcc cgt cac ccg gat acc ctg ctg gcg gca cgt tct ggt 528
 Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly
 165 170 175

agt ccg ctg gtg att ggc ctg ggg atg ggc gaa aac ttt atc gct tct	576
Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser	
180 185 190	
gac cag ctg gcg ctg ttg ccg gtg acc cgt cgc ttt atc ttc ctt gaa	624
Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu	
195 200 205	
gag ggc gat att gcg gaa atc act cgc cgt tcg gta aac atc ttc gat	672
Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp	
210 215 220	
aaa act ggc gcg gaa gta aaa cgt cag gat atc gaa tcc aat ctg caa	720
Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln	
225 230 235 240	
tat gac gcg ggc gat aaa ggc att tac cgt cac tac atg cag aaa gag	768
Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu	
245 250 255	
atc tac gaa cag ccg aac gcg atc aaa aac acc ctt acc gga cgc atc	816
Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile	
260 265 270	
agc cac ggt cag gtt gat tta agc gag ctg gga ccg aac gcc gac gaa	864
Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu	
275 280 285	
ctg ctg tcg aag gtt gag cat att cag atc ctc gcc tgt ggt act tct	912
Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser	
290 295 300	
tat aac tcc ggt atg gtt tcc cgc tac tgg ttt gaa tcg cta gca ggt	960
Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly	
305 310 315 320	
att ccg tgc gac gtc gaa atc gcc tct gaa ttc cgc tat cgc aaa tct	1008
Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser	
325 330 335	
gcc gtg cgt cgt aac agc ctg atg atc acc ttg tca cag tct ggc gaa	1056
Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu	
340 345 350	
acc gcg gat acc ctg gct ggc ctg cgt ctg tcg aaa gag ctg ggt tac	1104
Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr	
355 360 365	
ctt ggt tca ctg gca atc tgt aac gtt ccg ggt tct tct ctg gtg cgc	1152
Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg	
370 375 380	
gaa tcc gat ctg gcg cta atg acc aac gcg ggt aca gaa atc ggc gtg	1200
Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val	
385 390 395 400	

gca tcc act aaa gca ttc acc act cag tta act gtg ctg ttg atg ctg Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu	1248
405 410 415	
gtg gcg aag ctg tct cgc ctg aaa ggt ctg gat gcc tcc att gaa cat Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His	1296
420 425 430	
gac atc gtg cat ggt ctg cag gcg ctg ccg agc cgt att gag cag atg Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met	1344
435 440 445	
ctg tct cag gac aaa cgc att gaa gcg ctg gca gaa gat ttc tct gac Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp	1392
450 455 460	
aaa cat cac gcg ctg ttc ctg ggc cgt ggc gat cag tac cca atc gcg Lys His His Ala Leu Phe Leu Gly Arg Gly Asp Gln Tyr Pro Ile Ala	1440
465 470 475 480	
ctg gaa ggc gca ttg aag ttg aaa gag atc tct tac att cac gct gaa Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu	1488
485 490 495	
gcc tac gct gct ggc gaa ctg aaa cac ggt ccg ctg gcg cta att gat Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp	1536
500 505 510	
gcc gat atg ccg gtt att gtt gtt gca ccg aac aac gaa ttg ctg gaa Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu	1584
515 520 525	
aaa ctg aaa tcc aac att gaa gaa gtt cgc gcg cgt ggc ggt cag ttg Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu	1632
530 535 540	
tat gtc ttc gcc gat cag gat gcg ggt ttt gta agt agc gat aac atg Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met	1680
545 550 555 560	
cac atc atc gag atg ccg cat gtg gaa gag gtg att gca ccg atc ttc His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe	1728
565 570 575	
tac acc gtt ccg ctg cag ctg ctg gct tac cat gtc gcg ctg atc aaa Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys	1776
580 585 590	
ggc acc gac gtt gac cag ccg cgt aac ctg gca aaa tcg gtt acg gtt Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val	1824
595 600 605	
gag taa Glu	1830
610	

<210> 16

<211> 609

<212> PRT

<213> Escherichia coli

<400> 16

Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15

Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30

Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45

Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60

His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80

Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95

Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110

Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
 115 120 125

Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
 130 135 140

Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
 145 150 155 160

Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly
 165 170 175

Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser
 180 185 190

Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu
 195 200 205

Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp
 210 215 220

Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln
 225 230 235 240

Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu
 245 250 255

Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile
 260 265 270

Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu
 275 280 285
 Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser
 290 295 300
 Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly
 305 310 315 320
 Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser
 325 330 335
 Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu
 340 345 350
 Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr
 355 360 365
 Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg
 370 375 380
 Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val
 385 390 395 400
 Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu
 405 410 415
 Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His
 420 425 430
 Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met
 435 440 445
 Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp
 450 455 460
 Lys His His Ala Leu Phe Leu Gly Arg Gly Asp Gln Tyr Pro Ile Ala
 465 470 475 480
 Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu
 485 490 495
 Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp
 500 505 510
 Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu
 515 520 525
 Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu
 530 535 540
 Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met
 545 550 555 560
 His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe
 565 570 575

Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
 580 585 590

Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
 595 600 605

Glu

<210> 17

<211> 2184

<212> DNA

<213> Escherichia coli

<400> 17

ccgctctaga actagtggat ctcgatcccg cgaaattaat acgactcact ataggggaat 60
 tgtgagcgga taacaattcc cctctagaaa taattttggt taactttaag aaggagatat 120
 accatgtgtg gaactgttgg cgcgatcgcg caacgtgatg tagcagaaat ctttcttgaa 180
 ggtttacgtc gtctggaata ccgcgatat gactctgccg gtctggccgt tgttgatgca 240
 gaaggtcata tgacccgcct gcgtcgccct ggtaaagtcc agatgctggc acaggcagcg 300
 gaagaacatc ctctgcatgg cggcactggg attgctcaca ctgctgggc gaccacggg 360
 gaaccttcag aagtgaatgc gcatccgat gtttctgaac acattgtggg ggtgcataac 420
 ggcacatcg aaaacatga accgctgctg gaagagctaa aagcgcgtgg ctataccttc 480
 gtttctgaaa ccgacaccga agtgattgcc catctggtga actgggagct gaaacaaggc 540
 gggactctgc gtgaggcgt tctgctgct atccgcagc tgcgtggtgc gtacggtaca 600
 gtgatcatgg actcccgta cccggatacc ctgctggcgg cacgttctgg tagtccgtg 660
 gtgattggcc tggggatgg cgaaaacttt atcgcttctg accagctggc gctgttgccg 720
 gtgaccgtc gctttatctt ccttgaagag ggcgatattg cggaatcac tcgccgttcg 780
 gtaaacaatc tcgataaaac tggcgcgga gtaaaacgtc aggatatcga atccaatctg 840
 caatatgacg cgggcgataa aggcatttac cgtcactaca tgcagaaaga gatctacgaa 900
 cagccgaacg cgatcaaaaa cacccttacc ggacgcacca gccacggtca ggttgattta 960
 agcgagctgg gaccgaacgc cgacgaactg ctgtcgaagg ttgagcatat tcagatcctc 1020
 gcctgtggtg cttcttataa ctccggtatg gtttcccgct actggtttga atcgctagca 1080
 ggtattccgt gcgacgtcga aatgcctct gaattccgct atcgcaaac tgccgtgcgt 1140
 cgtaacagcc tgatgatcac cttgtcacag tctggcgaaa ccgcggtac cctggctggc 1200
 ctgctctgt cgaaagagct gggttacctt ggttactgg caatctgtaa cgttccgggt 1260

tcttctctg tgcgcgaatc cgatctggcg ctaatgacca acgcgggtac agaaatcggc 1320
 gtggcatcca ctaaagcatt caccactcag ttaactgtgc tgttgatgct ggtggcgaag 1380
 ctgtctcgcc tgaaaggtct ggatgcctcc attgaacatg acatcgtgca tggctctgcag 1440
 gcgctgccga gccgtattga gcagatgctg cctcaggaca aacgcattga agcgctggca 1500
 gaagatttct ctgacaaaca tcacgcgctg ttcctggggc gtggcgatca gtaccaatc 1560
 gcgctggaag gcgcattgaa gttgaaagag atctcttaca ttcacgctga agcctacgct 1620
 gctggcgaac tgaaacacgg tccgctggcg ctaattgatg ccgatatgcc ggttattgtt 1680
 gttgcaccga acaacgaatt gctggaaaaa ctgaaatcca acattgaaga agttcgcgcg 1740
 cgtggcggtc agttgtatgt cttcgccgat caggatgcgg gttttgtaag tagcgataac 1800
 atgcacatca tcgagatgcc gcatgtggaa gaggtgattg caccgatctt ctacaccgtt 1860
 ccgctgcagc tgctggctta ccatgtcgcg ctgatcaaag gcaccgacgt tgaccagccg 1920
 cgtaacctgg caaaatcggg tacggttgag taataaatgg atgccctgcg taagcggggc 1980
 atttttcttc ctgttatgtt tttaatcaaa catcctgcc actccatgtg acaaaccgtc 2040
 atcttcggct actttttctc tgtcacagaa tgaaaatttt tctgtcatct cttcgttatt 2100
 aatgtttgta attgactgaa tatcaacgct ctagaggggc tagagcggcc gccaccgcg 2160
 tggagctccg tcgacaagct tacc 2184

<210> 18

<211> 1830

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1)..(1830)

<400> 18

atg tgt gga act gtt ggc gcg atc gcg caa cgt gat gta gca gaa atc 48
 Met Cys Gly Thr Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15

ctt ctt gaa ggt tta cgt cgt ctg gaa tac cgc gga tat gac tct gcc 96
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30

ggt ctg gcc gtt gtt gat gca gaa ggt cat atg acc cgc ctg cgt cgc 144
 Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45

ctc ggt aaa gtc cag atg ctg gca cag gca gcg gaa gaa cat cct ctg 192
 Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu

50	55	60	
cat ggc ggc act ggt att gct cac act cgc tgg gcg acc cac ggt gaa			240
His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu			
65	70	75	80
cct tca gaa gtg aat gcg cat ccg cat gtt tct gaa cac att gtg gtg			288
Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val			
	85	90	95
gtg cat aac ggc atc atc gaa aac cat gaa ccg ctg cgt gaa gag cta			336
Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu			
	100	105	110
aaa gcg cgt ggc tat acc ttc gtt tct gaa acc gac acc gaa gtg att			384
Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile			
	115	120	125
gcc cat ctg gtg aac tgg gag ctg aaa caa gcg ggg act ctg cgt gag			432
Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu			
	130	135	140
gcc gtt ctg cgt gct atc ccg cag ctg cgt ggt gcg tac ggt aca gtg			480
Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val			
	145	150	155
atc atg gac tcc cgt cac ccg gat acc ctg ctg gcg gca cgt tct ggt			528
Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly			
	165	170	175
agt ccg ctg gtg att ggc ctg ggg atg ggc gaa aac ttt atc gct tct			576
Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser			
	180	185	190
gac cag ctg gcg ctg ttg ccg gtg acc cgt cgc ttt atc ttc ctt gaa			624
Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu			
	195	200	205
gag ggc gat att gcg gaa atc act cgc cgt tcc gta aac atc ttc gat			672
Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp			
	210	215	220
aaa act ggc gcg gaa gta aaa cgt cag gat atc gaa tcc aat ctg caa			720
Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln			
	225	230	235
tat gac gcg ggc gat aaa ggc att tac cgt cac tac atg cag aaa gag			768
Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu			
	245	250	255
atc tac gaa cag ccg aac gcg atc aaa aac acc ctt acc gga cgc acc			816
Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Thr			
	260	265	270
agc cac ggt cag gtt gat tta agc gag ctg gga ccg aac gcc gac gaa			864
Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu			
	275	280	285

ctg ctg tcg aag gtt gag cat att cag atc ctc gcc tgt ggt act tct Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser 290 295 300	912
tat aac tcc ggt atg gtt tcc cgc tac tgg ttt gaa tcg cta gca ggt Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly 305 310 315 320	960
att ccg tgc gac gtc gaa atc gcc tct gaa ttc cgc tat cgc aaa tct Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser 325 330 335	1008
gcc gtg cgt cgt aac agc ctg atg atc acc ttg tca cag tct ggc gaa Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu 340 345 350	1056
acc gcg gat acc ctg gct ggc ctg cgt ctg tcg aaa gag ctg ggt tac Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr 355 360 365	1104
ctt ggt tca ctg gca atc tgt aac gtt ccg ggt tct tct ctg gtg cgc Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg 370 375 380	1152
gaa tcc gat ctg gcg cta atg acc aac gcg ggt aca gaa atc ggc gtg Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val 385 390 395 400	1200
gca tcc act aaa gca ttc acc act cag tta act gtg ctg ttg atg ctg Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu 405 410 415	1248
gtg gcg aag ctg tct cgc ctg aaa ggt ctg gat gcc tcc att gaa cat Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His 420 425 430	1296
gac atc gtg cat ggt ctg cag gcg ctg ccg agc cgt att gag cag atg Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met 435 440 445	1344
ctg cct cag gac aaa cgc att gaa gcg ctg gca gaa gat ttc tct gac Leu Pro Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp 450 455 460	1392
aaa cat cac gcg ctg ttc ctg ggc cgt ggc gat cag tac cca atc gcg Lys His His Ala Leu Phe Leu Gly Arg Gly Asp Gln Tyr Pro Ile Ala 465 470 475 480	1440
ctg gaa ggc gca ttg aag ttg aaa gag atc tct tac att cac gct gaa Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu 485 490 495	1488
gcc tac gct gct ggc gaa ctg aaa cac ggt ccg ctg gcg cta att gat Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp 500 505 510	1536

gcc gat atg ccg gtt att gtt gtt gca ccg aac aac gaa ttg ctg gaa 1584
 Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu
 515 520 525
 aaa ctg aaa tcc aac att gaa gaa gtt cgc gcg cgt ggc ggt cag ttg 1632
 Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu
 530 535 540
 tat gtc ttc gcc gat cag gat gcg ggt ttt gta agt agc gat aac atg 1680
 Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met
 545 550 555 560
 cac atc atc gag atg ccg cat gtg gaa gag gtg att gca ccg atc ttc 1728
 His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe
 565 570 575
 tac acc gtt ccg ctg cag ctg ctg gct tac cat gtc gcg ctg atc aaa 1776
 Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
 580 585 590
 ggc acc gac gtt gac cag ccg cgt aac ctg gca aaa tcg gtt acg gtt 1824
 Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
 595 600 605
 gag taa 1830
 Glu
 610

<210> 19
 <211> 609
 <212> PRT
 <213> Escherichia coli

<400> 19
 Met Cys Gly Thr Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30
 Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45
 Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60
 His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80
 Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95
 Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110
 Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile

115	120	125
Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu		
130	135	140
Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val		
145	150	155
Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly		
	165	170
Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser		
	180	185
Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu		
	195	200
Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp		
	210	215
Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln		
	225	230
Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu		
	245	250
Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Thr		
	260	265
Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu		
	275	280
Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser		
	290	295
Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly		
	305	310
Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser		
	325	330
Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu		
	340	345
Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr		
	355	360
Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg		
	370	375
Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val		
	385	390
Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu		
	405	410
Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His		

420 425 430
 Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met
 435 440 445
 Leu Pro Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp
 450 455 460
 Lys His His Ala Leu Phe Leu Gly Arg Gly Asp Gln Tyr Pro Ile Ala
 465 470 475 480
 Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu
 485 490 495
 Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp
 500 505 510
 Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu
 515 520 525
 Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu
 530 535 540
 Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met
 545 550 555 560
 His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe
 565 570 575
 Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
 580 585 590
 Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
 595 600 605

Glu

<210> 20
 <211> 2184
 <212> DNA
 <213> Escherichia coli

<400> 20
 ccgctctaga actagtggat ctcgatcccg cgaaattaat acgactcact atagggaat 60
 tctgagcga taacaattcc cctctagaaa taattttgtt taactttaag aaggagatat 120
 accatgtgtg gaattgttgg cgcgatcgcg caacgtgatg tagcagaaat ccttcttgaa 180
 ggtttacgtc gtctggaata ccgcggatat gactctgccg gtctggccgt tgttgataca 240
 gaaggtcata tgaccgcct gcgtcgctc ggtaaagtcc agatgctggc acaggcagcg 300
 gaagaacatc ctctgcatgg cggcactggt attgctcaca ctgctgggc gaccacgggt 360
 gaaccttcag aagtgaatgc gcatccgcat gtttctgaac acattgtggt ggtgcataac 420

ggcatcatcg aaaaccatga accgctgcgt gaagagctaa aagcgcggtg ctataccttc 480
gtttctgaaa ccgacaccga agtgattgcc catctggtga actgggagct gaaacaaggc 540
gggactctgc gtgaggccgt tctgcgtgct atcccgcagc tgcgtggtgc gtacggtaca 600
gtgatcatgg actcccgtca cccggatacc ctgctggcgg cacgttctgg tagtccgctg 660
gtgattggcc tggggatggg cgaaaacttt atcgcttctg accagctggc gctgttgccg 720
gtgaccgctc gctttatctt ccttgaagag ggcgatattg cggaaatcac tcgccgttcg 780
gtaaacaatct tcgataaaac tggcgcgga gtaaaacgtc aggatatcga atccaatctg 840
caatatgacg cgggcgataa aggcatttac tgtcactaca tgcagaaaga gatctacgaa 900
cagccgaacg cgatcaaaaa cacccttacc ggacgcatca gccacggtca ggttgattta 960
agcgagctgg gaccgaacgc cgacgaactg ctgtcgaagg ttgagcatat tcagatoctc 1020
gcctgtggtg cttcttataa ctccggtatg gtttcccgct actggtttga atcgctagca 1080
ggtattccgt gcgacgtcga aatcgctcc gaattccgct atcgcaaac tgccgtgcgt 1140
cgtaacagcc tgatgatcac cttgtcacag tctggcgaaa ccgcggtac cctggctggc 1200
ctgcgtctgt cgaaagagct gggttacctt ggttactg caatctgtaa cgttccgggt 1260
tcttctctgg tgcggaatc cgatctggcg ctaatgacca acgcggtac agaaatcggc 1320
gtggcatcca ctaaagcatt caccactcag ttaactgtgc tgttgatgct ggtggcgaag 1380
ctgtctcgcc tgaaaggtct ggatgcctcc attgaacatg acatcggtga tggctcgcag 1440
gcgctgccga gccgtattga gcagatgctg tctcaggaca aacgcattga agcgctggca 1500
gaagatttct ctgacaaaca tcacgcgtg ttcctgagcc gtggcgatca gtaccaatc 1560
gcgctggaag gcgcattgaa gttgaaagag atctcttaca ttcacgtga agcctacgt 1620
gctggcgaac tgaaacacgg tccgctggcg ctaattgatg ccgatatgcc ggttattgtt 1680
gttgacccga acaacgaatt gctggaaaaa ctgaaatcca acattgaaga agttcgcgcg 1740
cgtggcggtc agttgtatgt cttcgccgat caggatgcgg gttttgtaag tagcgataac 1800
atgcacatca tcgagatgcc gcatgtggaa gaggtgattg caccgatctt ctacaccgtt 1860
ccgctgcagc tgctggctta ccatgtcgcg ctgatcaaag gcaccgacgt tgaccagccg 1920
cgtaacctgg caaaatcggg tacggttgag taataaatgg atgccctgcg taagcggggc 1980
atcttctctc ctgttatgtt tttaatcaaa catcctgcc actccatgtg acaaaccgtc 2040
atcttcggct acttttctc tgtcacagaa tgaaaatttt tctgtcatct cttcgttatt 2100

aatgtttgta attgactgaa tatcaacgct ctaggggggc tagagcggcc gccaccgcg 2160

tggagctccg tcgacaagct tatic

2184

<210> 21

<211> 1830

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1)..(1830)

<400> 21

atg tgt gga att gtt ggc gcg atc gcg caa cgt gat gta gca gaa atc 48

Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
1 5 10 15

ctt ctt gaa ggt tta cgt cgt ctg gaa tac cgc gga tat gac tct gcc 96

Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
20 25 30

ggt ctg gcc gtt gtt gat aca gaa ggt cat atg acc cgc ctg cgt cgc 144

Gly Leu Ala Val Val Asp Thr Glu Gly His Met Thr Arg Leu Arg Arg
35 40 45

ctc ggt aaa gtc cag atg ctg gca cag gca gcg gaa gaa cat cct ctg 192

Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
50 55 60

cat ggc ggc act ggt att gct cac act cgc tgg gcg acc cac ggt gaa 240

His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
65 70 75 80

cct tca gaa gtg aat gcg cat ccg cat gtt tct gaa cac att gtg gtg 288

Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
85 90 95

gtg cat aac ggc atc atc gaa aac cat gaa ccg ctg cgt gaa gag cta 336

Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
100 105 110

aaa gcg cgt ggc tat acc ttc gtt tct gaa acc gac acc gaa gtg att 384

Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
115 120 125

gcc cat ctg gtg aac tgg gag ctg aaa caa ggc ggg act ctg cgt gag 432

Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
130 135 140

gcc gtt ctg cgt gct atc ccg cag ctg cgt ggt gcg tac ggt aca gtg 480

Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
145 150 155 160

atc atg gac tcc cgt cac ccg gat acc ctg ctg gcg gca cgt tct ggt 528

Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly

	165	170	175	
agt ccg ctg gtg att ggc ctg ggg atg ggc gaa aac ttt atc gct tct				576
Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser				
	180	185	190	
gac cag ctg gcg ctg ttg ccg gtg acc cgt cgc ttt atc ttc ctt gaa				624
Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu				
	195	200	205	
gag ggc gat att gcg gaa atc act cgc cgt tcg gta aac atc ttc gat				672
Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp				
	210	215	220	
aaa act ggc gcg gaa gta aaa cgt cag gat atc gaa tcc aat ctg caa				720
Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln				
	225	230	235	240
tat gac gcg ggc gat aaa ggc att tac tgt cac tac atg cag aaa gag				768
Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Cys His Tyr Met Gln Lys Glu				
	245	250	255	
atc tac gaa cag ccg aac gcg atc aaa aac acc ctt acc gga cgc atc				816
Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile				
	260	265	270	
agc cac ggt cag gtt gat tta agc gag ctg gga ccg aac gcc gac gaa				864
Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu				
	275	280	285	
ctg ctg tcg aag gtt gag cat att cag atc ctc gcc tgt ggt act tct				912
Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser				
	290	295	300	
tat aac tcc ggt atg gtt tcc cgc tac tgg ttt gaa tcg cta gca ggt				960
Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly				
	305	310	315	320
att ccg tgc gac gtc gaa atc gcc tcc gaa ttc cgc tat cgc aaa tct				1008
Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser				
	325	330	335	
gcc gtg cgt cgt aac agc ctg atg atc acc ttg tca cag tct ggc gaa				1056
Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu				
	340	345	350	
acc gcg gat atc ctg gct ggc ctg cgt ctg tcg aaa gag ctg ggt tac				1104
Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr				
	355	360	365	
ctt ggt tca ctg gca atc tgt aac gtt ccg ggt tct tct ctg gtg cgc				1152
Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg				
	370	375	380	
gaa tcc gat ctg gcg cta atg acc aac gcg ggt aca gaa atc ggc gtg				1200
Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val				
	385	390	395	400

gca tcc act aaa gca ttc acc act cag tta act gtg ctg ttg atg ctg	1248
Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu	
405 410 415	
gtg gcg aag ctg tct cgc ctg aaa ggt ctg gat gcc tcc att gaa cat	1296
Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His	
420 425 430	
gac atc gtg cat ggt ctg cag gcg ctg ccg agc cgt att gag cag atg	1344
Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met	
435 440 445	
ctg tct cag gac aaa cgc att gaa gcg ctg gca gaa gat ttc tct gac	1392
Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp	
450 455 460	
aaa cat cac gcg ctg ttc ctg agc cgt ggc gat cag tac cca atc gcg	1440
Lys His His Ala Leu Phe Leu Ser Arg Gly Asp Gln Tyr Pro Ile Ala	
465 470 475 480	
ctg gaa ggc gca ttg aag ttg aaa gag atc tct tac att cac gct gaa	1488
Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu	
485 490 495	
gcc tac gct gct ggc gaa ctg aaa cac ggt ccg ctg gcg cta att gat	1536
Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp	
500 505 510	
gcc gat atg ccg gtt att gtt gtt gca ccg aac aac gaa ttg ctg gaa	1584
Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu	
515 520 525	
aaa ctg aaa tcc aac att gaa gaa gtt cgc gcg cgt ggc ggt cag ttg	1632
Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu	
530 535 540	
tat gtc ttc gcc gat cag gat gcg ggt ttt gta agt agc gat aac atg	1680
Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met	
545 550 555 560	
cac atc atc gag atg ccg cat gtg gaa gag gtg att gca ccg atc ttc	1728
His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe	
565 570 575	
tac acc gtt ccg ctg cag ctg ctg gct tac cat gtc gcg ctg atc aaa	1776
Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys	
580 585 590	
ggc acc gac gtt gac cag ccg cgt aac ctg gca aaa tcg gtt acg gtt	1824
Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val	
595 600 605	
gag taa	1830
Glu	
610	

<210> 22
 <211> 609
 <212> PRT
 <213> Escherichia coli

<400> 22
 Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30
 Gly Leu Ala Val Val Asp Thr Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45
 Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60
 His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80
 Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95
 Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110
 Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
 115 120 125
 Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
 130 135 140
 Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
 145 150 155 160
 Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly
 165 170 175
 Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser
 180 185 190
 Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu
 195 200 205
 Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp
 210 215 220
 Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln
 225 230 235 240
 Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Cys His Tyr Met Gln Lys Glu
 245 250 255
 Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile
 260 265 270

Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu
 275 280 285
 Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser
 290 295 300
 Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly
 305 310 315 320
 Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser
 325 330 335
 Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu
 340 345 350
 Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr
 355 360 365
 Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg
 370 375 380
 Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val
 385 390 395 400
 Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu
 405 410 415
 Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His
 420 425 430
 Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met
 435 440 445
 Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp
 450 455 460
 Lys His His Ala Leu Phe Leu Ser Arg Gly Asp Gln Tyr Pro Ile Ala
 465 470 475 480
 Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu
 485 490 495
 Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp
 500 505 510
 Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu
 515 520 525
 Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu
 530 535 540
 Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met
 545 550 555 560
 His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe
 565 570 575

Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
580 585 590

Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
595 600 605

Glu

<210> 23
<211> 2184
<212> DNA
<213> Escherichia coli

<400> 23
ccgctctaga actagtggat ctcgatcccg cgaaattaat acgactcact ataggggaat 60
tgtgagcgga taacaattcc cctctagaaa taattttggt taactttaag aaggagatat 120
accatgtgtg gaattgttgg cgcgatcgcg caacgtgatg tagcagaaat ccttcttgaa 180
ggtttacgtc gtctggaata ccgcggatat gactctgccg gtctggccgt tgttgatgca 240
gaaggtcata tgaccgcct cgcgcgcctc ggtaaagtcc agatgctggc acaggcagcg 300
gaagaacatc ctctgcatgg cggcactggg attgctcaca ctcgctgggc gaccacgggt 360
gaaccttcag aagtgaatgc gcacccgat gtttccgaac acattgtggt ggtgcataac 420
ggcatcatcg aaaaccatga accgctgcgt gaagagctaa aagcgcgtgg ctataccttc 480
gtttctgaaa ccgacaccga agtgattgcc catctggtga actgggagct gaaacaaggc 540
gggactctgc gtgaggccgt tctgcgtgct atccgcgagc tgcgtggtgc gtacggtaca 600
gtgatcatgg actcccgtca cccggatacc ctgctggcgg caggttctgg tagtccgctg 660
gtgattggcc tggggatggg cgaaaacttt atcgcttctg accagctggc gctgttgccg 720
gtgaccgctc gctttatctt ccttgaagag ggcgatattg cggaaatcac tcgccgttcg 780
gtaaacatct tcgataaaac tggcgcggaa gtaaaacgtc aggatatcga atccaatctg 840
caatatgacg cgggcgataa aggcatttac cgtcactaca tgcagaaaga gatctacgaa 900
cagccgaaatg cgatcaaaaa cacccttacc ggacgcatca gccacgggtca ggttgattta 960
agcgagctgg gaccgaacgc cgacgaactg ctgtcgaagg ttgagcatat tcagatcctc 1020
gcctgtggta cttcttataa ctccggtatg gtttcccgct actggtttga atcgctagca 1080
ggtattccgt gcgacgtcga aatgcctct gaattccgct atcgcaaata tgccgtgcgt 1140
cgtaacagcc tgatgatcac cttgtcacag tctggcgaac ccgcggatac cctggctggc 1200
ctgcgtctgt cgaaagagct gggttacctt ggttcaactg caatctgtaa cgttccgggt 1260

tcttctctgg tgcgcgaatc cgatctggcg ctaatgacca acgcgggtac agaaatcggc 1320
 gtggcatcca ctaaagcatt caccactcag ttaactgtgc tgttgatgct ggtggcgaag 1380
 ctgtctcgcc tgaaaggtct ggatgcctcc attgaacatg acatcgtgca tggctcgcag 1440
 gcgctgccga gccgtattga gcagatgctg tctcaggaca aacgcattga agcgtcggca 1500
 gaagatttct ctgacaaaca tcacgcgccg ttcctggggc gtggcgatca gtaccaatc 1560
 gcgctggaag gcgcattgaa gttgaaagag atctcttaca ttcacgctga agcctacgct 1620
 gctggcgaac tgaaacacgg tccgctggcg ctaattgatg ccgatatgcc gggtattggt 1680
 gttgcaccga acaacgaatt gctggaaaaa ctgaaatcca acattgaaga agttcgcgcg 1740
 cgtggcggtc agttgtatgt cttcgccgat caggatgcgg gttttgtaag tagcgataac 1800
 atgcacatca tcgagatgcc gcagtgtgaa gaggtgattg caccgatctt ctacaccggt 1860
 ccgctgcagc tgctggctta ccatgtcgcg ctgatcaaag gcaccgacgt tgaccagccg 1920
 cgtaacctgg caaaatcggg tacggttgag taataaatgg atgccctgcg taagcggggc 1980
 atttttcttc ctgttatgtt tttaatcaaa catcctgcc actccatgtg acaaaccgtc 2040
 atcttggct actttttctc tgtcacagaa tgaaaatttt tctgtcatct cttcgttatt 2100
 aatgtttgta attgactgaa tatcaacgct ctgagggggc tagagcggcc accaccgcgg 2160
 tggagctccg tcgacaagct tacc 2184

<210> 24

<211> 1830

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1)..(1830)

<400> 24

atg tgt gga att gtt ggc gcg atc gcg caa cgt gat gta gca gaa atc 48
 Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile

1

5

10

15

ctt ctt gaa ggt tta cgt cgt ctg gaa tac cgc gga tat gac tct gcc 96
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala

20

25

30

ggt ctg gcc gtt gtt gat gca gaa ggt cat atg acc cgc ctg cgt cgc 144
 Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg

35

40

45

ctc ggt aaa gtc cag atg ctg gca cag gca gcg gaa gaa cat cct ctg 192

Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60

cat ggc ggc act ggt att gct cac act cgc tgg gcg acc cac ggt gaa 240
 His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80

cct tca gaa gtg aat gcg cat ccg cat gtt tcc gaa cac att gtg gtg 288
 Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95

gtg cat aac ggc atc atc gaa aac cat gaa ccg ctg cgt gaa gag cta 336
 Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110

aaa gcg cgt ggc tat acc ttc gtt tct gaa acc gac acc gaa gtg att 384
 Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
 115 120 125

gcc cat ctg gtg aac tgg gag ctg aaa caa ggc ggg act ctg cgt gag 432
 Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
 130 135 140

gcc gtt ctg cgt gct atc ccg cag ctg cgt ggt gcg tac ggt aca gtg 480
 Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
 145 150 155 160

atc atg gac tcc cgt cac ccg gat acc ctg ctg gcg gca cgt tct ggt 528
 Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly
 165 170 175

agt ccg ctg gtg att ggc ctg ggg atg ggc gaa aac ttt atc gct tct 576
 Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser
 180 185 190

gac cag ctg gcg ctg ttg ccg gtg acc cgt cgc ttt atc ttc ctt gaa 624
 Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu
 195 200 205

gag ggc gat att gcg gaa atc act cgc cgt tcc gta aac atc ttc gat 672
 Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp
 210 215 220

aaa act ggc gcg gaa gta aaa cgt cag gat atc gaa tcc aat ctg caa 720
 Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln
 225 230 235 240

tat gac gcg ggc gat aaa ggc att tac cgt cac tac atg cag aaa gag 768
 Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu
 245 250 255

atc tac gaa cag ccg aac gcg atc aaa aac acc ctt acc gga cgc atc 816
 Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile
 260 265 270

agc cac ggt cag gtt gat tta agc gag ctg gga ccg aac gcc gac gaa 864
 Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu

275	280	285	
ctg ctg tcg aag gtt gag cat att cag atc ctc gcc tgt ggt act tct			912
Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser			
290	295	300	
tat aac tcc ggt atg gtt tcc cgc tac tgg ttt gaa tcg cta gca ggt			960
Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly			
305	310	315	320
att ccg tgc gac gtc gaa atc gcc tct gaa ttc cgc tat cgc aaa tct			1008
Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser			
	325	330	335
gcc gtg cgt cgt aac agc ctg atg atc acc ttg tca cag tct ggc gaa			1056
Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu			
	340	345	350
acc gcg gat acc ctg gct ggc ctg cgt ctg tcg aaa gag ctg ggt tac			1104
Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr			
	355	360	365
ctt ggt tca ctg gca atc tgt aac gtt ccg ggt tct tct ctg gtg cgc			1152
Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg			
	370	375	380
gaa tcc gat ctg gcg cta atg acc aac gcg ggt aca gaa atc ggc gtg			1200
Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val			
385	390	395	400
gca tcc act aaa gca ttc acc act cag tta act gtg ctg ttg atg ctg			1248
Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu			
	405	410	415
gtg gcg aag ctg tct cgc ctg aaa ggt ctg gat gcc tcc att gaa cat			1296
Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His			
	420	425	430
gac atc gtg cat ggt ctg cag gcg ctg ccg agc cgt att gag cag atg			1344
Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met			
	435	440	445
ctg tct cag gac aaa cgc att gaa gcg ctg gca gaa gat ttc tct gac			1392
Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp			
	450	455	460
aaa cat gac gcg ccg ttc ctg ggc cgt ggc gat cag tac cca atc gcg			1440
Lys His His Ala Pro Phe Leu Gly Arg Gly Asp Gln Tyr Pro Ile Ala			
465	470	475	480
ctg gaa ggc gca ttg aag ttg aaa gag atc tct tac att cac gct gaa			1488
Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu			
	485	490	495
gcc tac gct gct ggc gaa ctg aaa cac ggt ccg ctg gcg cta att gat			1536
Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp			
	500	505	510

gcc gat atg ccg gtt att gtt gtt gca ccg aac aac gaa ttg ctg gaa 1584
 Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu
 515 520 525

aaa ctg aaa tcc aac att gaa gaa gtt cgc gcg cgt ggc ggt cag ttg 1632
 Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu
 530 535 540

tat gtc ttc gcc gat cag gat gcg ggt ttt gta agt agc gat aac atg 1680
 Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met
 545 550 555 560

cac atc atc gag atg ccg cat gtg gaa gag gtg att gca ccg atc ttc 1728
 His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe
 565 570 575

tac acc gtt ccg ctg cag ctg ctg gct tac cat gtc gcg ctg atc aaa 1776
 Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
 580 585 590

ggc acc gac gtt gac cag ccg cgt aac ctg gca aaa tcg gtt acg gtt 1824
 Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
 595 600 605

gag taa 1830
 Glu
 610

<210> 25
 <211> 609
 <212> PRT
 <213> Escherichia coli

<400> 25
 Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15

Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30

Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45

Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60

His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80

Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95

Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110

Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
 115 120 125
 Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
 130 135 140
 Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
 145 150 155 160
 Ile Met Asp Ser Arg His Pro Asp Thr Leu Ala Ala Arg Ser Gly
 165 170 175
 Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser
 180 185 190
 Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu
 195 200 205
 Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp
 210 215 220
 Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln
 225 230 235 240
 Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu
 245 250 255
 Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile
 260 265 270
 Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu
 275 280 285
 Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser
 290 295 300
 Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly
 305 310 315 320
 Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser
 325 330 335
 Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu
 340 345 350
 Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr
 355 360 365
 Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg
 370 375 380
 Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val
 385 390 395 400
 Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu
 405 410 415

Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His
 420 425 430
 Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met
 435 440 445
 Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp
 450 455 460
 Lys His His Ala Pro Phe Leu Gly Arg Gly Asp Gln Tyr Pro Ile Ala
 465 470 475 480
 Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu
 485 490 495
 Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp
 500 505 510
 Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu
 515 520 525
 Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu
 530 535 540
 Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met
 545 550 555 560
 His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe
 565 570 575
 Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
 580 585 590
 Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
 595 600 605
 Glu

<210> 26
 <211> 2184
 <212> DNA
 <213> Escherichia coli

<400> 26
 ccgctctaga actagtggat ctcgatcccg cgaaattaat acgactcact ataggggaat 60
 tgtgagcgga taacaattcc cctctagaaa taattttggt taactttaag aaggagatat 120
 accatgtgtg gaattgttgg cgcgatcgcg caacgtgatg tagcagaaat ctttcttgaa 180
 ggtttacgtc gtctggaata cgcgggatat gactctgccg gtctggccgt tgttgatgca 240
 gaaggtcata tgacccgcct gcgtcgctc ggtaaagtcc agatgctggc acaggcagcg 300
 gaagaacatc ctctgcatgg cggcactggt attgctcaca ctcgctgggc gaccacgggt 360

gaaccttcag aagtgaatgc gcatccgcat gtttctgaac acattgtggt ggtgcataac 420
 ggcatcatcg aaaaccatga accgctgcgt gaagagctaa aagcgcgtgg ctataccttc 480
 gtttctgaaa ccgacaccga agtgattgcc catctggtga actgggagct gaaacaaggc 540
 gggactctgc gtgaggccgt tctgcgtgct atcccgagc tgcgtggtgc gtacggtaca 600
 gtgatcatgg actcccgta cccggatacc ctgctggcgg cacgttctgg tagtccgctg 660
 gtgattggcc tggggatggg cgaaaacttt atcgcttctg accagctggc gctgttgccg 720
 gtgaccctgc gctttatctt ccttgaagag ggcgatattg cggaatcac tcgccgttcg 780
 gtaaaccatct tcgataaaac tggcgcgga gtaaacgctc aggatatoga atccaatctg 840
 caatatgacg cgggcgataa aggcatttac cgtcactaca tgcagaaaga gatctacgaa 900
 cagccgaacg cgatcaaaaa cacccttacc ggacgcatca gccacgggtca ggttgattta 960
 agcgagctgg gaccgaacgc cgacgaactg ctgtcgaagg ttgagcatat tcagatcctc 1020
 gcctgtggta cttcttataa ctccggtatg gtttcccgct actggtttga atcgctagca 1080
 ggtattccgt gcgacgtcga aatgcctct gaattccgct atcgcaaata tgcgctgcgt 1140
 cgtaacagcc tgatgatcac cttgtcacag tctggcgaaa ccgcggtac cctggctggc 1200
 ctgcgtctgt cgaaagagct gggttacctt gggtcactgg caatctgtaa cgttccgggt 1260
 tcttctctgg tgcgcgaatc cgatctggcg ctaatgacca acgcggttac agaaatcggc 1320
 gtggcatcca ctaaagcatt caccactcag ttaactgtgc tgttgatgct ggtggcgaag 1380
 ctgtctcgcc tgaaaggctt ggatgcctcc attgaacatg acatcgtgca tggctcgcag 1440
 gcgctgccga gccgtattga gcagatgctg tctcaggaca aacgcattga agcgctggca 1500
 gaagatttct ctgacaaaca tcacgcgtg ttcctgagcc gtggcgatca gtaccaatc 1560
 gcgctggaag gcgattgaa gttgaaagag atctcttaca ttcacgctga agcctacgct 1620
 gctggcgaac tgaaacacgg tccgctggcg ctaattgatg ccgatatgcc ggttattgtt 1680
 gttgcaccga acaacgaatt gctggaaaaa ctgaaatcca acattgaaga agttcgcgcg 1740
 cgtggcgcgc agttgtatgt cttcgccgat caggatgcgg gttttgtaag tagcgataac 1800
 atgcacatca tcgagatgcc gcatgtggaa gaggtgattg caccgatctt ctacaccgtt 1860
 ccgctgcagc tgctggctta ccatgtcgcg ctgatcaaag gcaccgacgt tgaccagccg 1920
 cgtaacctgg caaaatcggg tacggttgag taataaatgg atgccctgcg taagcggggc 1980
 attttcttc ctgttatgtt tttaatcaaa catectgcca actccatgtg acaaaccgtc 2040
 atcttcggt actttttctc tgtcacagaa tgaaaatttt tctgtcatct cttcgttatt 2100

aatgttttga attgactgaa tatcaacgct ctaggggggc tagagcggcc gccaccgcgg 2160

tggagctccg tcgacaagct tatic

2184

<210> 27

<211> 1830

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1)..(1830)

<400> 27

atg tgt gga att gtt ggc gcg atc gcg caa cgt gat gta gca gaa atc 48
Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
1 5 10 15

ctt ctt gaa ggt tta cgt cgt ctg gaa tac cgc gga tat gac tct gcc 96
Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
20 25 30

ggc ctg gcc gtt gtt gat gca gaa ggt cat atg acc cgc ctg cgt cgc 144
Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
35 40 45

ctc ggt aaa gtc cag atg ctg gca cag gca gcg gaa gaa cat cct ctg 192
Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
50 55 60

cat ggc ggc act ggt att gct cac act cgc tgg gcg acc cac ggt gaa 240
His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
65 70 75 80

cct tca gaa gtg aat gcg cat ccg cat gtt tct gaa cac att gtg gtg 288
Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
85 90 95

gtg cat aac ggc atc atc gaa aac cat gaa ccg ctg cgt gaa gag cta 336
Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
100 105 110

aaa gcg cgt ggc tat acc ttc gtt tct gaa acc gac acc gaa gtg att 384
Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
115 120 125

gcc cat ctg gtg aac tgg gag ctg aaa caa ggc ggg act ctg cgt gag 432
Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
130 135 140

gcc gtt ctg cgt gct atc ccg cag ctg cgt ggt gcg tac ggt aca gtg 480
Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
145 150 155 160

atc atg gac tcc cgt cac ccg gat acc ctg ctg gcg gca cgt tct ggt 528

Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly	
165 170 175	
agt ccg ctg gtg att ggc ctg ggg atg ggc gaa aac ttt atc gct tct	576
Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser	
180 185 190	
gac cag ctg gcg ctg ttg ccg gtg acc cgt cgc ttt atc ttc ctt gaa	624
Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu	
195 200 205	
gag ggc gat att gcg gaa atc act cgc cgt tcg gta aac atc ttc gat	672
Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp	
210 215 220	
aaa act ggc gcg gaa gta aaa cgt cag gat atc gaa tcc aat ctg caa	720
Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln	
225 230 235 240	
tat gac gcg ggc gat aaa ggc att tac cgt cac tac atg cag aaa gag	768
Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu	
245 250 255	
atc tac gaa cag ccg aac gcg atc aaa aac acc ctt acc gga cgc atc	816
Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile	
260 265 270	
agc cac ggt cag gtt gat tta agc gag ctg gga ccg aac gcc gac gaa	864
Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu	
275 280 285	
ctg ctg tcg aag gtt gag cat att cag atc ctc gcc tgt ggt act tct	912
Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser	
290 295 300	
tat aac tcc ggt atg gtt tcc cgc tac tgg ttt gaa tcg cta gca ggt	960
Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly	
305 310 315 320	
att ccg tgc gac gtc gaa atc gcc tct gaa ttc cgc tat cgc aaa tct	1008
Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser	
325 330 335	
gcc gtg cgt cgt aac agc ctg atg atc acc ttg tca cag tct ggc gaa	1056
Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu	
340 345 350	
acc gcg gat acc ctg gct ggc ctg cgt ctg tcg aaa gag ctg ggt tac	1104
Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr	
355 360 365	
ctt ggt tca ctg gca atc tgt aac gtt ccg ggt tct tct ctg gtg cgc	1152
Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg	
370 375 380	
gaa tcc gat ctg gcg cta atg acc aac gcg ggt aca gaa atc ggc gtg	1200
Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val	

385	390	395	400	
gca tcc act aaa	gca ttc acc act	cag tta act	gtg ctg ttg atg ctg	1248
Ala Ser Thr Lys	Ala Phe Thr Thr	Gln Leu Thr Val	Leu Leu Met Leu	
405		410	415	
gtg gcg aag ctg	tct cgc ctg aaa	ggt ctg gat gcc	tcc att gaa cat	1296
Val Ala Lys Leu	Ser Arg Leu Lys	Gly Leu Asp Ala	Ser Ile Glu His	
420		425	430	
gac atc gtg cat	ggt ctg cag gcg	ctg ccg agc cgt	att gag cag atg	1344
Asp Ile Val His	Gly Leu Gln Ala	Leu Pro Ser Arg	Ile Glu Gln Met	
435		440	445	
ctg tct cag gac	aaa cgc att gaa	gcg ctg gca gaa	gat ttc tct gac	1392
Leu Ser Gln Asp	Lys Arg Ile Glu	Ala Leu Ala Glu	Asp Phe Ser Asp	
450		455	460	
aaa cat cac gcg	ctg ttc ctg agc	cgt ggc gat cag	tac cca atc gcg	1440
Lys His His Ala	Leu Phe Leu Ser	Arg Gly Asp Gln	Tyr Pro Ile Ala	
465		470	475	480
ctg gaa ggc gca	ttg aag ttg aaa	gag atc tct tac	att cac gct gaa	1488
Leu Glu Gly Ala	Leu Lys Leu Lys	Glu Ile Ser Tyr	Ile His Ala Glu	
485		490	495	
gcc tac gct gct	ggc gaa ctg aaa	cac ggt ccg ctg	gcg cta att gat	1536
Ala Tyr Ala Ala	Gly Glu Leu Lys	His Gly Pro Leu	Ala Leu Ile Asp	
500		505	510	
gcc gat atg ccg	ggt att gtt gtt	gca ccg aac aac	gaa ttg ctg gaa	1584
Ala Asp Met Pro	Val Ile Val Val	Ala Pro Asn Asn	Glu Leu Leu Glu	
515		520	525	
aaa ctg aaa tcc	aac att gaa gaa	gtt cgc gcg cgt	ggc ggt cag ttg	1632
Lys Leu Lys Ser	Asn Ile Glu Glu	Val Arg Ala Arg	Gly Gly Gln Leu	
530		535	540	
tat gtc ttc gcc	gat cag gat gcg	ggt ttt gta agt	agc gat aac atg	1680
Tyr Val Phe Ala	Asp Gln Asp Ala	Gly Phe Val Ser	Ser Ser Asp Asn	Met
545		550	555	560
cac atc atc gag	atg ccg cat gtg	gaa gag gtg att	gca ccg atc ttc	1728
His Ile Ile Glu	Met Pro His Val	Glu Glu Val Ile	Ala Pro Ile Phe	
565		570	575	
tac acc att ccg	ctg cag ctg ctg	gct tac cat gtc	gcg ctg atc aaa	1776
Tyr Thr Val Pro	Leu Gln Leu Leu	Ala Tyr His Val	Ala Leu Ile Lys	
580		585	590	
ggc acc gac gtt	gac cag ccg cgt	aac ctg gca aaa	tcg gtt acg gtt	1824
Gly Thr Asp Val	Asp Gln Pro Arg	Asn Leu Ala Lys	Ser Val Thr Val	
595		600	605	
gag taa				1830
Glu				
610				

<210> 28
 <211> 609
 <212> PRT
 <213> Escherichia coli

<400> 28

Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30
 Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45
 Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60
 His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80
 Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95
 Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110
 Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
 115 120 125
 Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
 130 135 140
 Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
 145 150 155 160
 Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly
 165 170 175
 Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser
 180 185 190
 Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu
 195 200 205
 Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp
 210 215 220
 Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln
 225 230 235 240
 Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu
 245 250 255
 Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile

260	265	270
Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu 275 280 285		
Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser 290 295 300		
Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly 305 310 315 320		
Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser 325 330 335		
Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu 340 345 350		
Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr 355 360 365		
Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg 370 375 380		
Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val 385 390 395 400		
Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu 405 410 415		
Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His 420 425 430		
Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met 435 440 445		
Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp 450 455 460		
Lys His His Ala Leu Phe Leu Ser Arg Gly Asp Gln Tyr Pro Ile Ala 465 470 475 480		
Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu 485 490 495		
Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp 500 505 510		
Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu 515 520 525		
Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu 530 535 540		
Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met 545 550 555 560		
His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe		

565

570

575

Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
 580 585 590

Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
 595 600 605

Glu

<210> 29

<211> 2184

<212> DNA

<213> Escherichia coli

<400> 29

ccgctctaga actagtggat ctcgatcccg cgaaattaat acgactcact ataggggaat 60
 tgtgagcggga taacaattcc cctctagaaa taattttggt taactttaag aaggagatat 120
 accatgtgtg gaattgttg cgcgatcgcg caacgtgatg tagcagaaat ccttcttgaa 180
 ggtttacgtc gtctggaata ccgcggatat gactctgccg gtctggccgt tgttgatgca 240
 gaaggtcata tgaccgcct gcgtcgctc ggtaaagtcc agatgctggc acaggcagcg 300
 gaagaacatc ctctgcatgg cggcactggg attgctcaca ctgctgggc gaccacggg 360
 gaaccttcag aagtgaatgc gcatccgcat gtttctgaac acattgtggg ggtgcataac 420
 ggcacatcg aaaacatga accgctgcgt gaagagctaa aagcgcgtgg ctataccttc 480
 gtttctgaaa ccgacaccga agtgattgcc catctgggta actgggagct gaaacaaggc 540
 gggactctgc gtgaggccgt tctgcgtgct atccgcagc tgcgtgggtc gtacggtaca 600
 gtgatcatgg actcccgta cccggatacc ctgctggcgg cagttcttg tagtccgctg 660
 gtgattggcc tggggatggg cgaaaacttt atcgcttctg accagctggc gctgttgccg 720
 gtgaccgctc gctttatctt ccttgaagag ggcgatattg cggaaatcac tcgccgttcg 780
 gtaaacatct tcgataaaac tggcgcggaa gtaaaacgtc aggatatcga atccaatctg 840
 caatatgacg cgggcgataa aggcatttac cgtcactaca tgcagaaaga gatctacgaa 900
 cagccgaacg cgatcaaaaa cacccttacc ggacgcatca gccacggtca ggttgattta 960
 agcgagctgg gaccgaacgc cgacgaactg ctgtcgaagg ttgagcatat tcagatcctc 1020
 gcctgtggta cttcttataa ctccggtatg gtttcccgct actggtttga atcgctagca 1080
 ggtattccgt gcgacgtcga aatcgctct gaattccgct atcgcaaate tgccgtgcgt 1140
 cgtaacagcc tgatgatcac cttgtcacag tctggcgaaa ccgcggatac cctggctggc 1200

ctgcgtctgt cgaagagct gggttacctt gggtcactgg caatctgtaa cggtccgggt 1260
 tcttctctgg tgcgcgaatc cgatctggcg ctaatgacca acgcgggtac agaaatcggc 1320
 gtggcatcca ctaaagcatt caccactcag ttaactgtgc tggtgatgct ggtggcgaag 1380
 ctgtctcgcc tgaaggtct ggatgcctcc attgaacatg acatcgtgca tggctcgcag 1440
 gcgctgccga gccgtattga gcagatgctg tctcaggaca aacgcattga agcgctggca 1500
 gaagatttct ctgacaaaca tcacgcgctg ttcctgagcc gtggcgatca gtaccaatc 1560
 gcgctggaag gcgcattgaa gttgaaagag atctcttaca ttcacgctga agcctacgct 1620
 gctggcgaac tgaacacgg tccgctggcg ctaattgatg ccgatatgcc gggtattgtt 1680
 gttgcaccga acaacgaatt gctggaaaaa ctgaaatcca acattgaaga agttcgcgcg 1740
 cgtggcggtc agttgtatgt cttcgccgat caggatgcgg gttttgtaag tagcgataac 1800
 atgcacatca tcgagatgcc gcattgtgaa gaggtgattg caccgatctt ctacaccgtt 1860
 ccgctgcagc tgctggctta ccatgtcgcg ctgatcaaag gcaccgacgt tgaccagccg 1920
 cgtaacctgg caaaatcggg tacggttgag taataaatgg atgccctgcg taagcggggc 1980
 atttttcttc ctgttatgtt tttaatcaaa catcctgcc actccatgtg acaaaccgtc 2040
 atcttcggt actttttctc tgtcacagaa tgaaaatttt tctgtcatct cttcgttatt 2100
 aatgtttgta attgactgaa tatcaacgct ctaggggggc tagagcggcc gccaccgcgg 2160
 tggagctccg tcgacaagct tacc 2184

<210> 30

<211> 1830

<212> DNA

<213> Escherichia coli

<220>

<221> CDS

<222> (1)..(1830)

<400> 30

atg tgt gga att gtt ggc gcg atc gcg caa cgt gat gta gca gaa atc 48
 Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile 15
 1 5 10 15

ctt ctt gaa ggt tta cgt cgt ctg gaa tac cgc gga tat gac tct gcc 96
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala 30
 20 25 30

ggt ctg gcc gtt gtt gat gca gaa ggt cat atg acc cgc ctg cgt cgc 144
 Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg 45
 35 40 45

ctc ggt aaa gtc cag atg ctg gca cag gca gcg gaa gaa cat cct ctg	192
Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu	
50 55 60	
cat ggc ggc act ggt att gct cac act cgc tgg gcg acc cac ggt gaa	240
His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu	
65 70 75 80	
cct tca gaa gtg aat gcg cat ccg cat gtt tct gaa cac att gtg gtg	288
Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val	
85 90 95	
gtg cat aac ggc atc atc gaa aac cat gaa ccg ctg cgt gaa gag cta	336
Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu	
100 105 110	
aaa gcg cgt ggc tat acc ttc gtt tct gaa acc gac acc gaa gtg att	384
Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile	
115 120 125	
gcc cat ctg gtg aac tgg gag ctg aaa caa ggc ggg act ctg cgt gag	432
Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu	
130 135 140	
gcc gtt ctg cgt gct atc ccg cag ctg cgt ggt gcg tac ggt aca gtg	480
Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val	
145 150 155 160	
atc atg gac tcc cgt cac ccg gat acc ctg ctg gcg gca cgt tct ggt	528
Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly	
165 170 175	
agt ccg ctg gtg att ggc ctg ggg atg ggc gaa aac ttt atc gct tct	576
Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser	
180 185 190	
gac cag ctg gcg ctg ttg ccg gtg acc cgt cgc ttt atc ttc ctt gaa	624
Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu	
195 200 205	
gag ggc gat att gcg gaa atc act cgc cgt tgc gta aac atc ttc gat	672
Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp	
210 215 220	
aaa act ggc gcg gaa gta aaa cgt cag gat atc gaa tcc aat ctg caa	720
Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln	
225 230 235 240	
tat gac gcg ggc gat aaa ggc att tac cgt cac tac atg cag aaa gag	768
Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu	
245 250 255	
atc tac gaa cag ccg aac gcg atc aaa aac acc ctt acc gga cgc atc	816
Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile	
260 265 270	
agc cac ggt cag gtt gat tta agc gag ctg gga ccg aac gcc gac gaa	864

Ser	His	Gly	Gln	Val	Asp	Leu	Ser	Glu	Leu	Gly	Pro	Asn	Ala	Asp	Glu		
		275					280					285					
ctg	ctg	tcg	aag	gtt	gag	cat	att	cag	atc	ctc	gcc	tgt	ggg	act	tct	912	
Leu	Leu	Ser	Lys	Val	Glu	His	Ile	Gln	Ile	Leu	Ala	Cys	Gly	Thr	Ser		
		290				295				300							
tat	aac	tcc	ggg	atg	gtt	tcc	cgc	tac	tgg	ttt	gaa	tcg	cta	gca	ggg	960	
Tyr	Asn	Ser	Gly	Met	Val	Ser	Arg	Tyr	Trp	Phe	Glu	Ser	Leu	Ala	Gly		
305					310					315					320		
att	ccg	tgc	gac	gtc	gaa	atc	gcc	tct	gaa	ttc	cgc	tat	cgc	aaa	tct	1008	
Ile	Pro	Cys	Asp	Val	Glu	Ile	Ala	Ser	Glu	Phe	Arg	Tyr	Arg	Lys	Ser		
				325					330					335			
gcc	gtg	cgt	cgt	aac	agc	ctg	atg	atc	acc	ttg	tca	cag	tct	ggc	gaa	1056	
Ala	Val	Arg	Arg	Asn	Ser	Leu	Met	Ile	Thr	Leu	Ser	Gln	Ser	Gly	Glu		
				340				345					350				
acc	gcg	gat	acc	ctg	gct	ggc	ctg	cgt	ctg	tcg	aaa	gag	ctg	ggg	tac	1104	
Thr	Ala	Asp	Thr	Leu	Ala	Gly	Leu	Arg	Leu	Ser	Lys	Glu	Leu	Gly	Tyr		
		355				360						365					
ctt	ggg	tca	ctg	gca	atc	tgt	aac	gtt	ccg	ggg	tct	tct	ctg	gtg	cgc	1152	
Leu	Gly	Ser	Leu	Ala	Ile	Cys	Asn	Val	Pro	Gly	Ser	Ser	Leu	Val	Arg		
	370					375					380						
gaa	tcc	gat	ctg	gcg	cta	atg	acc	aac	gcg	ggg	aca	gaa	atc	ggc	gtg	1200	
Glu	Ser	Asp	Leu	Ala	Leu	Met	Thr	Asn	Ala	Gly	Thr	Glu	Ile	Gly	Val		
385					390					395					400		
gca	tcc	act	aaa	gca	ttc	acc	act	cag	tta	act	gtg	ctg	ttg	atg	ctg	1248	
Ala	Ser	Thr	Lys	Ala	Phe	Thr	Thr	Gln	Leu	Thr	Val	Leu	Leu	Met	Leu		
				405				410						415			
gtg	gcg	aag	ctg	tct	cgc	ctg	aaa	ggg	ctg	gat	gcc	tcc	att	gaa	cat	1296	
Val	Ala	Lys	Leu	Ser	Arg	Leu	Lys	Gly	Leu	Asp	Ala	Ser	Ile	Glu	His		
		420					425						430				
gac	atc	gtg	cat	ggg	ctg	cag	gcg	ctg	ccg	agc	cgt	att	gag	cag	atg	1344	
Asp	Ile	Val	His	Gly	Leu	Gln	Ala	Leu	Pro	Ser	Arg	Ile	Glu	Gln	Met		
		435					440					445					
ctg	tct	cag	gac	aaa	cgc	att	gaa	gcg	ctg	gca	gaa	gat	ttc	tct	gac	1392	
Leu	Ser	Gln	Asp	Lys	Arg	Ile	Glu	Ala	Leu	Ala	Glu	Asp	Phe	Ser	Asp		
		450				455					460						
aaa	cat	cac	gcg	ctg	ttc	ctg	agc	cgt	ggc	gat	cag	tac	cca	atc	gcg	1440	
Lys	His	His	Ala	Leu	Phe	Leu	Ser	Arg	Gly	Asp	Gln	Tyr	Pro	Ile	Ala		
465					470				475						480		
ctg	gaa	ggc	gca	ttg	aag	ttg	aaa	gag	atc	tct	tac	att	cac	gct	gaa	1488	
Leu	Glu	Gly	Ala	Leu	Lys	Leu	Lys	Glu	Ile	Ser	Tyr	Ile	His	Ala	Glu		
				485				490						495			
gcc	tac	gct	gct	ggc	gaa	ctg	aaa	cac	ggg	ccg	ctg	gcg	cta	att	gat	1536	
Ala	Tyr	Ala	Ala	Gly	Glu	Leu	Lys	His	Gly	Pro	Leu	Ala	Leu	Ile	Asp		

500	505	510	
gcc gat atg ccg gtt att gtt gtt gca ccg aac aac gaa ttg ctg gaa Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu 515 520 525			1584
aaa ctg aaa tcc aac att gaa gaa gtt cgc gcg cgt ggc ggt cag ttg Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu 530 535 540			1632
tat gtc ttc gcc gat cag gat gcg ggt ttt gta agt agc gat aac atg Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met 545 550 555 560			1680
cac atc atc gag atg ccg cat gtg gaa gag gtg att gca ccg atc ttc His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe 565 570 575			1728
tac acc gtt ccg ctg cag ctg ctg gct tac cat gtc gcg ctg atc aaa Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys 580 585 590			1776
ggc acc gac gtt gac cag ccg cgt aac ctg gca aaa tcg gtt acg gtt Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val 595 600 605			1824
gag taa Glu 610			1830

<210> 31
 <211> 609
 <212> PRT
 <213> Escherichia coli

<400> 31
 Met Cys Gly Ile Val Gly Ala Ile Ala Gln Arg Asp Val Ala Glu Ile
 1 5 10 15
 Leu Leu Glu Gly Leu Arg Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30
 Gly Leu Ala Val Val Asp Ala Glu Gly His Met Thr Arg Leu Arg Arg
 35 40 45
 Leu Gly Lys Val Gln Met Leu Ala Gln Ala Ala Glu Glu His Pro Leu
 50 55 60
 His Gly Gly Thr Gly Ile Ala His Thr Arg Trp Ala Thr His Gly Glu
 65 70 75 80
 Pro Ser Glu Val Asn Ala His Pro His Val Ser Glu His Ile Val Val
 85 90 95
 Val His Asn Gly Ile Ile Glu Asn His Glu Pro Leu Arg Glu Glu Leu
 100 105 110

Lys Ala Arg Gly Tyr Thr Phe Val Ser Glu Thr Asp Thr Glu Val Ile
 115 120 125
 Ala His Leu Val Asn Trp Glu Leu Lys Gln Gly Gly Thr Leu Arg Glu
 130 135 140
 Ala Val Leu Arg Ala Ile Pro Gln Leu Arg Gly Ala Tyr Gly Thr Val
 145 150 155 160
 Ile Met Asp Ser Arg His Pro Asp Thr Leu Leu Ala Ala Arg Ser Gly
 165 170 175
 Ser Pro Leu Val Ile Gly Leu Gly Met Gly Glu Asn Phe Ile Ala Ser
 180 185 190
 Asp Gln Leu Ala Leu Leu Pro Val Thr Arg Arg Phe Ile Phe Leu Glu
 195 200 205
 Glu Gly Asp Ile Ala Glu Ile Thr Arg Arg Ser Val Asn Ile Phe Asp
 210 215 220
 Lys Thr Gly Ala Glu Val Lys Arg Gln Asp Ile Glu Ser Asn Leu Gln
 225 230 235 240
 Tyr Asp Ala Gly Asp Lys Gly Ile Tyr Arg His Tyr Met Gln Lys Glu
 245 250 255
 Ile Tyr Glu Gln Pro Asn Ala Ile Lys Asn Thr Leu Thr Gly Arg Ile
 260 265 270
 Ser His Gly Gln Val Asp Leu Ser Glu Leu Gly Pro Asn Ala Asp Glu
 275 280 285
 Leu Leu Ser Lys Val Glu His Ile Gln Ile Leu Ala Cys Gly Thr Ser
 290 295 300
 Tyr Asn Ser Gly Met Val Ser Arg Tyr Trp Phe Glu Ser Leu Ala Gly
 305 310 315 320
 Ile Pro Cys Asp Val Glu Ile Ala Ser Glu Phe Arg Tyr Arg Lys Ser
 325 330 335
 Ala Val Arg Arg Asn Ser Leu Met Ile Thr Leu Ser Gln Ser Gly Glu
 340 345 350
 Thr Ala Asp Thr Leu Ala Gly Leu Arg Leu Ser Lys Glu Leu Gly Tyr
 355 360 365
 Leu Gly Ser Leu Ala Ile Cys Asn Val Pro Gly Ser Ser Leu Val Arg
 370 375 380
 Glu Ser Asp Leu Ala Leu Met Thr Asn Ala Gly Thr Glu Ile Gly Val
 385 390 395 400
 Ala Ser Thr Lys Ala Phe Thr Thr Gln Leu Thr Val Leu Leu Met Leu
 405 410 415

Val Ala Lys Leu Ser Arg Leu Lys Gly Leu Asp Ala Ser Ile Glu His
 420 425 430
 Asp Ile Val His Gly Leu Gln Ala Leu Pro Ser Arg Ile Glu Gln Met
 435 440 445
 Leu Ser Gln Asp Lys Arg Ile Glu Ala Leu Ala Glu Asp Phe Ser Asp
 450 455 460
 Lys His His Ala Leu Phe Leu Ser Arg Gly Asp Gln Tyr Pro Ile Ala
 465 470 475 480
 Leu Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu
 485 490 495
 Ala Tyr Ala Ala Gly Glu Leu Lys His Gly Pro Leu Ala Leu Ile Asp
 500 505 510
 Ala Asp Met Pro Val Ile Val Val Ala Pro Asn Asn Glu Leu Leu Glu
 515 520 525
 Lys Leu Lys Ser Asn Ile Glu Glu Val Arg Ala Arg Gly Gly Gln Leu
 530 535 540
 Tyr Val Phe Ala Asp Gln Asp Ala Gly Phe Val Ser Ser Asp Asn Met
 545 550 555 560
 His Ile Ile Glu Met Pro His Val Glu Glu Val Ile Ala Pro Ile Phe
 565 570 575
 Tyr Thr Val Pro Leu Gln Leu Leu Ala Tyr His Val Ala Leu Ile Lys
 580 585 590
 Gly Thr Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Ser Val Thr Val
 595 600 605
 Glu

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/15976

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : C12P 19/26; C12N 9/00, 9/02, 9/04, 9/06; C07H 21/04 US CL : 435/84, 183, 189, 190, 191; 536-23.2 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/84, 183, 189, 190, 191; 536/23.2 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST, STN search terms: \$glucosamine, phosphate, enzyme, \$ase		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	VOGLER et al. Analysis of the nag regulon from Escherichia coli K12 and Klebsiella pneumoniae and of its regulation. MGG: Mol. Gen. Genet. 1989, Vol. 219, Nos. 1-2, pages 97-105.	1-10 and 36-39
A	PERI et al. Cloning and characterization of the N-acetylglucosamine operon of Escherichia coli Biochem. Cell Biol. 1990 Vol. 68, No. 1, pages 123-137.	1-10 and 36-39
A	SOUZA et al. N-acetylglucosamine-6-phosphate deacetylase from Escherichia coli: Purification and molecular and kinetic characterization. Arch. Biochem. Biophys. 15 April 1997, Vol. 340, No. 2, pages 338-346.	1-10 and 36-39
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
06 OCTOBER 1999	21 OCT 1999	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer ROBERT A. WAX JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX	
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/15976

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,702,939 A (FUJISHIMA et al.) 30 December 1997.	1-10 and 36-39
A	US 5,744,325 A (FUJISHIMA et al.) 28 April 1998.	1-10 and 36-39

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/15976

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10 and 36-39

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/15976

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

- Group I, claim(s) 1-42, drawn to method of making glucosamine.
- Group II, claim(s) 43-51, drawn to microorganism transfected with a glucosamine-6-phosphate synthase gene.
- Group III, claim(s) 52-55, drawn to nucleic acid encoding a modified glucosamine-6-phosphate synthase.
- Group IV, claims 56-59, drawn to modified glucosamine-6-phosphate synthase.
- Group V, claim 60, drawn to another method of making glucosamine.

This application also contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

Group I: Claims 1-10 - five different pathways; claims 11-35, further subdivided as follows: claims 13 and 18 recite transformation with nucleic acid encoding glucosamine-6-phosphate synthase, claim 14 recites a homologue and claims 15-17 recite 7 particular sequences, claims 19, 21 and 31 recite modified glucosamine-6-phosphate synthase which has increased glucosamine-6-phosphate synthase action, claims 22-30 recite 37 specific mutations, claims 32-33 recite one of 9 additional modifications, claims 34-35 recite any three of the nine listed in claim 32. Claim 40 is roughly equivalent to claim 19, claim 41 recites one additional modification selected from 13 possibilities, claim 41 recites one additional modification selected from 6 choices.

Group II: Claims 43 and 49 recite microorganism transformed with modified glucosamine-6-phosphate synthase gene, claims 44-45 recite one additional modification selected from 9 possibilities, claim 46 limits the microorganism to E. coli having an additional modification selected from 11 choices, claim 47 recites E. coli having the nag regulon deleted and claim 48 recites E. coli having the nag regulon deleted and a modification in the manxyz gene, claims 50-51 are equivalent to claims 44-45, reciting 8 additional options for modification.

Group III: Claims 52-53 recite nucleic acid encoding modified glucosamine-6-phosphate synthase which has increased action, claims 54-55 recite 15 specific sequences.

Group IV: Claims 56-57 recite modified glucosamine-6-phosphate synthase which has increased action, claim 58 recites 10 specific nucleic acid sequences which encode the enzyme, claim 59 recites 5 specific amino acid sequences.

Group V: Claim 60 provides a single species constituting another method of making glucosamine.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the method of Group I makes glucosamine using any microorganism that has a modification in any of five different pathways. Since there are so many genes involved in the five pathways it is not seen how there can be a single "special" technical feature. The microorganism of Group II contains one of the genes involved in one of the pathways but since there is nothing "special" about it unity is lacking. The DNA of Group III and enzyme of Group IV lack unity with Group I for the same reason. The second method of Group V clearly lacks unity since it recites different steps.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the species all represent different chemical moieties which would be expected to have different properties and the search for any one of them would not uncover references for any of the others.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

